{"meta":{"query_hash":"e549f4ad412f","filters":{"venue":"CNS Drugs"},"cohort_total":173,"direct_labels_cover":0,"predictions_cover":173,"exported":173,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/e549f4ad412f","api":"https://metacan.xera.ac/api/v1/cohort?venue=CNS+Drugs"},"results":[{"id":"W1166074170","doi":"10.1007/s40263-015-0270-y","title":"Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Aggression; Psychopharmacology; Dementia; Psychiatry; Psychology; Clinical trial; Alzheimer's disease; Disease; Medicine; Internal medicine","score_opus":0.09630533766773305,"score_gpt":0.42002174040197104,"score_spread":0.32371640273423796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1166074170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012220904,0.9992142,0.00004274003,0.00007512362,0.00006873165,0.000004871431,0.0000145096865,0.0000030668343,0.0004545738],"genre_scores_gemma":[0.0009803266,0.99830484,0.00013704688,0.00010263554,0.00007732169,0.0000048153215,0.000017372833,7.602991e-7,0.00037490233],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99985445,0.000023364071,0.000029056238,0.00001975009,0.00005853875,0.000014812662],"domain_scores_gemma":[0.99971503,0.00014724905,0.00005435464,0.0000069337,0.000054209224,0.000022208227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004914915,0.00071878085,0.0017374239,0.0022985942,0.0002842593,0.0007695499,0.00075270014,0.0009180348,0.0041266032],"category_scores_gemma":[0.0006851347,0.00024489177,0.00066630024,0.001897003,0.00037940987,0.0006794704,0.00057648617,0.0014772408,0.00093461206],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019271427,0.00012585685,0.00013496469,0.029897738,0.00026415783,0.00020090991,0.00005448991,0.00023834831,0.0015448306,0.0016857914,0.014957586,0.9507027],"study_design_scores_gemma":[0.00024365289,0.0003176118,0.002311269,0.014654281,0.001322898,0.0022110913,0.0001344076,0.00023741361,0.0010788251,0.0025415744,0.9748921,0.000054731976],"about_ca_topic_score_codex":0.0030855397,"about_ca_topic_score_gemma":0.008435279,"teacher_disagreement_score":0.0041266032,"about_ca_system_score_codex":0.0004577259,"about_ca_system_score_gemma":0.0010720115,"threshold_uncertainty_score":0.013804853},"labels":[],"label_agreement":null},{"id":"W120655898","doi":"10.2165/11534420-000000000-00000","title":"Agomelatine in the Treatment of Major Depressive Disorder","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"University Health Network","keywords":"Agomelatine; Venlafaxine; Sertraline; Antidepressant; Fluoxetine; Major depressive disorder; Medicine; Discontinuation; Escitalopram; Placebo; Adverse effect; Psychology; Psychiatry; Internal medicine; Mood; Serotonin; Anxiety; Receptor","score_opus":0.029761622584474318,"score_gpt":0.34473524870846084,"score_spread":0.3149736261239865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W120655898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026231332,0.9986885,0.000085424945,0.00009820496,0.00010672081,0.000007862434,0.000023096552,0.000010071169,0.0007178329],"genre_scores_gemma":[0.0018004738,0.9969202,0.0002478173,0.00022058823,0.000085406675,0.000007785742,0.000041151787,0.0000019654149,0.00067445624],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.999905,0.000017833925,0.000016703201,0.00001828525,0.00003284669,0.00000929582],"domain_scores_gemma":[0.9998554,0.00006673556,0.000031989155,0.0000040486793,0.000025578733,0.00001623968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036975383,0.00078023813,0.0017739623,0.0015000077,0.00019148277,0.000574781,0.0009946253,0.00079595856,0.0035380155],"category_scores_gemma":[0.0004245595,0.00025459903,0.0005432894,0.0015650571,0.00030274357,0.00056372903,0.00043042147,0.0014939486,0.0011953532],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032961933,0.0001529543,0.00012775324,0.02337742,0.00033139862,0.00016324967,0.00003406118,0.00031045772,0.0017659733,0.0007659842,0.019303674,0.9533375],"study_design_scores_gemma":[0.00058250246,0.0006333723,0.0033233876,0.009004706,0.0021084324,0.0024898653,0.000094030765,0.00040751413,0.0013174239,0.0013455105,0.97864425,0.000048999795],"about_ca_topic_score_codex":0.0028686628,"about_ca_topic_score_gemma":0.008433955,"teacher_disagreement_score":0.0035380155,"about_ca_system_score_codex":0.00039340116,"about_ca_system_score_gemma":0.0006755057,"threshold_uncertainty_score":0.0118358135},"labels":[],"label_agreement":null},{"id":"W14166098","doi":"10.2165/00023210-200721060-00001","title":"Long-Acting Formulations of Atypical Antipsychotics","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Risperidone; Tolerability; Discontinuation; Paliperidone Palmitate; Paliperidone; Antipsychotic; Medicine; Atypical antipsychotic; Psychiatry; Schizophrenia (object-oriented programming); Amisulpride; Clozapine; Psychopharmacology; Psychosis; Psychology; Pediatrics; Pharmacology; Adverse effect","score_opus":0.1295796801124919,"score_gpt":0.4456436120748377,"score_spread":0.31606393196234583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W14166098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019004606,0.99854577,0.0001439563,0.00008421308,0.00010492659,0.0000078891735,0.00002482182,0.000008241333,0.0008901115],"genre_scores_gemma":[0.0009993177,0.99758923,0.00039064453,0.00015834348,0.00008579178,0.0000075773205,0.00004544814,0.0000017126222,0.0007219196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979347,0.0000317318,0.000038945043,0.00003171135,0.00008930317,0.000014842627],"domain_scores_gemma":[0.99968374,0.00014318577,0.00009299929,0.00000851778,0.000049932936,0.000021687447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004940566,0.0010854173,0.0016810754,0.0017546245,0.00022015438,0.0007959305,0.0011685181,0.00086417707,0.00423903],"category_scores_gemma":[0.000700052,0.00024807182,0.0005575406,0.0018304721,0.00032413163,0.0009868024,0.0004751612,0.0014014055,0.001597332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018172791,0.0000776053,0.00012864423,0.017941853,0.00012776381,0.00020830898,0.000028875322,0.00017624596,0.0018489435,0.0008521507,0.015232821,0.963195],"study_design_scores_gemma":[0.00013906624,0.0002660526,0.0016423,0.005095093,0.00057630206,0.0025222937,0.00006528424,0.000156529,0.0010286772,0.0009219236,0.9875572,0.000029329589],"about_ca_topic_score_codex":0.0013213401,"about_ca_topic_score_gemma":0.003688282,"teacher_disagreement_score":0.00423903,"about_ca_system_score_codex":0.00047574728,"about_ca_system_score_gemma":0.00076093955,"threshold_uncertainty_score":0.014180958},"labels":[],"label_agreement":null},{"id":"W143349262","doi":"10.2165/11588160-000000000-00000","title":"Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimerʼs Disease","year":2011,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; North York General Hospital; Sunnybrook Health Science Centre; University of Toronto","funders":"H. Lundbeck A/S","keywords":"Memantine; Psychopharmacology; Aggression; Medicine; Disease; Neurology; Psychiatry; Alzheimer's disease; Dementia; Psychology; Intensive care medicine; Internal medicine","score_opus":0.024210451479408535,"score_gpt":0.3406652819355511,"score_spread":0.3164548304561426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W143349262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992812,0.00015214462,0.000012605469,0.000039197323,0.000011202239,0.0000069236494,0.0000760767,0.0000014573533,0.00041924432],"genre_scores_gemma":[0.99925584,0.00013591586,0.00003895537,0.00003915534,0.000017867891,0.000010075208,0.00021535602,8.4656796e-7,0.00028602968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996569,0.000077124845,0.000056408848,0.00003272337,0.000091586364,0.00008525145],"domain_scores_gemma":[0.99808985,0.00020129439,0.0007805098,0.000043630556,0.00036393502,0.0005207717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040310557,0.00025211365,0.0006041327,0.0006116393,0.0008448018,0.0004853152,0.00036422844,0.00050486333,0.0012513305],"category_scores_gemma":[0.0040593357,0.00018803502,0.0005986953,0.00049978745,0.00018426449,0.0006263204,0.0004827991,0.00080609747,0.00021472266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032157404,0.0006183567,0.9850852,0.000046879235,0.00017066971,0.0006288811,0.00047766545,0.00009823034,0.0005623209,0.000008870213,0.0002924994,0.008794666],"study_design_scores_gemma":[0.000010841001,0.00042675322,0.9989015,0.000006389429,0.000029532364,0.000121674086,0.00031068726,0.00008089372,0.0000418092,0.000006820635,0.00005766638,0.0000054635116],"about_ca_topic_score_codex":0.016558006,"about_ca_topic_score_gemma":0.043778997,"teacher_disagreement_score":0.016558006,"about_ca_system_score_codex":0.00093315734,"about_ca_system_score_gemma":0.00058213633,"threshold_uncertainty_score":0.03292322},"labels":[],"label_agreement":null},{"id":"W149262272","doi":"10.2165/00023210-200115060-00002","title":"Homocysteine Levels in Patients with Stroke","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Stroke (engine); Homocysteine; Neurology; Medicine; Psychopharmacology; Internal medicine; Cardiology; Pharmacology; Psychiatry","score_opus":0.051505983492836485,"score_gpt":0.3499109390735307,"score_spread":0.29840495558069424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W149262272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041394585,0.99906117,0.000038314192,0.00012538706,0.000067746216,0.000002923441,0.000025142812,0.0000030222443,0.0002622836],"genre_scores_gemma":[0.003989771,0.99529606,0.00013016188,0.00019849738,0.00012755864,0.00000910277,0.00004063139,6.577155e-7,0.00020744854],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996848,0.000068721136,0.00010267572,0.000046758036,0.00008266285,0.000014247263],"domain_scores_gemma":[0.99947613,0.0002659546,0.00013794635,0.000009632471,0.000088332155,0.000022092052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062888203,0.0008175522,0.003514261,0.0023168197,0.00018496842,0.000644997,0.0005370063,0.00093624846,0.0014431002],"category_scores_gemma":[0.001393503,0.00028703955,0.0008025927,0.002567675,0.0002403748,0.0005018883,0.0003316727,0.00076627155,0.00038736014],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011224176,0.000102114085,0.0038796375,0.05441407,0.0022783962,0.00071035203,0.00008411716,0.00017943777,0.0009659899,0.00032053594,0.017607676,0.91833526],"study_design_scores_gemma":[0.0022609276,0.0022765792,0.079238154,0.064592086,0.03680623,0.017847652,0.0005500895,0.0007167511,0.0039137593,0.0028581372,0.78872377,0.0002158457],"about_ca_topic_score_codex":0.002586579,"about_ca_topic_score_gemma":0.0055128126,"teacher_disagreement_score":0.003514261,"about_ca_system_score_codex":0.00040305444,"about_ca_system_score_gemma":0.0009986849,"threshold_uncertainty_score":0.005143106},"labels":[],"label_agreement":null},{"id":"W1819417743","doi":"10.1007/s40263-015-0263-x","title":"The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Major depressive disorder; Cognition; Clinical psychology; Psychology; MEDLINE; Psychiatry; Psychotherapist","score_opus":0.054123109356715667,"score_gpt":0.33149881329799513,"score_spread":0.2773757039412795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1819417743","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028371578,0.999451,0.00003727871,0.00007449832,0.000021805263,0.000003282534,0.000018950288,0.000001268011,0.00010814299],"genre_scores_gemma":[0.00299524,0.996608,0.00018094454,0.00010498305,0.000037564896,0.0000049981595,0.000025993977,5.6151373e-7,0.00004172745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99919766,0.00017628468,0.00021319506,0.00012513755,0.00025549394,0.000032213156],"domain_scores_gemma":[0.9974528,0.0015817425,0.00058737036,0.00004328546,0.00028223352,0.000052452397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022288817,0.00068656716,0.0024187912,0.0023417526,0.00017561928,0.0010729551,0.0012512422,0.0009579978,0.0011072356],"category_scores_gemma":[0.0037957896,0.00046347838,0.0014491479,0.0026871753,0.0006297661,0.0008502837,0.0006399692,0.0014648052,0.000246511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025328642,0.000091733906,0.0034591088,0.057322506,0.0012429365,0.00007593659,0.00009039856,0.00028256088,0.00053145137,0.00078100106,0.0040979446,0.93177104],"study_design_scores_gemma":[0.0006429841,0.0015199285,0.15848856,0.15122469,0.02259789,0.0071339384,0.0010378544,0.0015924127,0.00280971,0.0061908136,0.64643836,0.00032285685],"about_ca_topic_score_codex":0.0057511297,"about_ca_topic_score_gemma":0.014000743,"teacher_disagreement_score":0.0057511297,"about_ca_system_score_codex":0.0007827664,"about_ca_system_score_gemma":0.0016178887,"threshold_uncertainty_score":0.011787593},"labels":[],"label_agreement":null},{"id":"W183088063","doi":"10.2165/00023210-200216080-00004","title":"Newer Antiepileptic Drugs in Bipolar Disorder","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University","funders":"","keywords":"Lamotrigine; Topiramate; Gabapentin; Bipolar disorder; Adjunctive treatment; Carbamazepine; Medicine; Valproic Acid; Mood stabilizer; Mania; Tiagabine; Mood; Mood disorders; Psychiatry; Epilepsy; Internal medicine; Anxiety","score_opus":0.026611214741317578,"score_gpt":0.306428633989374,"score_spread":0.2798174192480564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W183088063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016477554,0.9982723,0.000087606575,0.00011972002,0.0002205279,0.000008141962,0.000023695782,0.0000065640797,0.0010967508],"genre_scores_gemma":[0.000841757,0.9975091,0.0002521339,0.00020536457,0.00022658563,0.000009215816,0.000029709467,0.0000011689006,0.00092481804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998116,0.000030752202,0.00005291951,0.000026173182,0.00006567418,0.000012871391],"domain_scores_gemma":[0.9995751,0.00016608715,0.00013544667,0.000010409166,0.000080960315,0.000032004136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005003175,0.0010860959,0.0018887934,0.0034267956,0.00024530236,0.0008072412,0.0007109369,0.0008892404,0.0052303574],"category_scores_gemma":[0.0007976198,0.00034894026,0.00051467196,0.0031636367,0.00030998274,0.0013472263,0.000487706,0.00112612,0.0015193325],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017534792,0.000082326136,0.00018312554,0.025835834,0.00014401405,0.00031325757,0.000051847775,0.00025254095,0.0013769565,0.00069351017,0.024660435,0.9462308],"study_design_scores_gemma":[0.0001772209,0.000315806,0.002396656,0.009080658,0.0010092414,0.003454553,0.00009197222,0.00016361114,0.00051994424,0.0007646903,0.981998,0.000027561684],"about_ca_topic_score_codex":0.0017103277,"about_ca_topic_score_gemma":0.0066252113,"teacher_disagreement_score":0.0052303574,"about_ca_system_score_codex":0.0004732862,"about_ca_system_score_gemma":0.00090536114,"threshold_uncertainty_score":0.017497301},"labels":[],"label_agreement":null},{"id":"W1965399275","doi":"10.2165/00023210-200822100-00007","title":"Oral Zolmitriptan in the Short-Term Prevention of Menstrual Migraine","year":2008,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Allergan; AstraZeneca","keywords":"Zolmitriptan; Placebo; Medicine; Migraine; Tolerability; Population; Anesthesia; Sumatriptan; Internal medicine; Adverse effect","score_opus":0.05251262070736227,"score_gpt":0.32524584845227344,"score_spread":0.27273322774491116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965399275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6666747,0.32972005,0.00009326443,0.0004320523,0.0002844052,0.000105837775,0.00042208587,0.000007450123,0.0022601022],"genre_scores_gemma":[0.887602,0.1104798,0.00022066814,0.00025262934,0.00048443902,0.000052624688,0.00023164118,0.0000016343892,0.00067462266],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990188,0.00051729614,0.00016376632,0.000052033385,0.0001933426,0.000054836637],"domain_scores_gemma":[0.9974527,0.0014940393,0.00062982197,0.000068914625,0.0001400746,0.00021439295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001726607,0.00027992047,0.001220633,0.00081020896,0.0002931078,0.000495711,0.00030161568,0.00046794742,0.00199232],"category_scores_gemma":[0.004351076,0.00020438606,0.00086594425,0.000963423,0.00034978322,0.00040932608,0.00027794007,0.0005840189,0.00012565895],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28368366,0.0042084134,0.13663684,0.030147862,0.015917465,0.00091776415,0.0010246204,0.00038756765,0.007569281,0.0008920442,0.0026248472,0.5159897],"study_design_scores_gemma":[0.03927204,0.13338305,0.77283067,0.0032287668,0.025506627,0.002049701,0.00097403885,0.00035618755,0.0036446168,0.00045288977,0.018215194,0.000086158514],"about_ca_topic_score_codex":0.0028337098,"about_ca_topic_score_gemma":0.004893349,"teacher_disagreement_score":0.0028337098,"about_ca_system_score_codex":0.00039192164,"about_ca_system_score_gemma":0.00069533713,"threshold_uncertainty_score":0.009131312},"labels":[],"label_agreement":null},{"id":"W1966938384","doi":"10.2165/11533710-000000000-00000","title":"Medication Errors in Psychiatry","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Psychiatry; Pharmacy; MEDLINE; Health care; Patient safety; Family medicine","score_opus":0.14679243568557324,"score_gpt":0.4773872628042648,"score_spread":0.3305948271186916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966938384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019705713,0.99867624,0.000044512133,0.00039353062,0.00025874356,0.000010921335,0.00003046981,0.0000048685674,0.0003836668],"genre_scores_gemma":[0.0016056721,0.9973023,0.00018691464,0.00042411237,0.00026361752,0.000010278333,0.00003319558,0.0000010746786,0.00017289349],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977744,0.00046428898,0.0007205443,0.00022730198,0.00070978346,0.00010366269],"domain_scores_gemma":[0.99236065,0.0030732984,0.0031876827,0.00013524381,0.001012365,0.00023079365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002220092,0.0011579081,0.0029316896,0.006774415,0.00044072178,0.0016070436,0.0011670942,0.0015535931,0.00394766],"category_scores_gemma":[0.008620266,0.0005959586,0.001676703,0.0074630766,0.0006979596,0.0018962142,0.0016030472,0.0018172052,0.0007687653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011205144,0.00008804016,0.0017700293,0.07524276,0.0009840598,0.000250904,0.00011293739,0.00023943595,0.0002005684,0.00045311236,0.027466359,0.89307964],"study_design_scores_gemma":[0.00041800138,0.00059810386,0.027860103,0.20977354,0.007844005,0.0058658756,0.0005752827,0.00047705942,0.00069448946,0.0017276515,0.7440614,0.00010446696],"about_ca_topic_score_codex":0.005977227,"about_ca_topic_score_gemma":0.015658936,"teacher_disagreement_score":0.006774415,"about_ca_system_score_codex":0.001488393,"about_ca_system_score_gemma":0.0050331517,"threshold_uncertainty_score":0.013206184},"labels":[],"label_agreement":null},{"id":"W1968958193","doi":"10.2165/00023210-200216050-00005","title":"Brain Metastases","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Prophylactic cranial irradiation; Radiation therapy; Chemotherapy; Neurosurgery; Brain tumor; Neurology; Oncology; Surgery; Internal medicine; Pathology","score_opus":0.07425616006804142,"score_gpt":0.36175676949319985,"score_spread":0.2875006094251584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968958193","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037374056,0.99165946,0.00023175703,0.00031319336,0.00041387166,0.000017647573,0.000060100385,0.000023717595,0.006906557],"genre_scores_gemma":[0.003739196,0.9871159,0.00036532935,0.00069331855,0.00041659578,0.00002100849,0.00013961417,0.0000053651224,0.0075036855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988973,0.000019200936,0.000014436019,0.000024336554,0.000036634985,0.000015744014],"domain_scores_gemma":[0.999853,0.000050610768,0.000038288617,0.00000811158,0.000035717418,0.000014222887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019427021,0.0009021019,0.0014864801,0.0020948718,0.0003062816,0.00075304526,0.00052780105,0.0007478751,0.010935961],"category_scores_gemma":[0.0005080282,0.00020462922,0.00043422118,0.0019506513,0.0003417706,0.0007984594,0.00051145826,0.0010998034,0.0038624958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010088468,0.00006655548,0.00012051469,0.007693425,0.00005709021,0.0004566391,0.000020181189,0.00022492466,0.001565047,0.0010208687,0.049559157,0.93911475],"study_design_scores_gemma":[0.0000755435,0.00022144006,0.0012610446,0.003380985,0.0002633636,0.0070615388,0.000036076013,0.0001192385,0.0014463927,0.0009075328,0.9852093,0.000017535893],"about_ca_topic_score_codex":0.0015540606,"about_ca_topic_score_gemma":0.00565902,"teacher_disagreement_score":0.010935961,"about_ca_system_score_codex":0.00047509014,"about_ca_system_score_gemma":0.000756833,"threshold_uncertainty_score":0.036584437},"labels":[],"label_agreement":null},{"id":"W1970445748","doi":"10.1007/s40263-013-0074-x","title":"Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"H. Lundbeck A/S","keywords":"Memantine; Meta-analysis; Context (archaeology); Clinical trial; Psychology; Placebo; Concomitant; Disease; Medicine; Pharmacology; Internal medicine; Clinical psychology; Dementia; Alternative medicine; Pathology","score_opus":0.40846183247815765,"score_gpt":0.4981860252367227,"score_spread":0.08972419275856502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970445748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021619705,0.8988978,0.023155505,0.0017462476,0.0030416725,0.015750574,0.032313444,0.0007802295,0.0026948755],"genre_scores_gemma":[0.37414932,0.46350136,0.04613411,0.003585273,0.0012421173,0.09027848,0.01658347,0.00059469097,0.0039312188],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9560621,0.02445102,0.011278449,0.0036326798,0.0037890393,0.00078666233],"domain_scores_gemma":[0.9534587,0.03528687,0.0057813227,0.002554966,0.00257145,0.00034661498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04202491,0.005642147,0.035566814,0.012979186,0.00081308495,0.0049807923,0.004056645,0.0037600978,0.0098089045],"category_scores_gemma":[0.11837863,0.0024907687,0.07335708,0.0143109355,0.001061314,0.0033571655,0.0029975793,0.0037833974,0.0011392507],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020761483,0.000014069226,0.0010951024,0.34178528,0.64741665,0.00017075676,0.00008784884,0.0011646681,0.00021581663,0.00039918578,0.001195647,0.0043788143],"study_design_scores_gemma":[0.0015415985,0.0001577046,0.001940191,0.019503277,0.97171336,0.000083055995,0.000050158225,0.00031456075,0.00023039275,0.00082811405,0.003595118,0.000042480606],"about_ca_topic_score_codex":0.006504611,"about_ca_topic_score_gemma":0.008600861,"teacher_disagreement_score":0.04202491,"about_ca_system_score_codex":0.004447662,"about_ca_system_score_gemma":0.0048851366,"threshold_uncertainty_score":0.22225165},"labels":[],"label_agreement":null},{"id":"W1970668720","doi":"10.2165/00023210-200317130-00006","title":"Gabapentin","year":2003,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Gabapentin; Medicine; Psychopharmacology; Pharmacology","score_opus":0.05921623046700229,"score_gpt":0.3718747708260612,"score_spread":0.3126585403590589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970668720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010099746,0.98280704,0.00089127576,0.000691641,0.00084362,0.000036401707,0.000096150245,0.00010302772,0.013520834],"genre_scores_gemma":[0.0052925767,0.9762877,0.0011585621,0.0011225898,0.00041704916,0.000042047224,0.00019145905,0.000011391615,0.015476583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999149,0.000012714186,0.000015279942,0.000018023242,0.000026807213,0.000012261245],"domain_scores_gemma":[0.9998982,0.000030016256,0.000034463792,0.000005083647,0.00001894167,0.000013298613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001844202,0.0013109304,0.0013684096,0.0017124946,0.0002882726,0.00062650285,0.0006639042,0.0007590204,0.008834026],"category_scores_gemma":[0.0002761982,0.00021495599,0.0003302399,0.0012763657,0.00034367986,0.0007811409,0.00063158735,0.0015006106,0.0061067585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021074545,0.000084056424,0.000073263174,0.004501845,0.00003850597,0.00041935686,0.000018102493,0.00012417545,0.0038994064,0.00093796937,0.023846118,0.9658464],"study_design_scores_gemma":[0.00014527621,0.0004037302,0.0011339698,0.0020866962,0.00021696046,0.0050216317,0.000043840653,0.00012893156,0.00303574,0.0008400853,0.9869212,0.000021962376],"about_ca_topic_score_codex":0.0011741141,"about_ca_topic_score_gemma":0.0037731829,"teacher_disagreement_score":0.008834026,"about_ca_system_score_codex":0.0003781192,"about_ca_system_score_gemma":0.000838469,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W1973032604","doi":"10.2165/00023210-200923040-00004","title":"Insomnia in Patients with Depression","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sleep and related disorders","field":"Psychology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Mirtazapine; Venlafaxine; Trazodone; Antidepressant; Depression (economics); Insomnia; Psychiatry; Medicine; Agomelatine; Psychology; Bupropion; Anxiety","score_opus":0.013013225737509685,"score_gpt":0.3057613353038931,"score_spread":0.2927481095663834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973032604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004221869,0.99854577,0.000058535654,0.00014603557,0.00016614428,0.000009690209,0.000026463365,0.0000042053007,0.00062104483],"genre_scores_gemma":[0.0038843877,0.9947524,0.00017311749,0.00030353465,0.0002568218,0.000017230997,0.00005243881,9.050785e-7,0.0005592224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998776,0.000023853718,0.000031667598,0.00002023115,0.000035147197,0.000011506998],"domain_scores_gemma":[0.9997404,0.000104622406,0.00008069194,0.0000069860203,0.000044047276,0.000023201103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034083446,0.00074567006,0.0017715878,0.0018903338,0.00026487422,0.00053066754,0.00053935905,0.0005527939,0.0030603134],"category_scores_gemma":[0.000648609,0.00023446712,0.00069516816,0.0018285739,0.00023608067,0.0004946728,0.0005238371,0.00080012664,0.0006692695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002352523,0.000102273116,0.0015079519,0.023549277,0.00044712727,0.00030388217,0.000046233712,0.00009611318,0.0006906995,0.00023127618,0.016693313,0.9560966],"study_design_scores_gemma":[0.0010635131,0.0014363904,0.07382077,0.038790666,0.006280687,0.014073803,0.00048220402,0.0005831788,0.0010114426,0.0017493111,0.8605844,0.00012380033],"about_ca_topic_score_codex":0.0021270006,"about_ca_topic_score_gemma":0.008782251,"teacher_disagreement_score":0.0030603134,"about_ca_system_score_codex":0.00033362306,"about_ca_system_score_gemma":0.00078789715,"threshold_uncertainty_score":0.010237753},"labels":[],"label_agreement":null},{"id":"W1974781892","doi":"10.2165/00023210-200620080-00004","title":"Management of Psychiatric Comorbidity in Anorexia Nervosa and??Bulimia Nervosa","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Eating Disorders and Behaviors","field":"Psychology","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Comorbidity; Anorexia nervosa; Bulimia nervosa; Psychiatry; Eating disorders; Panic disorder; Anxiety; Psychology; Phobias; Clinical psychology; Substance abuse; Medicine","score_opus":0.03855472855716737,"score_gpt":0.35430935541663194,"score_spread":0.3157546268594646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974781892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005810487,0.99870586,0.00008938545,0.00016143128,0.000056531957,0.000003990992,0.000008593405,0.000005185267,0.00038794917],"genre_scores_gemma":[0.004703249,0.9941493,0.00045570385,0.00027150378,0.00014769699,0.000008992543,0.00003180038,0.0000011187415,0.00023063751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981993,0.000040328352,0.000038646383,0.0000254646,0.000061002687,0.0000146477805],"domain_scores_gemma":[0.9996604,0.0001773202,0.00008685446,0.000005698394,0.000042000956,0.000027830973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046391907,0.00051702105,0.0016447753,0.0012318293,0.00020039047,0.00061005517,0.00080763135,0.000793582,0.0013272775],"category_scores_gemma":[0.0009053012,0.00020782364,0.0005718902,0.000980749,0.00022896947,0.00054988835,0.00046568888,0.0011387162,0.00035538763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018141716,0.00012425634,0.0009573479,0.010240265,0.00027091516,0.000474734,0.00003703909,0.00019301684,0.00069522153,0.00032340304,0.00769005,0.9788124],"study_design_scores_gemma":[0.0008485534,0.0015186507,0.056401514,0.02738868,0.003568535,0.029823365,0.0005372567,0.0014073998,0.0017839009,0.0026031784,0.8739608,0.00015818591],"about_ca_topic_score_codex":0.0017523742,"about_ca_topic_score_gemma":0.006184377,"teacher_disagreement_score":0.0017523742,"about_ca_system_score_codex":0.00033334328,"about_ca_system_score_gemma":0.0006837327,"threshold_uncertainty_score":0.0044401884},"labels":[],"label_agreement":null},{"id":"W1975713412","doi":"10.1007/s40263-014-0154-6","title":"Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; British Columbia Centre of Excellence for Women's Health; University of British Columbia; BC Centre for Disease Control; B.C. Women's Hospital & Health Centre; University of British Columbia Hospital; Vancouver Coastal Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Birth weight; Glatiramer acetate; Pediatrics; Gestational age; Population; Pregnancy; Cohort; Multiple sclerosis; Obstetrics; Internal medicine; Immunology; Biology; Environmental health","score_opus":0.04489987703917808,"score_gpt":0.2901461299783005,"score_spread":0.24524625293912244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975713412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772364,0.0013310708,0.000030502439,0.0000795676,0.000018823272,0.000002981906,0.00030275562,0.0000017588901,0.00050892535],"genre_scores_gemma":[0.9981117,0.0010321836,0.000039679042,0.00004836661,0.000013343826,0.000005351927,0.00032701608,0.000002282091,0.00041997666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993906,0.00022561423,0.00006772618,0.00009208563,0.00007415387,0.00014986811],"domain_scores_gemma":[0.9975885,0.0007804879,0.0009707046,0.00017900356,0.00016002741,0.00032120864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079839205,0.0002494377,0.00044190706,0.0007431429,0.0005090473,0.00073587225,0.00038578728,0.00056638964,0.002197137],"category_scores_gemma":[0.0061470577,0.00021863631,0.0006605406,0.000946667,0.0002715639,0.00042100824,0.00050774834,0.0010071174,0.00017923959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062019285,0.000083703846,0.9953778,0.000044254783,0.00021896188,0.00041148646,0.00040146135,0.00002439459,0.00025437644,0.00008950554,0.00011311411,0.0023608608],"study_design_scores_gemma":[0.000015260439,0.00056974683,0.996557,0.00006913765,0.00020363733,0.00073379214,0.0012273323,0.00005896689,0.00018793867,0.00006890891,0.00029941372,0.000008881696],"about_ca_topic_score_codex":0.009590248,"about_ca_topic_score_gemma":0.005385456,"teacher_disagreement_score":0.009590248,"about_ca_system_score_codex":0.00037925184,"about_ca_system_score_gemma":0.00040399245,"threshold_uncertainty_score":0.019068837},"labels":[],"label_agreement":null},{"id":"W1975732958","doi":"10.2165/00023210-200721110-00003","title":"Long-Term and Preventative Treatment for Seasonal Affective Disorder","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Light therapy; Psychiatry; Antidepressant; Medicine; Population; Major depressive disorder; Psychosocial; Bupropion; Pharmacotherapy; Depression (economics); Placebo; Pediatrics; Mood; Psychology; Anxiety; Smoking cessation; Alternative medicine","score_opus":0.06740838111612428,"score_gpt":0.38238176173023886,"score_spread":0.31497338061411456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975732958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002555443,0.9980136,0.0001497867,0.00021883119,0.00022709492,0.0000061353644,0.000024944125,0.000009089108,0.0010949076],"genre_scores_gemma":[0.0023285374,0.9951727,0.00033538422,0.0003568468,0.0003576089,0.000015165388,0.00004574544,0.000002636938,0.0013853558],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99989843,0.00001892488,0.000022067206,0.00001936717,0.000031940628,0.000009291592],"domain_scores_gemma":[0.99975604,0.00011494549,0.00006456497,0.000008080198,0.00003549514,0.00002083204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037990752,0.0007731001,0.0013515591,0.0010590663,0.00022873205,0.000561373,0.0007786453,0.0009677809,0.0036742578],"category_scores_gemma":[0.0005394542,0.00020582815,0.00035414958,0.0010946601,0.00031921972,0.0007113459,0.00034867672,0.0012610051,0.0015112285],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018262755,0.00012473088,0.00016800388,0.008807759,0.00011741835,0.00023317734,0.000024452127,0.00017497418,0.0014921791,0.00072747766,0.021716002,0.9662312],"study_design_scores_gemma":[0.00019617335,0.0005038449,0.0038295367,0.0035928965,0.0005896417,0.0036322598,0.00008740461,0.0002443131,0.0011086565,0.0012064844,0.984976,0.000032964344],"about_ca_topic_score_codex":0.0011388161,"about_ca_topic_score_gemma":0.005028366,"teacher_disagreement_score":0.0036742578,"about_ca_system_score_codex":0.00043820322,"about_ca_system_score_gemma":0.00069112773,"threshold_uncertainty_score":0.01229167},"labels":[],"label_agreement":null},{"id":"W1975745615","doi":"10.1007/s40263-014-0181-3","title":"Effect of Extended-Release Dexmethylphenidate and Mixed Amphetamine Salts on Sleep: A Double-Blind, Randomized, Crossover Study in Youth with Attention-Deficit Hyperactivity Disorder","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"National Center for Research Resources; University of Illinois at Chicago; Shire; Pfizer","keywords":"Placebo; Attention deficit hyperactivity disorder; Actigraphy; Crossover study; Randomized controlled trial; Medicine; Methylphenidate; Child and adolescent psychiatry; Psychology; Pediatrics; Psychiatry; Physical therapy; Internal medicine; Insomnia","score_opus":0.016511864475409747,"score_gpt":0.302332137416213,"score_spread":0.28582027294080325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975745615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954775,0.0013562727,0.00040289736,0.00012161764,0.00029143743,0.0013713952,0.00044389284,0.000067774454,0.00046718906],"genre_scores_gemma":[0.99101967,0.0018513198,0.0014528979,0.00031109448,0.00046086928,0.0026716434,0.00057282206,0.00003485407,0.001624824],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99880624,0.0005025496,0.00013934074,0.00024726772,0.00011208992,0.00019265733],"domain_scores_gemma":[0.9982497,0.00047101724,0.00024514546,0.00018071654,0.00014294397,0.0007105225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015547577,0.0018320829,0.0060626687,0.00077220035,0.00080739125,0.0008825072,0.001650171,0.0020552354,0.004559504],"category_scores_gemma":[0.0020847348,0.0013517316,0.0016945517,0.00069081166,0.0020626003,0.0017255554,0.00074027525,0.0032623797,0.00074069656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98105407,0.010633185,0.0003447551,0.0002064785,0.00034066613,0.00001699012,0.00004608529,0.00008399685,0.0020220426,0.000026351678,0.00011824947,0.0051070205],"study_design_scores_gemma":[0.8722344,0.12333017,0.002788078,0.000017080749,0.000416153,0.000019444886,0.00003950621,0.00029301865,0.00058069837,0.00005275913,0.0002083071,0.000020452186],"about_ca_topic_score_codex":0.0031531292,"about_ca_topic_score_gemma":0.004974992,"teacher_disagreement_score":0.0060626687,"about_ca_system_score_codex":0.0009286033,"about_ca_system_score_gemma":0.0017213975,"threshold_uncertainty_score":0.015253127},"labels":[],"label_agreement":null},{"id":"W1977367905","doi":"10.2165/11318660-000000000-00000","title":"Agomelatine","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"St. Jude Medical","keywords":"Agomelatine; Clinical Global Impression; Tolerability; Venlafaxine; Antidepressant; Placebo; Medicine; Major depressive disorder; Internal medicine; Pharmacotherapy; Psychology; Psychiatry; Mood; Anxiety; Adverse effect","score_opus":0.05068819814957893,"score_gpt":0.3752197086533771,"score_spread":0.3245315105037982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977367905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067120575,0.99409795,0.0002230317,0.00025212884,0.00026215526,0.000024546067,0.00009507556,0.000035124922,0.0043388098],"genre_scores_gemma":[0.0065744394,0.98630667,0.0006406207,0.00080716045,0.00016070368,0.00002829364,0.00025280358,0.000006451275,0.005222811],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999188,0.000013678108,0.000013798987,0.000022091173,0.000021536589,0.0000100421275],"domain_scores_gemma":[0.99993217,0.000025194578,0.000019040805,0.0000032001815,0.000011389253,0.000008904098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017150056,0.00082007627,0.0014029566,0.0015358581,0.00020430304,0.0005575353,0.0007248344,0.0006270688,0.009385809],"category_scores_gemma":[0.0002964078,0.00023829938,0.00054987316,0.0011348617,0.00023463192,0.0005206001,0.0004782403,0.0013182762,0.0031463096],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036648105,0.0001281352,0.00017150767,0.01456827,0.0002545608,0.0002551008,0.000024595902,0.00015766356,0.0028893838,0.0006956379,0.02294484,0.95754373],"study_design_scores_gemma":[0.00059192727,0.0004998256,0.0034756486,0.0046787225,0.0013046684,0.0036922654,0.000048163034,0.00020122148,0.002325366,0.0010957487,0.98204833,0.000038113107],"about_ca_topic_score_codex":0.001942487,"about_ca_topic_score_gemma":0.0065126712,"teacher_disagreement_score":0.009385809,"about_ca_system_score_codex":0.0003396714,"about_ca_system_score_gemma":0.0005575524,"threshold_uncertainty_score":0.031398594},"labels":[],"label_agreement":null},{"id":"W1979036437","doi":"10.2165/00023210-200822070-00003","title":"Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Parkinson's UK; Valeant Pharmaceuticals International","keywords":"Ropinirole; Pramipexole; Rasagiline; Medicine; Levodopa; Parkinson's disease; Quality of life (healthcare); Clinical trial; Selegiline; Disease; Psychology; Physical medicine and rehabilitation; Internal medicine","score_opus":0.05992035562253328,"score_gpt":0.38266966703549743,"score_spread":0.32274931141296415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979036437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031973302,0.9989716,0.000028294957,0.00013102047,0.00004550149,0.0000021281407,0.000016992257,0.0000016654724,0.0004831606],"genre_scores_gemma":[0.0028921661,0.9965527,0.00011947025,0.00015930619,0.00008884442,0.000004609251,0.000028613802,4.165118e-7,0.0001539401],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99980575,0.00004176778,0.000038893482,0.00002439569,0.00007317552,0.000016037595],"domain_scores_gemma":[0.999561,0.00024383754,0.000108919005,0.000004884843,0.000062498024,0.000018830333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053668185,0.00053052447,0.0019074222,0.0011113791,0.00013886078,0.00052974373,0.0004998044,0.00061486475,0.0022987123],"category_scores_gemma":[0.000793283,0.00014557259,0.00088366953,0.0013117153,0.00020597049,0.00050073786,0.00030679043,0.0008584097,0.0003280381],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040823975,0.00010299518,0.0009584503,0.021341674,0.0007908592,0.00018922065,0.000035681904,0.00023499914,0.0005492806,0.00065052445,0.009217364,0.9655207],"study_design_scores_gemma":[0.00096287095,0.0015585565,0.051265538,0.045849722,0.009338422,0.006045007,0.00035740092,0.000902856,0.0012509519,0.003607044,0.878752,0.00010963811],"about_ca_topic_score_codex":0.0016311031,"about_ca_topic_score_gemma":0.0047911955,"teacher_disagreement_score":0.0022987123,"about_ca_system_score_codex":0.00047891954,"about_ca_system_score_gemma":0.0005938162,"threshold_uncertainty_score":0.007689953},"labels":[],"label_agreement":null},{"id":"W1980903742","doi":"10.2165/00023210-200721060-00006","title":"Impact of Psychotropic Medications on Simulated Driving","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Older Adults Driving Studies","field":"Health Professions","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"PsycINFO; Psychotropic drug; Medicine; Poison control; Driving simulator; Injury prevention; MEDLINE; Human factors and ergonomics; Population; Psychiatry; Physical medicine and rehabilitation; Emergency medicine; Simulation; Drug; Computer science","score_opus":0.1407989081027825,"score_gpt":0.5623821765905959,"score_spread":0.42158326848781336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980903742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016590601,0.9976659,0.000018665076,0.000069671674,0.00005737089,0.000017900367,0.00012358381,0.000001924744,0.0003859283],"genre_scores_gemma":[0.009518047,0.99010426,0.000087250555,0.000088411995,0.00003393057,0.000012645815,0.00006630669,6.779926e-7,0.000088467394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992587,0.00022181509,0.00022352069,0.00007206586,0.00019515709,0.000028868362],"domain_scores_gemma":[0.9967327,0.0023955358,0.0005178444,0.00004007784,0.00026551232,0.000048326423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013505631,0.0006201226,0.002146984,0.0018276871,0.00019939424,0.0007487679,0.0007528953,0.00065588043,0.0032376675],"category_scores_gemma":[0.005861392,0.0002976728,0.0027908233,0.002241671,0.00022856245,0.0004203033,0.0004556915,0.00055824046,0.00019336797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014935359,0.00017619465,0.00418582,0.3424437,0.012850289,0.00025013046,0.00016889587,0.0004684247,0.00041236295,0.00022034551,0.005769197,0.63156104],"study_design_scores_gemma":[0.0025178057,0.004069724,0.11316178,0.36179918,0.16670817,0.002737689,0.001310917,0.00058367196,0.0021319743,0.0007798489,0.34402737,0.0001717846],"about_ca_topic_score_codex":0.010664423,"about_ca_topic_score_gemma":0.030332321,"teacher_disagreement_score":0.010664423,"about_ca_system_score_codex":0.00073685497,"about_ca_system_score_gemma":0.0019510513,"threshold_uncertainty_score":0.02120471},"labels":[],"label_agreement":null},{"id":"W1981711813","doi":"10.2165/00023210-200620010-00003","title":"Polytherapy in Bipolar Disorder","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"H. Lundbeck A/S; Eli Lilly and Company","keywords":"Bipolar disorder; Lamotrigine; Lithium (medication); Olanzapine; Treatment of bipolar disorder; Mania; Mood stabilizer; Quetiapine; Psychiatry; Psychology; Polypharmacy; Antipsychotic; Medicine; Atypical antipsychotic; Bipolar I disorder; Antidepressant; Mood; Fluoxetine; Internal medicine; Schizophrenia (object-oriented programming); Epilepsy; Anxiety","score_opus":0.02294556742025127,"score_gpt":0.32654263498281927,"score_spread":0.303597067562568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981711813","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015467918,0.9984773,0.000072593175,0.00010182129,0.00015534677,0.000007261488,0.000016173399,0.0000059174363,0.0010089764],"genre_scores_gemma":[0.0012841804,0.9971205,0.00021566737,0.0002627824,0.0001936156,0.000015348518,0.000028429366,0.0000016813597,0.0008778748],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99981946,0.00004411264,0.00004452957,0.000027493588,0.000048589012,0.000015739573],"domain_scores_gemma":[0.99969184,0.0001271029,0.00010618235,0.000010973136,0.000037231122,0.000026705578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041501303,0.0010000484,0.0018511844,0.0030399067,0.00036017966,0.00088076567,0.00069736916,0.0009415648,0.006565164],"category_scores_gemma":[0.00053695845,0.00032869205,0.00058706466,0.0028825346,0.00043315534,0.0010231156,0.00078951,0.001306338,0.0018577246],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016469829,0.00009785635,0.00014644029,0.022498213,0.00014575549,0.0002481352,0.00004788598,0.00012776781,0.0009800392,0.0007735326,0.022539295,0.9522304],"study_design_scores_gemma":[0.0002375124,0.00035191484,0.0032974326,0.01354991,0.0008948204,0.0041118697,0.00010794758,0.00018116683,0.0006189795,0.0013179922,0.9752922,0.000038328028],"about_ca_topic_score_codex":0.0014092092,"about_ca_topic_score_gemma":0.005849958,"teacher_disagreement_score":0.006565164,"about_ca_system_score_codex":0.00048858847,"about_ca_system_score_gemma":0.0008338947,"threshold_uncertainty_score":0.021962643},"labels":[],"label_agreement":null},{"id":"W1981954205","doi":"10.2165/11204820-000000000-00000","title":"Spotlight on Cerebrolysin in Dementia†","year":2010,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Neurological Disorders and Treatments","field":"Neuroscience","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cerebrolysin; Dementia; Medicine; Clinical trial; Placebo; Randomized controlled trial; Vascular dementia; Internal medicine; Disease; Pathology; Alternative medicine","score_opus":0.016491946130179354,"score_gpt":0.2528667359144064,"score_spread":0.23637478978422705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981954205","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010105541,0.8612605,0.00047469986,0.09284598,0.03576178,0.000018041981,0.00021261741,0.00005267576,0.008363208],"genre_scores_gemma":[0.014826361,0.79911995,0.0015091419,0.06967859,0.091121376,0.00007552318,0.00028626504,0.0000696586,0.023313109],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999468,0.00013166177,0.000084740124,0.00008191829,0.00012741555,0.000106382446],"domain_scores_gemma":[0.9975333,0.0010412313,0.00019503315,0.00008734275,0.00078813516,0.0003549097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021438622,0.000883133,0.0018416545,0.0013225361,0.0008352677,0.002133115,0.00082753133,0.005146626,0.009804223],"category_scores_gemma":[0.0023026995,0.0002766805,0.00050809985,0.0012541817,0.0015877336,0.0038233395,0.0012276132,0.0055985986,0.004180284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014813411,0.0001377768,0.00024708724,0.0028555763,0.0000430163,0.00028360856,0.000058629957,0.000112401154,0.0025990165,0.010088088,0.56036097,0.4217324],"study_design_scores_gemma":[0.0002955968,0.0005440482,0.0007655219,0.0011232399,0.00007622908,0.0005395692,0.000090726004,0.00014010703,0.0009542468,0.007257637,0.9881803,0.00003284387],"about_ca_topic_score_codex":0.0016865861,"about_ca_topic_score_gemma":0.0036202027,"teacher_disagreement_score":0.009804223,"about_ca_system_score_codex":0.001163239,"about_ca_system_score_gemma":0.0026576598,"threshold_uncertainty_score":0.03279841},"labels":[],"label_agreement":null},{"id":"W1986575050","doi":"10.1007/s40263-014-0170-6","title":"Changes in Gait Variability with Anti-dementia Drugs: A Systematic Review and Meta-analysis","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Balance, Gait, and Falls Prevention","field":"Health Professions","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dementia; Memantine; Meta-analysis; Galantamine; Medicine; Donepezil; Gait; Delirium; Strictly standardized mean difference; Confidence interval; Physical medicine and rehabilitation; Psychology; Psychiatry; Physical therapy; Disease; Internal medicine","score_opus":0.06437633476044347,"score_gpt":0.3955352433222,"score_spread":0.33115890856175656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986575050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007446263,0.9916174,0.0002441499,0.00007338496,0.000107362015,0.000120882,0.00025401893,0.000012012187,0.0001245749],"genre_scores_gemma":[0.17159812,0.82487553,0.0015542926,0.0006231355,0.00018584529,0.00039246687,0.00045231113,0.000013259444,0.00030501827],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971209,0.00090417074,0.0010464909,0.00043639462,0.00035129153,0.00014077248],"domain_scores_gemma":[0.99528015,0.0029970089,0.0010408708,0.0001770178,0.0004127245,0.000092250826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046356926,0.0022001276,0.014618822,0.0029949495,0.00056398945,0.0019086719,0.0014712744,0.001813418,0.0024780864],"category_scores_gemma":[0.012373815,0.001180855,0.023760464,0.004544711,0.0005810404,0.0012387737,0.0012843569,0.0016931873,0.0002011842],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045074117,0.000097029326,0.005735253,0.34025988,0.62486464,0.0001668829,0.0001043155,0.00035397103,0.00032578286,0.00007504727,0.00063879025,0.022870915],"study_design_scores_gemma":[0.0010330572,0.00030250865,0.0068143103,0.011654698,0.9784999,0.000116500414,0.00006063984,0.000094514566,0.00009315368,0.0000913021,0.0012117536,0.000027608381],"about_ca_topic_score_codex":0.007233401,"about_ca_topic_score_gemma":0.022124656,"teacher_disagreement_score":0.014618822,"about_ca_system_score_codex":0.0014928686,"about_ca_system_score_gemma":0.001942341,"threshold_uncertainty_score":0.024516165},"labels":[],"label_agreement":null},{"id":"W1989649280","doi":"10.2165/00023210-200721010-00004","title":"Pharmacological Management of Attention-Deficit Hyperactivity Disorder in Adolescents","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"Pfizer","keywords":"Evening; Discontinuation; Methylphenidate; Attention deficit hyperactivity disorder; Comorbidity; Psychiatry; Stimulant; Psychology; Atomoxetine; Medicine; Clinical psychology; Pediatrics","score_opus":0.07513405611314446,"score_gpt":0.40225640376968713,"score_spread":0.3271223476565427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989649280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000167011,0.9990771,0.000089624686,0.00009154659,0.000091044225,0.000005160998,0.000012651231,0.000005725073,0.00046018456],"genre_scores_gemma":[0.0009970196,0.99818134,0.00026030882,0.0001542511,0.000110346526,0.0000062769577,0.000025186804,0.0000010392545,0.0002642034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983454,0.000027982154,0.00003761663,0.000028831664,0.000058427482,0.000012578395],"domain_scores_gemma":[0.9996624,0.0001726079,0.00008389988,0.0000055533533,0.000052135176,0.000023486149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040434868,0.0007525162,0.0018226876,0.002042375,0.00019284045,0.0006552678,0.00092596875,0.0007468751,0.002029114],"category_scores_gemma":[0.0006718122,0.00026694196,0.00066997885,0.0014285458,0.00024992306,0.0006292153,0.00037098472,0.0014218728,0.00070512533],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012098125,0.00013061434,0.00032998194,0.021492915,0.00026887158,0.0003691888,0.00003396184,0.00029097302,0.0009791588,0.0005315523,0.014413375,0.9610385],"study_design_scores_gemma":[0.00033627925,0.0005256727,0.0075940504,0.02147247,0.0020109185,0.008110458,0.00016535072,0.00054000923,0.0011470808,0.0011088414,0.95693105,0.00005783723],"about_ca_topic_score_codex":0.0022344622,"about_ca_topic_score_gemma":0.005763074,"teacher_disagreement_score":0.0022344622,"about_ca_system_score_codex":0.00041374206,"about_ca_system_score_gemma":0.00070025754,"threshold_uncertainty_score":0.006788075},"labels":[],"label_agreement":null},{"id":"W1989957365","doi":"10.2165/11530220-000000000-00000","title":"Medical Management of Lennox-Gastaut Syndrome","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Lennox–Gastaut syndrome; Lamotrigine; Topiramate; Felbamate; Epilepsy; Medicine; Vigabatrin; Dravet syndrome; Seizure types; Pediatrics; Epilepsy syndromes; Anticonvulsant; Adjunctive treatment; Ketogenic diet; Psychiatry; Anesthesia; Psychology; Internal medicine","score_opus":0.03815240175996676,"score_gpt":0.37968651696910316,"score_spread":0.3415341152091364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989957365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016165663,0.99909425,0.000077686214,0.00011459106,0.00007707321,0.0000029786872,0.000011129336,0.000005061759,0.000455571],"genre_scores_gemma":[0.0018631936,0.9969702,0.00028842452,0.00028746994,0.0001968025,0.0000051202946,0.000040344356,0.0000017238535,0.0003467237],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998252,0.000031283766,0.000043584743,0.000028468443,0.00005889715,0.000012626123],"domain_scores_gemma":[0.999723,0.00014772211,0.00006895019,0.000005202541,0.00003550081,0.000019477528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034600086,0.0007089529,0.00180756,0.0022284277,0.0001939757,0.0005815241,0.00091209554,0.0007115025,0.0022599944],"category_scores_gemma":[0.00066126214,0.00022827368,0.00054169475,0.0013775969,0.00029220016,0.000743711,0.00039499244,0.001185744,0.0007122634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001681644,0.0000754883,0.00028766372,0.02262974,0.00026593535,0.00092439994,0.000030296002,0.00029266393,0.0011300166,0.0008663344,0.02166129,0.951668],"study_design_scores_gemma":[0.0003356284,0.00036436826,0.004775827,0.014912806,0.0016236386,0.014669639,0.00013561835,0.00047008385,0.0011441691,0.0015703203,0.95993555,0.000062318046],"about_ca_topic_score_codex":0.0010837337,"about_ca_topic_score_gemma":0.0028872753,"teacher_disagreement_score":0.0022599944,"about_ca_system_score_codex":0.00036727253,"about_ca_system_score_gemma":0.00054235087,"threshold_uncertainty_score":0.007560432},"labels":[],"label_agreement":null},{"id":"W1992472429","doi":"10.2165/00023210-200317090-00005","title":"Speed of Onset and Efficacy of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Zolmitriptan; Migraine; Medicine; Aura; Tolerability; Sumatriptan; Nasal spray; Anesthesia; Placebo; Migraine treatment; Headaches; Neurology; Adverse effect; Internal medicine; Surgery; Nasal administration; Agonist; Pharmacology","score_opus":0.023659572465400125,"score_gpt":0.3068186002694172,"score_spread":0.2831590278040171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992472429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932181,0.0057428004,0.0000651728,0.000033468223,0.000030324325,0.00003984146,0.00012698484,0.000003912714,0.00073935546],"genre_scores_gemma":[0.9975701,0.0019074476,0.00008319721,0.000031811564,0.00007077974,0.000013777871,0.00009762946,0.0000018096537,0.00022339317],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993476,0.00027064208,0.00011417108,0.000051155705,0.00016055362,0.000055824745],"domain_scores_gemma":[0.99463755,0.0030330243,0.0014901195,0.0002217192,0.000256092,0.00036150872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001657815,0.00024208183,0.0007673476,0.0005598411,0.00026297467,0.000390621,0.0002837643,0.00035552366,0.0014128112],"category_scores_gemma":[0.0075392197,0.0002185169,0.0005564436,0.0004650752,0.00034357354,0.0007218231,0.0001895921,0.0006201743,0.00022913021],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26412472,0.0056993547,0.5044796,0.0021318826,0.0024639065,0.0008528796,0.0013916147,0.0009944605,0.027286239,0.000620871,0.0009451791,0.18900919],"study_design_scores_gemma":[0.0055000004,0.06928634,0.91742563,0.0000698741,0.000950861,0.0011065324,0.00025482412,0.00049393385,0.0032465328,0.0001208694,0.0015103641,0.00003425626],"about_ca_topic_score_codex":0.0009831927,"about_ca_topic_score_gemma":0.0008605927,"teacher_disagreement_score":0.001657815,"about_ca_system_score_codex":0.00033431046,"about_ca_system_score_gemma":0.00031435164,"threshold_uncertainty_score":0.008767486},"labels":[],"label_agreement":null},{"id":"W1993556404","doi":"10.1007/s40263-014-0171-5","title":"Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; H. Lundbeck A/S; Canadian Network for Mood and Anxiety Treatments; GlaxoSmithKline; Servier; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Antidepressant; Major depressive disorder; Medicine; Randomized controlled trial; Depression (economics); Psychiatry; Clinical trial; Psychology; Internal medicine; Mood; Anxiety","score_opus":0.13009671777666748,"score_gpt":0.46305596167243873,"score_spread":0.33295924389577125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993556404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002482206,0.99933904,0.000044859007,0.00009742863,0.000048576785,0.0000066062307,0.000015979678,0.0000023098937,0.0001970569],"genre_scores_gemma":[0.002508973,0.99679846,0.00026205592,0.00019822945,0.000070663635,0.000010391265,0.000026775244,0.0000010367019,0.0001234746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970907,0.000075976706,0.00007077932,0.000054191536,0.000066132576,0.000023763607],"domain_scores_gemma":[0.99876666,0.00089438003,0.00018292732,0.000016663706,0.000105413324,0.000034060613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011232541,0.00075144996,0.0031469273,0.0010065545,0.00017002862,0.0011494741,0.0012491464,0.0011769683,0.0051044556],"category_scores_gemma":[0.0022954645,0.00027504904,0.0016417885,0.0011085438,0.00030032246,0.0009058426,0.00038602218,0.0016390184,0.0005566963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008308416,0.00019694238,0.0005779517,0.082783245,0.0011630738,0.00013464545,0.00006074319,0.0003156546,0.00060812314,0.0009966188,0.006463034,0.905869],"study_design_scores_gemma":[0.0030861204,0.0025618274,0.019234892,0.19208728,0.024489509,0.0038887833,0.0006783553,0.0011421265,0.0015559073,0.0069786743,0.7441326,0.00016391637],"about_ca_topic_score_codex":0.0016704664,"about_ca_topic_score_gemma":0.0060037686,"teacher_disagreement_score":0.0051044556,"about_ca_system_score_codex":0.0004973147,"about_ca_system_score_gemma":0.0010284637,"threshold_uncertainty_score":0.017076075},"labels":[],"label_agreement":null},{"id":"W1997515685","doi":"10.2165/00023210-200418001-00003","title":"Sociodemographic Profile of Insomniac Patients across National Surveys","year":2004,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Sleep and related disorders","field":"Psychology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Psychopharmacology; Medicine; MEDLINE; Psychology; Psychiatry; Clinical psychology; Political science","score_opus":0.013071866697118809,"score_gpt":0.30012676987453624,"score_spread":0.28705490317741744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997515685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981008,0.000087320215,0.00003644421,0.00006575611,0.0000042991664,0.000014836629,0.0010834677,0.000002646049,0.0006045692],"genre_scores_gemma":[0.99854136,0.00009666865,0.000042200725,0.00007623891,0.000005669083,0.00002014887,0.0009773509,0.0000015859894,0.00023880471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99953055,0.00010881892,0.00008619696,0.00005612303,0.00009388143,0.00012453303],"domain_scores_gemma":[0.99873906,0.00016440262,0.00047214396,0.000053614465,0.00023709451,0.00033372894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056679087,0.0001487698,0.00036401008,0.0012934924,0.0007002595,0.00046812097,0.00025644372,0.00042082806,0.001724299],"category_scores_gemma":[0.0020305533,0.0002211573,0.0003927278,0.0014403729,0.00026329205,0.0006081918,0.00071919913,0.00048894744,0.00025990405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049466315,0.000024541116,0.9990195,0.0000062262698,0.000016290167,0.0000195676,0.00014906467,0.000010151905,0.00007512518,0.000006697813,0.00010602525,0.0005173123],"study_design_scores_gemma":[0.0000012822729,0.000031353677,0.9993824,0.0000016564073,0.0000043299624,0.000045030563,0.00042868042,0.000018805182,0.000007824908,0.0000027006206,0.000074631724,0.0000013173677],"about_ca_topic_score_codex":0.026631646,"about_ca_topic_score_gemma":0.030933833,"teacher_disagreement_score":0.026631646,"about_ca_system_score_codex":0.00051263155,"about_ca_system_score_gemma":0.0005163114,"threshold_uncertainty_score":0.052953303},"labels":[],"label_agreement":null},{"id":"W2010260169","doi":"10.2165/0023210-200923010-00001","title":"Psychopharmacological Treatment of Oppositional Defiant Disorder","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psychopharmacology; Conduct disorder; Psychology; Psychotherapist; Neurology; Medicine; Psychiatry","score_opus":0.11637437986233445,"score_gpt":0.42922391749292177,"score_spread":0.3128495376305873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010260169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013847266,0.9988244,0.000081768325,0.00009287824,0.00012133041,0.000005265861,0.000016707698,0.0000070590177,0.0007121324],"genre_scores_gemma":[0.0011377246,0.99766505,0.00026823132,0.00024186922,0.00012660566,0.0000071882923,0.00003477286,0.0000018194756,0.0005168416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983287,0.00002770505,0.000034065968,0.000031430423,0.000059134945,0.0000147749115],"domain_scores_gemma":[0.9996482,0.00018778433,0.00007600911,0.000008665811,0.00005521776,0.000024171188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045759152,0.00092172256,0.002156799,0.0020219465,0.00022270199,0.00075413106,0.001087605,0.00094417366,0.004037341],"category_scores_gemma":[0.0007459725,0.00028589767,0.00067100313,0.0017834583,0.000352274,0.0007736226,0.0004357502,0.0016384498,0.0012432525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015845808,0.00012397833,0.00014598078,0.01972496,0.0002417663,0.00024668878,0.000032883778,0.00021599224,0.0010461237,0.000619732,0.01765532,0.95978814],"study_design_scores_gemma":[0.0003328543,0.00039432285,0.0034577274,0.01200731,0.0014129514,0.0041644485,0.00011153785,0.0002508611,0.00085659063,0.00102753,0.97594225,0.000041524396],"about_ca_topic_score_codex":0.0021149856,"about_ca_topic_score_gemma":0.0062374007,"teacher_disagreement_score":0.004037341,"about_ca_system_score_codex":0.00046452176,"about_ca_system_score_gemma":0.0006929361,"threshold_uncertainty_score":0.013506293},"labels":[],"label_agreement":null},{"id":"W2011191894","doi":"10.2165/11530250-000000000-00000","title":"Progress in Defining Optimal Treatment Outcome in Schizophrenia","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"National Institutes of Health; National Institute of Mental Health; Medicure; Eli Lilly and Company","keywords":"Conceptualization; Tolerability; Clozapine; Schizophrenia (object-oriented programming); Psychology; Quality of life (healthcare); Psychiatry; Cognition; Psychotherapist; Psychopharmacology; Medicine; Clinical psychology; Adverse effect","score_opus":0.0640252557170683,"score_gpt":0.39485922979359467,"score_spread":0.33083397407652637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011191894","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056202956,0.9994211,0.00006149508,0.00018329838,0.000042632033,0.0000026919413,0.000009218179,0.0000020824295,0.00022119307],"genre_scores_gemma":[0.00065687054,0.99884665,0.0002285907,0.0001317007,0.00005796978,0.0000043525956,0.0000127540825,6.778698e-7,0.00006038888],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993338,0.00019492007,0.00018127669,0.00008228812,0.00016333326,0.00004437113],"domain_scores_gemma":[0.9985379,0.0010367382,0.00019343873,0.000026110192,0.0001721617,0.000033716417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025052272,0.0011444902,0.004023055,0.0023794975,0.00032834252,0.0015288732,0.001178471,0.0012421771,0.0024925356],"category_scores_gemma":[0.003422608,0.00037443134,0.0013006384,0.003068461,0.0007223537,0.0013567132,0.00083384465,0.0017260662,0.000574373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016179275,0.00006076488,0.00033160934,0.036019705,0.00035865296,0.00008450297,0.000042062467,0.00033156047,0.00027114913,0.0035287295,0.009977112,0.9488323],"study_design_scores_gemma":[0.0003734434,0.00040637422,0.006224247,0.067797415,0.004259271,0.0017149914,0.00030949202,0.0004723818,0.0007576917,0.010328199,0.9072557,0.00010076152],"about_ca_topic_score_codex":0.005591677,"about_ca_topic_score_gemma":0.0107597355,"teacher_disagreement_score":0.005591677,"about_ca_system_score_codex":0.0016543258,"about_ca_system_score_gemma":0.0035231055,"threshold_uncertainty_score":0.013249099},"labels":[],"label_agreement":null},{"id":"W2012825205","doi":"10.2165/00023210-200317070-00001","title":"Vaccines for Alzheimer??s Disease","year":2003,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Genetically modified mouse; Disease; Amyloid precursor protein; Alzheimer's disease; Pathogenesis; Presenilin; Dementia; Amyloid (mycology); BACE1-AS; Transgene; Medicine; Neuroscience; Neurology; Pathology; Biology; Gene; Genetics","score_opus":0.09274854522922653,"score_gpt":0.4092834529539729,"score_spread":0.31653490772474635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012825205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001100554,0.99742764,0.00013927041,0.00037110524,0.00047785786,0.000015607657,0.00002485271,0.00000930655,0.0014243784],"genre_scores_gemma":[0.0006708214,0.9970625,0.00024967635,0.00035882057,0.00022335724,0.00001683475,0.000029561836,0.0000011967406,0.0013871986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998192,0.000037359794,0.00003481652,0.000021981507,0.00006346333,0.000023226],"domain_scores_gemma":[0.9996915,0.00012253497,0.00007909687,0.000010329324,0.000068320434,0.00002827897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084029586,0.001527368,0.002370535,0.0025506867,0.0003153503,0.0009115465,0.0006766423,0.0014379806,0.00537566],"category_scores_gemma":[0.0009404527,0.0003202494,0.0005305614,0.0019820575,0.00045776297,0.0013096718,0.0006270046,0.0017669348,0.00238936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018467952,0.00009244475,0.00008023279,0.015239267,0.0001009718,0.00018902338,0.000037371683,0.00022285379,0.0015338962,0.0019992352,0.048031684,0.9322884],"study_design_scores_gemma":[0.00009686354,0.00013250805,0.00034624248,0.0040777833,0.0002834186,0.0006703028,0.000030503226,0.000042898824,0.00048310083,0.0009127687,0.99291587,0.000007813462],"about_ca_topic_score_codex":0.00203756,"about_ca_topic_score_gemma":0.005722729,"teacher_disagreement_score":0.00537566,"about_ca_system_score_codex":0.0008872443,"about_ca_system_score_gemma":0.0016315093,"threshold_uncertainty_score":0.017983377},"labels":[],"label_agreement":null},{"id":"W2017931746","doi":"10.2165/00023210-200822040-00001","title":"Use of Smoking Cessation Therapies in Individuals with Psychiatric Illness","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Psychiatry; Medicine; Bupropion; Smoking cessation; Population; Psychological intervention; Mental illness; Nicotine replacement therapy; Mental health; Depression (economics); Medical prescription; Varenicline; Nicotine","score_opus":0.06734823777550802,"score_gpt":0.33724200484006217,"score_spread":0.26989376706455415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017931746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020563664,0.9986449,0.00007577396,0.00013425051,0.00009792927,0.0000053217864,0.000025787507,0.00000562871,0.00080471614],"genre_scores_gemma":[0.0014413494,0.9974848,0.0001956785,0.00022013781,0.00013797342,0.000008341868,0.00003452841,0.000001437071,0.00047580703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996929,0.00005294937,0.00006271688,0.00005491778,0.000117602445,0.000018987963],"domain_scores_gemma":[0.99896467,0.0005741765,0.00027481993,0.000020106436,0.00012231308,0.000043946155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006284901,0.00075983896,0.0020050472,0.0027483162,0.00022320665,0.00074684597,0.0009853466,0.0011631746,0.0037754406],"category_scores_gemma":[0.0015148037,0.00032453457,0.00079712144,0.0022791799,0.0002978735,0.00083629665,0.0004909348,0.0012691529,0.00091114367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012725209,0.00010337749,0.00050256244,0.022543924,0.00030653615,0.00012613831,0.000034570403,0.00014318255,0.00071729056,0.00031956835,0.010603123,0.96447253],"study_design_scores_gemma":[0.00022192429,0.00058269955,0.014029112,0.02577901,0.0033211433,0.0038739366,0.0001701762,0.00042188683,0.0011412888,0.00073473604,0.9496571,0.00006704138],"about_ca_topic_score_codex":0.0025020442,"about_ca_topic_score_gemma":0.010105629,"teacher_disagreement_score":0.0037754406,"about_ca_system_score_codex":0.00047927987,"about_ca_system_score_gemma":0.00093977456,"threshold_uncertainty_score":0.012630105},"labels":[],"label_agreement":null},{"id":"W2021985890","doi":"10.2165/00023210-200721090-00001","title":"Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Riverview Hospital; Simon Fraser University; University of British Columbia","funders":"","keywords":"Schizophrenia (object-oriented programming); Clinical trial; Psychiatry; Antipsychotic; Psychological intervention; Quality of life (healthcare); Medicine; Psychosis; Management of schizophrenia; Psychopharmacology; Psychology; Clinical psychology; Psychotherapist; Internal medicine","score_opus":0.7156904257415474,"score_gpt":0.6128598546362802,"score_spread":0.10283057110526717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021985890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028091788,0.9820417,0.007473009,0.0075848014,0.0013266212,0.00046768037,0.00006964155,0.000013943541,0.00074168446],"genre_scores_gemma":[0.026562767,0.907676,0.04298548,0.016137237,0.0033482139,0.0026641297,0.00017217203,0.000054378936,0.000399686],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.60704756,0.3361065,0.030482898,0.0056319945,0.019780384,0.0009506538],"domain_scores_gemma":[0.3233531,0.6385166,0.018551076,0.008928285,0.00981049,0.00084044464],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.30017042,0.002301022,0.01308214,0.0037464346,0.0014533238,0.008003664,0.0064057056,0.008576159,0.0025176841],"category_scores_gemma":[0.4725544,0.0021721066,0.0065985275,0.006022117,0.008954951,0.007625387,0.0033891988,0.009968472,0.0005407208],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020390477,0.000125692,0.0019979258,0.25537118,0.014645492,0.00019877116,0.00086243945,0.0025094051,0.00032122943,0.059072785,0.015262483,0.64759356],"study_design_scores_gemma":[0.006404806,0.0014922861,0.005659638,0.39609456,0.04876334,0.0016085389,0.0010427,0.0047157714,0.0011680683,0.25896236,0.2737291,0.0003588425],"about_ca_topic_score_codex":0.0033769913,"about_ca_topic_score_gemma":0.0073307133,"teacher_disagreement_score":0.6998296,"about_ca_system_score_codex":0.0071116583,"about_ca_system_score_gemma":0.017820282,"threshold_uncertainty_score":0.86301446},"labels":[],"label_agreement":null},{"id":"W2024978322","doi":"10.1007/s40263-013-0070-1","title":"The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital","funders":"","keywords":"Asenapine; Ziprasidone; Psychiatry; Medicine; Aripiprazole; Management of schizophrenia; Schizophrenia (object-oriented programming); Quality of life (healthcare); Paliperidone; Bipolar disorder; Antipsychotic; Pharmacoeconomics; Health care; Intensive care medicine; Mood; Nursing","score_opus":0.054409241382750044,"score_gpt":0.394740900139156,"score_spread":0.340331658756406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024978322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019917962,0.9995478,0.000014641852,0.00005489551,0.000027393402,0.000001983208,0.000017935638,0.0000010243788,0.00013508539],"genre_scores_gemma":[0.002000737,0.9977533,0.00006539158,0.00007634981,0.00003793091,0.0000025056922,0.000016597847,3.9245216e-7,0.000046812027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994925,0.000115408766,0.00014677946,0.000055157532,0.0001623418,0.000027643819],"domain_scores_gemma":[0.9982541,0.0010733991,0.00041110546,0.00001925553,0.00019587816,0.000046183955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013724366,0.0006970167,0.0024557658,0.0018130057,0.00016111799,0.00079894956,0.00085296156,0.0006622732,0.0024527595],"category_scores_gemma":[0.0027311784,0.0002766723,0.001634517,0.002243707,0.0003188544,0.0006600671,0.0005577902,0.0010367932,0.00021129023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055076275,0.000090605216,0.0012624736,0.07770566,0.0021640188,0.00014235618,0.00007134387,0.00036794337,0.00049099553,0.0005833589,0.0068920106,0.90967834],"study_design_scores_gemma":[0.0012905785,0.0017864896,0.05312092,0.14928602,0.03388577,0.003601109,0.00065709336,0.000993283,0.0014160423,0.0037647504,0.7499657,0.00023219746],"about_ca_topic_score_codex":0.0046927626,"about_ca_topic_score_gemma":0.014161111,"teacher_disagreement_score":0.0046927626,"about_ca_system_score_codex":0.0008071674,"about_ca_system_score_gemma":0.0012698149,"threshold_uncertainty_score":0.009330869},"labels":[],"label_agreement":null},{"id":"W2025609969","doi":"10.2165/00023210-200317110-00005","title":"Tolerability and Consistency of Effect of Zolmitriptan Nasal Spray in a Long-Term Migraine Treatment Trial","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Zolmitriptan; Medicine; Tolerability; Nasal spray; Migraine; Anesthesia; Adverse effect; Crossover study; Sumatriptan; Placebo; Neurology; Migraine treatment; Headaches; Aura; Clinical trial; Nasal administration; Internal medicine; Surgery; Pharmacology","score_opus":0.01741955514908747,"score_gpt":0.3084012574985081,"score_spread":0.2909817023494206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025609969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687636,0.0021251342,0.00010713509,0.000087980894,0.000048175447,0.0001545409,0.00027984518,0.000010357111,0.0003105149],"genre_scores_gemma":[0.9985208,0.0005391975,0.000120162564,0.000095184136,0.00009179374,0.000118661635,0.00030641077,0.0000042479496,0.00020359778],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633527,0.0021712484,0.00047099928,0.00035663816,0.00043909287,0.00022665443],"domain_scores_gemma":[0.992477,0.003061985,0.002384639,0.0007640507,0.0005401409,0.00077230175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069096144,0.00079722394,0.0026737396,0.00045053542,0.00067027356,0.00085456704,0.0007990645,0.0010573822,0.0023482877],"category_scores_gemma":[0.009487497,0.00049921015,0.0024841854,0.0006463576,0.0010254575,0.0015000677,0.0004939888,0.0016223907,0.00029721286],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92632484,0.0042034853,0.032849614,0.00068244495,0.008505745,0.00018642325,0.00043548577,0.000447851,0.00632675,0.00006901227,0.00039427713,0.019574042],"study_design_scores_gemma":[0.3350565,0.33335382,0.31399283,0.000110091096,0.010954214,0.0004984004,0.00040866685,0.0013559988,0.0027731522,0.00019166675,0.0011553193,0.00014935351],"about_ca_topic_score_codex":0.0012619422,"about_ca_topic_score_gemma":0.0019286135,"teacher_disagreement_score":0.0069096144,"about_ca_system_score_codex":0.0010616942,"about_ca_system_score_gemma":0.00068843877,"threshold_uncertainty_score":0.03654194},"labels":[],"label_agreement":null},{"id":"W2025802145","doi":"10.2165/0023210-200822120-00007","title":"Classifying Antipsychotic Agents","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tolerability; Antipsychotic; Psychopharmacology; Antipsychotic Agent; Atypical antipsychotic; Medicine; Pharmacology; Schizophrenia (object-oriented programming); Adverse effect; Psychology; Psychiatry","score_opus":0.14317742840228587,"score_gpt":0.41812196690521936,"score_spread":0.2749445385029335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025802145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028034888,0.99377877,0.00041704034,0.0006111741,0.0009970674,0.000056308447,0.00017973446,0.00002969993,0.0036498907],"genre_scores_gemma":[0.0012713579,0.9933211,0.0011790883,0.0009064876,0.0005348826,0.000038322712,0.00026039072,0.0000054750367,0.0024827565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991412,0.00014327056,0.00026619073,0.00011193841,0.00025832563,0.00007904406],"domain_scores_gemma":[0.9989581,0.00026138537,0.00037798504,0.00004277829,0.00030114062,0.0000585126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010275216,0.0022705412,0.0035079028,0.008225355,0.00034646626,0.0018131187,0.001319937,0.0012713573,0.007367618],"category_scores_gemma":[0.0022444865,0.0005184569,0.0012477415,0.0061708866,0.0008160057,0.002811018,0.0013620154,0.001578422,0.004956299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014308371,0.000048411683,0.00027007714,0.026285132,0.00013810459,0.000120322184,0.000054731005,0.00015482167,0.001267588,0.0019931728,0.032674074,0.9368505],"study_design_scores_gemma":[0.00009314832,0.00018865927,0.0017547193,0.020804984,0.0006893693,0.001066482,0.00010185706,0.00014694605,0.0005772341,0.0019042057,0.9726457,0.000026750737],"about_ca_topic_score_codex":0.0032788431,"about_ca_topic_score_gemma":0.007566717,"teacher_disagreement_score":0.008225355,"about_ca_system_score_codex":0.0013859419,"about_ca_system_score_gemma":0.0033113067,"threshold_uncertainty_score":0.024647117},"labels":[],"label_agreement":null},{"id":"W2033466502","doi":"10.2165/00023210-200822050-00003","title":"Burden of Bipolar Depression","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Bipolar disorder; Hypomania; Mania; Psychiatry; Psychology; Mood; Depression (economics); Quality of life (healthcare); Anxiety; Clinical psychology; Treatment of bipolar disorder; Prevalence of mental disorders; Schizophrenia (object-oriented programming); Psychotherapist","score_opus":0.031076717555406246,"score_gpt":0.32448693635578485,"score_spread":0.2934102188003786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033466502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018559396,0.9988851,0.000027919268,0.000223032,0.00008907036,0.00000224691,0.000031474618,0.0000022865834,0.00055329286],"genre_scores_gemma":[0.0018801838,0.99744606,0.00007725053,0.00020505568,0.00013640024,0.0000028306401,0.000041779545,4.7477977e-7,0.00020990442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964523,0.000085135005,0.00006348824,0.00004682008,0.00013589922,0.000023445196],"domain_scores_gemma":[0.9995441,0.00015859447,0.00016583367,0.0000087400995,0.00009201707,0.000030723982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006700117,0.00063576695,0.0017379433,0.002092453,0.00015552256,0.0010644662,0.0005398837,0.0007695048,0.003913195],"category_scores_gemma":[0.0010716119,0.00030598772,0.00079739187,0.0025321576,0.00021261351,0.0007568121,0.000538715,0.00081658637,0.00081470195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021251502,0.00003485056,0.0010096268,0.028519157,0.0005531003,0.00013215406,0.000049353977,0.00015934606,0.0004822782,0.0008653496,0.024663728,0.9433186],"study_design_scores_gemma":[0.00025454818,0.0004336734,0.028816685,0.043127973,0.0040771915,0.0040417104,0.00030421384,0.000359886,0.0004083651,0.002393107,0.91572714,0.000055514323],"about_ca_topic_score_codex":0.0035305056,"about_ca_topic_score_gemma":0.010195244,"teacher_disagreement_score":0.003913195,"about_ca_system_score_codex":0.00058718305,"about_ca_system_score_gemma":0.0012700212,"threshold_uncertainty_score":0.0130909085},"labels":[],"label_agreement":null},{"id":"W2033814944","doi":"10.2165/00023210-200822060-00005","title":"Intermittent Subcutaneous Apomorphine Therapy for ???Off??? Episodes in Parkinson??s Disease","year":2008,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Tolerability; Apomorphine; Medicine; Parkinson's disease; Anesthesia; Adverse effect; Outpatient clinic; Internal medicine; Disease; Physical therapy; Dopamine; Dopaminergic","score_opus":0.025429063344204098,"score_gpt":0.2721094218536344,"score_spread":0.24668035850943032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033814944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9229285,0.047635224,0.0024575666,0.003232637,0.0008277034,0.00011070029,0.0002544382,0.00020928915,0.022343958],"genre_scores_gemma":[0.9889438,0.006453207,0.0010431409,0.00056258455,0.0003782118,0.000026572214,0.00013833614,0.000010451748,0.0024436533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993026,0.00001887082,0.0000132935365,0.0000071961595,0.00001708409,0.000013268447],"domain_scores_gemma":[0.99984,0.000048905862,0.00003500645,0.00000986796,0.0000112619155,0.000054889886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015620903,0.00021196053,0.0003833965,0.00023050474,0.00023479418,0.000178448,0.00026307272,0.0003851907,0.0021259573],"category_scores_gemma":[0.0005197451,0.000059639504,0.0002389111,0.00018598745,0.00016989817,0.00022206016,0.00013618026,0.0006549094,0.000331921],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013632082,0.0018459957,0.022703676,0.0011362144,0.00040968775,0.010793207,0.00027685513,0.00031248384,0.025195682,0.0007881109,0.010398561,0.9125075],"study_design_scores_gemma":[0.011509115,0.04517773,0.6749008,0.0012487272,0.0012079958,0.11786412,0.00090165605,0.0056789694,0.020117138,0.003783886,0.11746382,0.00014595884],"about_ca_topic_score_codex":0.00062167656,"about_ca_topic_score_gemma":0.002367456,"teacher_disagreement_score":0.0021259573,"about_ca_system_score_codex":0.00019905498,"about_ca_system_score_gemma":0.00018464666,"threshold_uncertainty_score":0.007112026},"labels":[],"label_agreement":null},{"id":"W2035426363","doi":"10.2165/00023210-200721120-00004","title":"Role of the Melatonin System in the Control of Sleep","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Melatonin; Circadian rhythm; Dark therapy; Agomelatine; Suprachiasmatic nucleus; Internal medicine; Endocrinology; Insomnia; Delayed sleep phase; Hypnotic; Pineal gland; Melatonin receptor; Free-running sleep; Light effects on circadian rhythm; Sleep disorder; Psychology; Medicine; Pharmacology; Hippocampus; Antidepressant","score_opus":0.027649189449893023,"score_gpt":0.283628599143557,"score_spread":0.25597940969366395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035426363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009959082,0.9983038,0.00017746552,0.00019211577,0.00032356512,0.0000033951105,0.0000104366545,0.000005915111,0.0008836967],"genre_scores_gemma":[0.0005181264,0.9982503,0.00021031663,0.00009742426,0.0003436389,0.000004068999,0.000015415844,9.346059e-7,0.00055972487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998838,0.000015727384,0.000021359723,0.000024421593,0.000043015367,0.000011649108],"domain_scores_gemma":[0.9997086,0.000121372635,0.00005128797,0.000011322104,0.000071519564,0.00003591979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005673087,0.0011334313,0.0013963113,0.001626875,0.0003366632,0.0010386014,0.00113447,0.0011015502,0.0028311915],"category_scores_gemma":[0.0005530527,0.00027262102,0.00034859512,0.002302931,0.0007260325,0.0014484099,0.00072442763,0.0017586186,0.0018920836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001301183,0.00007056964,0.00020950528,0.008897523,0.00007937877,0.00034705986,0.000051627532,0.00045858434,0.003451358,0.0036285142,0.029437896,0.95323783],"study_design_scores_gemma":[0.000025197012,0.00008494516,0.0011469162,0.0015218868,0.000098254444,0.0013170292,0.00006725524,0.00011672834,0.0006572376,0.0025171568,0.9924291,0.000018440049],"about_ca_topic_score_codex":0.0015167219,"about_ca_topic_score_gemma":0.003290972,"teacher_disagreement_score":0.0028311915,"about_ca_system_score_codex":0.00069508736,"about_ca_system_score_gemma":0.0011525836,"threshold_uncertainty_score":0.009471297},"labels":[],"label_agreement":null},{"id":"W2035993893","doi":"10.2165/11599560-000000000-00000","title":"Depression Following Traumatic Brain Injury","year":2012,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Traumatic Brain Injury Research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Traumatic brain injury; Depression (economics); Medicine; Psychosocial; Psychiatry; Concussion; Neurology; Poison control; Comorbidity; Psychopharmacology; Psychology; Injury prevention; Clinical psychology","score_opus":0.18579872070985756,"score_gpt":0.44816357693944464,"score_spread":0.26236485622958705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035993893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009538187,0.9993019,0.000023317112,0.00010738655,0.00010282127,0.0000059038393,0.00001828597,0.0000017498344,0.00034318434],"genre_scores_gemma":[0.0009979362,0.99836093,0.000054089047,0.0001858071,0.00013134109,0.0000073089886,0.00002419688,4.0796752e-7,0.00023792373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997669,0.00005280528,0.000070188384,0.000032900018,0.00005790031,0.00001929663],"domain_scores_gemma":[0.9994686,0.00022968127,0.00019758813,0.000012844649,0.00006424322,0.000027132312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054070225,0.0009559436,0.0020856457,0.0026228775,0.0002429172,0.0009919121,0.0008267557,0.00089757884,0.0044759293],"category_scores_gemma":[0.00135157,0.00032116025,0.00080610934,0.0030071838,0.00040955085,0.0008324598,0.00072932715,0.0009891423,0.00090613955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022699444,0.00010351838,0.00031455752,0.07203949,0.00062127376,0.00020228175,0.000044239125,0.00011837921,0.0006163467,0.0005098824,0.026628826,0.8985742],"study_design_scores_gemma":[0.0006194952,0.00076869346,0.010287207,0.064774655,0.006080089,0.005527427,0.00029956587,0.00024066154,0.00087223336,0.0019494293,0.90849644,0.00008422193],"about_ca_topic_score_codex":0.0019656827,"about_ca_topic_score_gemma":0.0072479267,"teacher_disagreement_score":0.0044759293,"about_ca_system_score_codex":0.0005122718,"about_ca_system_score_gemma":0.0012921268,"threshold_uncertainty_score":0.014973462},"labels":[],"label_agreement":null},{"id":"W2036605937","doi":"10.1007/s40263-013-0080-z","title":"Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Teriflunomide; Fingolimod; Tolerability; Medicine; Relapsing remitting; Cladribine; Multiple sclerosis; Dimethyl fumarate; Clinical trial; Neurology; Adverse effect; Intensive care medicine; Internal medicine; Immunology; Psychiatry","score_opus":0.16802789843083926,"score_gpt":0.38202515296350203,"score_spread":0.21399725453266277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036605937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027888594,0.9994785,0.000028284758,0.000034740155,0.000017474744,0.000005778386,0.000023512035,0.0000017199894,0.00013122693],"genre_scores_gemma":[0.0022127482,0.9974291,0.00013829084,0.000070488444,0.000028039969,0.0000074302984,0.000027404116,7.100762e-7,0.000085786676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999468,0.00011972906,0.00015624805,0.000063290325,0.00016980682,0.000023035513],"domain_scores_gemma":[0.99872106,0.00081074843,0.00028715347,0.00001826466,0.00013455198,0.000028210758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016467167,0.0007610179,0.003568218,0.002156371,0.00018839104,0.000849524,0.0009984799,0.0008604024,0.002459014],"category_scores_gemma":[0.0022044647,0.00030073215,0.0015052983,0.0024167565,0.000427924,0.00070545735,0.00042269318,0.0011222188,0.0003360589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007918682,0.00011026557,0.00037059947,0.14828993,0.0016130834,0.00013217944,0.00008140047,0.00023642812,0.0014975423,0.0006095306,0.0057161264,0.8405509],"study_design_scores_gemma":[0.0022956782,0.002695735,0.016953563,0.14715281,0.031605873,0.0040461137,0.0006860047,0.0005805084,0.00566029,0.0030871318,0.78503704,0.00019933398],"about_ca_topic_score_codex":0.001978162,"about_ca_topic_score_gemma":0.0041193315,"teacher_disagreement_score":0.003568218,"about_ca_system_score_codex":0.00050040334,"about_ca_system_score_gemma":0.0010542058,"threshold_uncertainty_score":0.008708775},"labels":[],"label_agreement":null},{"id":"W2039589814","doi":"10.2165/00023210-200519020-00001","title":"Do Atypical Antipsychotics Cause Stroke?","year":2005,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Olanzapine; Risperidone; Medicine; Dementia; Adverse effect; Stroke (engine); Delirium; Incidence (geometry); Psychiatry; Internal medicine; Pediatrics; Schizophrenia (object-oriented programming)","score_opus":0.07937219987630402,"score_gpt":0.4347318961158408,"score_spread":0.3553596962395368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039589814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008165758,0.9992454,0.000023657703,0.00024064533,0.000118988755,0.000003330906,0.000016639178,0.0000023219545,0.00026732392],"genre_scores_gemma":[0.0007737375,0.99855596,0.000064045395,0.0002772351,0.00012877074,0.000004613824,0.000013934003,4.4290655e-7,0.00018121835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995047,0.000112433154,0.00016523153,0.000055148103,0.0001319994,0.000030469097],"domain_scores_gemma":[0.9986218,0.0006759871,0.00044056168,0.000026554575,0.00018913478,0.000045918874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013758084,0.0012672112,0.00421747,0.0030833578,0.00034923843,0.0012348449,0.0010174846,0.0021295594,0.0045050085],"category_scores_gemma":[0.0030353637,0.00053003186,0.0014763824,0.0029514579,0.0005613284,0.0014113298,0.0006233717,0.0012445551,0.0010479664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004075825,0.000064368054,0.0006045433,0.06202839,0.0010169483,0.00042316708,0.00006952848,0.00017231733,0.0004047124,0.00081422296,0.027888296,0.9061058],"study_design_scores_gemma":[0.00073813763,0.00057890825,0.008223035,0.059301667,0.010232791,0.0044628913,0.00036635212,0.0002367586,0.00063719763,0.0032797514,0.9118636,0.0000789551],"about_ca_topic_score_codex":0.004608837,"about_ca_topic_score_gemma":0.017521381,"teacher_disagreement_score":0.004608837,"about_ca_system_score_codex":0.0010762798,"about_ca_system_score_gemma":0.0023616136,"threshold_uncertainty_score":0.015070736},"labels":[],"label_agreement":null},{"id":"W2041110161","doi":"10.2165/11539530-000000000-00000","title":"The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"H. Lundbeck A/S; Pfizer","keywords":"Galantamine; Rivastigmine; Donepezil; Memantine; Medicine; Disease; Dementia; Alzheimer's disease; Pharmacoeconomics; Population; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.313348912749973,"score_gpt":0.4904148973609592,"score_spread":0.17706598461098622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041110161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000295307,0.9990495,0.00006670289,0.00027905457,0.000034623492,0.000004462074,0.00002837978,0.0000013090765,0.00024068422],"genre_scores_gemma":[0.006033341,0.9932284,0.00023092453,0.00024398054,0.00011236088,0.000010826203,0.00004077079,9.767045e-7,0.00009852093],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.999223,0.00033033037,0.000121838435,0.00005573698,0.0002346111,0.000034355362],"domain_scores_gemma":[0.997235,0.0020839304,0.00043073908,0.000024791245,0.00018376115,0.000041774572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002184126,0.00059138105,0.002484515,0.0016148038,0.00012928518,0.0008597317,0.00070340576,0.0009726185,0.0021193186],"category_scores_gemma":[0.0046842075,0.00024868373,0.0012516564,0.0024135388,0.0003858921,0.00057913625,0.00035317472,0.0012362979,0.00020919103],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006629802,0.00012794734,0.0008598744,0.041085407,0.0023204999,0.00011927049,0.000021282602,0.0011140316,0.0002494331,0.003217016,0.012979816,0.9372424],"study_design_scores_gemma":[0.003299096,0.0016466852,0.03341331,0.11907913,0.02286997,0.00389334,0.00032478696,0.0036572004,0.0015394031,0.025600838,0.7845288,0.0001474203],"about_ca_topic_score_codex":0.0032610185,"about_ca_topic_score_gemma":0.008549345,"teacher_disagreement_score":0.0032610185,"about_ca_system_score_codex":0.0010796449,"about_ca_system_score_gemma":0.0014921501,"threshold_uncertainty_score":0.011550903},"labels":[],"label_agreement":null},{"id":"W2042095037","doi":"10.1007/s40263-013-0131-5","title":"A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia Hospital; B.C. Women's Hospital & Health Centre; University of British Columbia; Stornoway Diamond (Canada); Vancouver Coastal Health Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Fingolimod; Medicine; Teriflunomide; Pregnancy; Multiple sclerosis; Clinical trial; Drug; Disease; Intensive care medicine; Pediatrics; Pharmacology; Psychiatry; Internal medicine","score_opus":0.32731455655854896,"score_gpt":0.4251250417444166,"score_spread":0.09781048518586766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042095037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011414908,0.999401,0.00004031949,0.00012289769,0.00006701314,0.000009474556,0.000055608532,0.000002234907,0.00018727955],"genre_scores_gemma":[0.0007162663,0.99870145,0.00016507057,0.00024210569,0.000050387192,0.000008171316,0.000040348485,7.8135184e-7,0.000075398435],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9990349,0.0002028562,0.0004070863,0.00008816871,0.00023555734,0.000031541575],"domain_scores_gemma":[0.99575776,0.0029280146,0.00083174824,0.00004416393,0.00037377464,0.00006444833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956625,0.0006838333,0.0025535368,0.0051244725,0.00027111068,0.0012103515,0.0010072528,0.0011113496,0.0037556922],"category_scores_gemma":[0.005335307,0.00041319634,0.0018005567,0.0054175574,0.00042121336,0.0012023756,0.0006642431,0.0011849824,0.00040069374],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003415007,0.00006682858,0.00041679174,0.43098968,0.0016392503,0.00029138406,0.00015100047,0.00019646116,0.0011432397,0.0010301891,0.015342028,0.54839176],"study_design_scores_gemma":[0.00027087782,0.00053569913,0.0054612653,0.25309414,0.014928836,0.002582188,0.00034628971,0.00014837134,0.0011207408,0.0014097448,0.7200139,0.00008798351],"about_ca_topic_score_codex":0.0022330403,"about_ca_topic_score_gemma":0.0062146364,"teacher_disagreement_score":0.0051244725,"about_ca_system_score_codex":0.00074044423,"about_ca_system_score_gemma":0.0026344953,"threshold_uncertainty_score":0.0125640035},"labels":[],"label_agreement":null},{"id":"W2043381283","doi":"10.1007/s40263-013-0076-8","title":"Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Regulation of Appetite and Obesity","field":"Neuroscience","cited_by":469,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"RWTH Aachen University; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Alzheimer Society; National Institute on Aging; Eli Lilly and Company; Deutsche Forschungsgemeinschaft; National Institutes of Health; John Simon Guggenheim Memorial Foundation","keywords":"Insulin; Insulin resistance; Insulin receptor; Medicine; Neuroprotection; Neuroscience; Internal medicine; Endocrinology; Psychology","score_opus":0.4543022185407687,"score_gpt":0.5255115660076726,"score_spread":0.07120934746690388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043381283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008645676,0.99948454,0.0000423783,0.00013450302,0.00007861699,0.000003742885,0.000008589777,0.0000025987201,0.00015857717],"genre_scores_gemma":[0.0004962135,0.9990188,0.0001227659,0.00014605919,0.00012629887,0.000008046375,0.000013845516,0.0000010867859,0.00006675181],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996866,0.00005550864,0.00009341582,0.000060550254,0.000085354375,0.000018629982],"domain_scores_gemma":[0.9991289,0.00058514625,0.00010309349,0.000020311116,0.00012631097,0.0000363107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010539267,0.0009061615,0.0021984347,0.0020322837,0.00028534868,0.0011738044,0.000986855,0.0013448853,0.0020358243],"category_scores_gemma":[0.0012263942,0.00031412995,0.0008323368,0.0022070853,0.00067204307,0.0014294079,0.00053706666,0.0018522535,0.00093450525],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032284902,0.00017558187,0.0002942241,0.047864385,0.00022401905,0.00023259933,0.00007699766,0.00019610414,0.0018003562,0.0019493047,0.011746639,0.93511695],"study_design_scores_gemma":[0.00015559985,0.0009259818,0.0036187023,0.037166268,0.0012252142,0.003227608,0.00020817967,0.0002530189,0.0013211842,0.0036777607,0.94814986,0.00007056715],"about_ca_topic_score_codex":0.00082557375,"about_ca_topic_score_gemma":0.0010274163,"teacher_disagreement_score":0.0021984347,"about_ca_system_score_codex":0.00051087845,"about_ca_system_score_gemma":0.00086848356,"threshold_uncertainty_score":0.006810546},"labels":[],"label_agreement":null},{"id":"W2045172500","doi":"10.2165/00023210-200923070-00002","title":"Lacosamide","year":2009,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"UCB Pharma; Canadian Institutes of Health Research; Fondazione Pierfranco e Luisa Mariani; Savoy Foundation; Valeant Pharmaceuticals International; Pfizer","keywords":"Lacosamide; Medicine; Psychopharmacology; Pharmacology; Psychology; Epilepsy; Psychiatry","score_opus":0.018692930926662993,"score_gpt":0.3253858074043506,"score_spread":0.3066928764776876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045172500","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.841884,0.040676974,0.005939877,0.0015634849,0.0015178171,0.0013482969,0.0047078365,0.0019981626,0.10036346],"genre_scores_gemma":[0.93726,0.0082464665,0.0027892848,0.00057683705,0.00016448386,0.00036368638,0.0028114764,0.000049979226,0.047737792],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996387,0.00006275422,0.000029416236,0.00007628194,0.00008501203,0.00010787394],"domain_scores_gemma":[0.999841,0.000018212379,0.00002285549,0.000019160672,0.000032918342,0.00006581649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022878988,0.00062327425,0.00060464337,0.0005834575,0.0005352173,0.0005057703,0.0007657325,0.000586755,0.01436247],"category_scores_gemma":[0.00043974188,0.000169705,0.00032982585,0.000537596,0.0005566011,0.00037122244,0.0003617592,0.0012297988,0.0031255616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056219365,0.004857917,0.0022271897,0.0015406878,0.0003250462,0.0020105918,0.00032219448,0.0006762816,0.6498229,0.006521254,0.017583428,0.25789306],"study_design_scores_gemma":[0.0069589624,0.04417304,0.010053345,0.00018835314,0.00034656448,0.004203465,0.0002502743,0.00095777167,0.7698754,0.0006362487,0.16227236,0.00008422083],"about_ca_topic_score_codex":0.005491558,"about_ca_topic_score_gemma":0.0053894348,"teacher_disagreement_score":0.01436247,"about_ca_system_score_codex":0.0008505945,"about_ca_system_score_gemma":0.0014804454,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2046049297","doi":"10.2165/00023210-200822060-00001","title":"Insulin, Insulin-Like Growth Factors??and Incretins","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University; University of Toronto; University Health Network","funders":"","keywords":"Insulin; Neurocognitive; Mood; Neuroscience; Psychology; Insulin receptor; Mood disorders; Psychopharmacology; Insulin-like growth factor; Cognition; Cognitive decline; Endocrinology; Internal medicine; Medicine; Insulin resistance; Disease; Growth factor; Dementia; Psychiatry; Receptor; Anxiety","score_opus":0.034875239274973026,"score_gpt":0.28947402411520184,"score_spread":0.2545987848402288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046049297","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006137475,0.9985744,0.000050146857,0.00022530445,0.00020432258,0.0000019426088,0.000008384386,0.0000034884486,0.0008707261],"genre_scores_gemma":[0.00043847907,0.9980757,0.00014902643,0.00026117018,0.00025644572,0.0000039837596,0.00001671697,8.491083e-7,0.00079767493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984527,0.000029006773,0.000023156164,0.000026684396,0.00006106488,0.000014842701],"domain_scores_gemma":[0.9997936,0.00010922179,0.000034557273,0.000006734965,0.000037954174,0.000017990076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004738814,0.0009905805,0.0017605452,0.001794751,0.00030714105,0.001092213,0.00072724954,0.0011118404,0.0038700602],"category_scores_gemma":[0.0005600858,0.00028626094,0.0004049408,0.002714531,0.0006509946,0.0015652856,0.000652843,0.001802619,0.0019241917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013148168,0.00008055093,0.00020245444,0.01315602,0.00009742184,0.00027138978,0.000048571226,0.00022785281,0.0016142462,0.0046100263,0.041003224,0.93855673],"study_design_scores_gemma":[0.00003244861,0.00005429349,0.0007252822,0.002386927,0.0000948704,0.00095606316,0.00006646135,0.000058631464,0.00027189392,0.0019979158,0.9933416,0.000013668095],"about_ca_topic_score_codex":0.0012428937,"about_ca_topic_score_gemma":0.0030781312,"teacher_disagreement_score":0.0038700602,"about_ca_system_score_codex":0.00061380933,"about_ca_system_score_gemma":0.0008148953,"threshold_uncertainty_score":0.012946665},"labels":[],"label_agreement":null},{"id":"W2046948383","doi":"10.2165/00023210-200519100-00004","title":"Augmentation Strategies in Clozapine-Resistant Schizophrenia","year":2005,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Clozapine; Schizophrenia (object-oriented programming); Intensive care medicine; Medicine; Psychiatry; Psychopharmacology; Adverse effect; Clinical trial; Electroconvulsive therapy; Psychology; Pharmacology; Internal medicine","score_opus":0.02067580920945473,"score_gpt":0.3038656170304971,"score_spread":0.28318980782104236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046948383","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028942145,0.028948046,0.0008924152,0.89483696,0.009183596,0.00009527487,0.000145,0.000113384966,0.036843233],"genre_scores_gemma":[0.31045353,0.030585967,0.0028216874,0.5806902,0.046538644,0.0004429417,0.00017153408,0.000039204617,0.028256334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963224,0.00014926553,0.00005727176,0.000022675811,0.00008185685,0.000056665507],"domain_scores_gemma":[0.99874157,0.000850658,0.00010946978,0.00003146062,0.00008329245,0.00018362448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068210234,0.00038392004,0.0006474933,0.00038124828,0.0013166381,0.0008872806,0.000768832,0.010006015,0.0030054857],"category_scores_gemma":[0.0034107426,0.00016843643,0.0006766017,0.00028626123,0.00086952694,0.0008715927,0.0005543301,0.005187517,0.00081788143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030972224,0.0006255276,0.006128154,0.0007900976,0.00011582075,0.05504774,0.0007826379,0.0008092041,0.0033960822,0.018824238,0.60685545,0.30352792],"study_design_scores_gemma":[0.0044443794,0.0017407808,0.015435354,0.0015268159,0.00036233768,0.045821585,0.00134578,0.0031244028,0.0020765616,0.038877998,0.8851079,0.0001360657],"about_ca_topic_score_codex":0.0031732724,"about_ca_topic_score_gemma":0.017506586,"teacher_disagreement_score":0.010006015,"about_ca_system_score_codex":0.0016299573,"about_ca_system_score_gemma":0.0015442461,"threshold_uncertainty_score":0.011826277},"labels":[],"label_agreement":null},{"id":"W2047152345","doi":"10.1007/s40263-013-0069-7","title":"Luteal Phase and Symptom-Onset Dosing of SSRIs/SNRIs in the Treatment of Premenstrual Dysphoria: Clinical Evidence and Rationale","year":2013,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Menstrual Health and Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; AstraZeneca","keywords":"Dosing; Psychopharmacology; Luteal phase; Medicine; Dysphoria; Premenstrual dysphoric disorder; Neurology; Internal medicine; Psychiatry; Menstrual cycle; Anxiety; Hormone","score_opus":0.0773305689568435,"score_gpt":0.41636075689494206,"score_spread":0.3390301879380986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047152345","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15572816,0.8084231,0.0029814765,0.010369705,0.0013131958,0.001776299,0.000979578,0.00007936429,0.01834904],"genre_scores_gemma":[0.6507406,0.3242508,0.010675243,0.006681967,0.0036619273,0.0007818879,0.0007210484,0.00003908323,0.002447467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99536264,0.002748115,0.0007752537,0.00037883586,0.00061323756,0.00012188366],"domain_scores_gemma":[0.9868976,0.010017374,0.0020234522,0.00031086805,0.00048038975,0.0002703876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00929714,0.00074955035,0.002992509,0.000715812,0.00040273007,0.0016553821,0.0017854356,0.0028381273,0.0022578954],"category_scores_gemma":[0.01204682,0.00058311585,0.0015813817,0.0009485192,0.0015996577,0.0009955448,0.00042832235,0.0024951736,0.00040540504],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076997444,0.005407781,0.02991124,0.029293109,0.0040515447,0.00048610632,0.00040194095,0.0019133623,0.015054076,0.006755422,0.0037403235,0.82598764],"study_design_scores_gemma":[0.12536055,0.23424304,0.2687464,0.052766208,0.031401362,0.006178694,0.0016185082,0.010178794,0.034112632,0.016029071,0.21871673,0.0006479485],"about_ca_topic_score_codex":0.0012220127,"about_ca_topic_score_gemma":0.0040462073,"teacher_disagreement_score":0.00929714,"about_ca_system_score_codex":0.00091411266,"about_ca_system_score_gemma":0.0020144754,"threshold_uncertainty_score":0.049168587},"labels":[],"label_agreement":null},{"id":"W2051981816","doi":"10.2165/00023210-200721100-00001","title":"The Role of Anti-Inflammatory Agents in Parkinson???s Disease","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Microglia; Neuroscience; Inflammation; Dopaminergic; Parkinson's disease; Basal ganglia; Disease; Medicine; Dementia; Neuroinflammation; Neurology; Pharmacology; Immunology; Dopamine; Pathology; Biology; Central nervous system","score_opus":0.03428443526629798,"score_gpt":0.3292433758723501,"score_spread":0.2949589406060521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051981816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078336016,0.9988649,0.00007704676,0.00015666569,0.00013682227,0.0000036858717,0.000010842982,0.0000042924653,0.00066742836],"genre_scores_gemma":[0.00053817284,0.9984421,0.0001968697,0.0001612439,0.00017765505,0.0000056441486,0.000015705007,8.201273e-7,0.00046176137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997955,0.000033037166,0.000034338675,0.000027845992,0.000089851965,0.000019407053],"domain_scores_gemma":[0.9996244,0.00017052297,0.00007423463,0.000010093468,0.00009127315,0.000029454131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060879794,0.0009848835,0.0020081287,0.0022210968,0.00032139578,0.0009884608,0.00087945996,0.0012776161,0.003426141],"category_scores_gemma":[0.0005614964,0.00031127187,0.00058669015,0.0023317335,0.0005396987,0.0012253106,0.00060529,0.0019162683,0.0020744612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014298839,0.00011617005,0.00015226145,0.011138613,0.000102775695,0.0002841308,0.000035805268,0.0002729589,0.0018964566,0.001749602,0.021658069,0.9624502],"study_design_scores_gemma":[0.00007949363,0.00020221215,0.0011808109,0.0031392002,0.00023207185,0.001955888,0.000056390498,0.00014640078,0.0007098517,0.0017538255,0.9905228,0.000021062107],"about_ca_topic_score_codex":0.0013467663,"about_ca_topic_score_gemma":0.0033853066,"teacher_disagreement_score":0.003426141,"about_ca_system_score_codex":0.0004951275,"about_ca_system_score_gemma":0.0009717243,"threshold_uncertainty_score":0.011461556},"labels":[],"label_agreement":null},{"id":"W2057023582","doi":"10.1007/s40263-014-0174-2","title":"Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence","year":2014,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Saint-Luc","funders":"","keywords":"Medicine; Stroke (engine); Etanercept; Neuroinflammation; Neuropathic pain; Neurology; Neuroscience; Chronic pain; Penumbra; Microglia; Neuroprotection; Tumor necrosis factor alpha; Inflammation; Psychology; Internal medicine; Pharmacology; Physical therapy; Psychiatry; Ischemia","score_opus":0.05813358585527987,"score_gpt":0.294226795298877,"score_spread":0.23609320944359716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057023582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015346782,0.9799959,0.00061952724,0.013639717,0.0010350867,0.000112864174,0.000091459835,0.000016371687,0.0029544411],"genre_scores_gemma":[0.026259322,0.9458635,0.0021900197,0.016831882,0.0071995105,0.0002749808,0.00014732043,0.000016426296,0.0012169845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782133,0.00079749594,0.0004661436,0.00034587376,0.00047755253,0.000091513524],"domain_scores_gemma":[0.98710865,0.009328191,0.0017110811,0.00028531294,0.0012533673,0.00031350562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009473602,0.00093750615,0.002728172,0.0012814618,0.00061610836,0.0031837423,0.002254419,0.0043484247,0.0055554938],"category_scores_gemma":[0.0089638755,0.00045930286,0.00132084,0.0014332619,0.0021632018,0.002347547,0.00077106134,0.0045377854,0.0021869764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004930211,0.0012690081,0.001832145,0.0615797,0.0014547973,0.0005574407,0.00012264572,0.0007119733,0.0033554444,0.024758236,0.014736568,0.88469183],"study_design_scores_gemma":[0.011186218,0.009347246,0.01042349,0.16994184,0.008510939,0.0024336306,0.00068218855,0.003015994,0.0060734483,0.08509037,0.69303834,0.0002563062],"about_ca_topic_score_codex":0.00080527517,"about_ca_topic_score_gemma":0.0018828156,"teacher_disagreement_score":0.009473602,"about_ca_system_score_codex":0.0015512569,"about_ca_system_score_gemma":0.0032903028,"threshold_uncertainty_score":0.050101817},"labels":[],"label_agreement":null},{"id":"W2059127737","doi":"10.2165/00023210-200418130-00004","title":"Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia","year":2004,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Schizophrenia Society of Ontario; Humber River Regional Hospital","funders":"","keywords":"Risperidone; Quetiapine; Amisulpride; Olanzapine; Tolerability; Psychiatry; Antipsychotic; Sertindole; Ziprasidone; Clozapine; Atypical antipsychotic; Psychology; Neurocognitive; Population; Aripiprazole; Schizophrenia (object-oriented programming); Medicine; Adverse effect; Cognition; Internal medicine","score_opus":0.05394648863535521,"score_gpt":0.39554153089717864,"score_spread":0.3415950422618234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059127737","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039499116,0.9992287,0.000018263665,0.000083213476,0.000029885769,0.0000019187794,0.000017211913,0.0000011779775,0.00022470253],"genre_scores_gemma":[0.0030283548,0.99670273,0.00007132173,0.000077467754,0.000035393863,0.0000026903936,0.000019264884,3.1469924e-7,0.000062381565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970514,0.00008559961,0.000066200395,0.000026876174,0.00010091584,0.000015336806],"domain_scores_gemma":[0.99931896,0.00040417988,0.00016486652,0.000008166448,0.00008067547,0.000023167626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007401173,0.0004866147,0.0016902874,0.0010832001,0.00011670593,0.0005534624,0.0004951778,0.0004908323,0.0012469734],"category_scores_gemma":[0.0013723131,0.00017238506,0.00085413887,0.0018688634,0.00019737895,0.0003773655,0.00030716677,0.0006355546,0.00014886261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000539453,0.000070670605,0.0015947,0.042693086,0.0014203486,0.00018453866,0.000058795304,0.0003137241,0.0004655612,0.00035543359,0.0075944266,0.94470924],"study_design_scores_gemma":[0.0012006817,0.0017608932,0.09847058,0.09366022,0.02037382,0.0059020794,0.00067897735,0.00095962366,0.0014147487,0.0032360826,0.772184,0.0001582419],"about_ca_topic_score_codex":0.003179017,"about_ca_topic_score_gemma":0.009807501,"teacher_disagreement_score":0.003179017,"about_ca_system_score_codex":0.00057366583,"about_ca_system_score_gemma":0.0008034659,"threshold_uncertainty_score":0.006321013},"labels":[],"label_agreement":null},{"id":"W2060699754","doi":"10.2165/11586460-000000000-00000","title":"Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram","year":2011,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Pfizer; Eli Lilly and Company","keywords":"Escitalopram; Hamilton Anxiety Rating Scale; Hamilton Rating Scale for Depression; Rating scale; Major depressive disorder; Internal medicine; Medicine; Psychology; Psychiatry; Anxiety; Antidepressant; Mood","score_opus":0.03580251983203029,"score_gpt":0.3033590042213166,"score_spread":0.2675564843892863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060699754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069804,0.0043828,0.00041983265,0.00043849295,0.00018902653,0.0007484134,0.0011630475,0.000042693624,0.0019176006],"genre_scores_gemma":[0.99057543,0.0035597458,0.0011613308,0.00048405287,0.00021107495,0.0009910482,0.0010492016,0.00000840948,0.0019597292],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996427,0.00017003309,0.000041592728,0.00005863837,0.00003686567,0.00005016978],"domain_scores_gemma":[0.9995372,0.00017523092,0.00010944045,0.00004097005,0.00002553202,0.000111656984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062248704,0.00042250325,0.0014803389,0.00030138745,0.00046585762,0.0003239988,0.00044084195,0.0010303422,0.004583048],"category_scores_gemma":[0.0014995479,0.0003148195,0.0007201078,0.00032006536,0.0004973936,0.0005238523,0.00023976662,0.0010016547,0.0004988132],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82723314,0.010899952,0.00819083,0.0008949918,0.00081980263,0.00033971903,0.00017761368,0.00032500506,0.013122817,0.00016726957,0.0017936978,0.13603519],"study_design_scores_gemma":[0.6837238,0.21210413,0.085782595,0.00023226115,0.0010369961,0.00086047145,0.0003049333,0.001648725,0.0036511337,0.0004537277,0.010120849,0.000080304904],"about_ca_topic_score_codex":0.001674578,"about_ca_topic_score_gemma":0.0056844326,"teacher_disagreement_score":0.004583048,"about_ca_system_score_codex":0.0005955041,"about_ca_system_score_gemma":0.00069800246,"threshold_uncertainty_score":0.015331864},"labels":[],"label_agreement":null},{"id":"W2061805713","doi":"10.1007/s40263-013-0098-2","title":"Comment on: “Publication Bias, with a Focus on Psychiatry: Causes and Solutions”","year":2013,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Clinical Reasoning and Diagnostic Skills","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Psychopharmacology; Focus (optics); Psychiatry; Clinical psychiatry; Psychology; Medicine","score_opus":0.04215796801755811,"score_gpt":0.30514262517499013,"score_spread":0.262984657157432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061805713","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015715761,0.00039076165,0.00007982945,0.9816945,0.016815476,0.000018577062,0.00011199941,0.000033931366,0.00069776055],"genre_scores_gemma":[0.0005651583,0.00013293696,0.00010237627,0.9832146,0.014968772,0.000030764506,0.000014966422,0.000015813317,0.000954575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9660905,0.008869445,0.0068900366,0.005274081,0.009116184,0.0037597306],"domain_scores_gemma":[0.8900785,0.0669765,0.011370355,0.0028242425,0.021853363,0.006896923],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028530957,0.0018731162,0.004500926,0.0028222331,0.00858303,0.008949608,0.0066172862,0.15207297,0.010823736],"category_scores_gemma":[0.18414074,0.0023386811,0.00457599,0.0035140524,0.008561624,0.007892216,0.0042111804,0.07404524,0.012761355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007106821,0.000015798183,0.00057511585,0.0001020185,0.000048839105,0.0006736995,0.00018427573,0.000038352795,0.00007577764,0.0011566513,0.99505025,0.0020080628],"study_design_scores_gemma":[0.0006663793,0.0001376277,0.0034309137,0.0018458919,0.00041019215,0.0022178858,0.0012771356,0.0010260141,0.0006544283,0.0149670625,0.9730152,0.00035129554],"about_ca_topic_score_codex":0.02182753,"about_ca_topic_score_gemma":0.032699417,"teacher_disagreement_score":0.97146904,"about_ca_system_score_codex":0.012843782,"about_ca_system_score_gemma":0.019505095,"threshold_uncertainty_score":0.1508879},"labels":[],"label_agreement":null},{"id":"W2062129453","doi":"10.1007/s40263-014-0175-1","title":"A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Lakehead University; START Clinic; University of Toronto; Adler","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Stimulant; Dosing; Atomoxetine; Psychiatry; Psychological intervention; Psychology; Substance abuse; Amphetamine; Clinical psychology; Medicine; Pharmacology","score_opus":0.0693815236239787,"score_gpt":0.39657237474306134,"score_spread":0.32719085111908264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062129453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006566752,0.99951756,0.00003171491,0.00006133629,0.000066621586,0.0000042132206,0.000019732503,0.0000024329129,0.00023075276],"genre_scores_gemma":[0.000333848,0.99923825,0.000112989896,0.000103111954,0.00005664793,0.000003874747,0.000019509269,5.1288873e-7,0.00013118188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997243,0.000045206154,0.00008019201,0.00004677692,0.00008437876,0.0000190629],"domain_scores_gemma":[0.99952495,0.00026467207,0.00009545767,0.0000073572064,0.0000783824,0.000029208748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262318,0.0009969115,0.0021649657,0.0035169171,0.00030239136,0.0009880221,0.0011132286,0.0010618925,0.0046063485],"category_scores_gemma":[0.0010820023,0.00037795684,0.0011786703,0.0035023103,0.00031733268,0.0011055866,0.00067316677,0.0013640682,0.00085915637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018776387,0.00009934399,0.0001958328,0.117794745,0.00052749953,0.00024962315,0.00007083226,0.00026031068,0.0012146943,0.0010086072,0.021620901,0.8567698],"study_design_scores_gemma":[0.00017898541,0.0003548531,0.0027193525,0.047508944,0.0032670435,0.002574717,0.0001456042,0.00021259423,0.00069498405,0.0011928169,0.94108367,0.00006644881],"about_ca_topic_score_codex":0.0030516929,"about_ca_topic_score_gemma":0.007209283,"teacher_disagreement_score":0.0046063485,"about_ca_system_score_codex":0.00050669553,"about_ca_system_score_gemma":0.0014226469,"threshold_uncertainty_score":0.015409708},"labels":[],"label_agreement":null},{"id":"W2062401860","doi":"10.2165/00023210-200620020-00002","title":"Media Portrayal of Mental Illness and its Treatments","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Mental illness; Mental health; Blame; Psychological intervention; Psychology; Stigma (botany); Psychiatry; Public health; Social stigma; Mentally ill; Medicine; Nursing","score_opus":0.06200841973063581,"score_gpt":0.4169263110639009,"score_spread":0.35491789133326507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062401860","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035918102,0.99543047,0.000019735107,0.00075897307,0.00032779772,0.0000035536698,0.00004301879,0.000002963765,0.0030543066],"genre_scores_gemma":[0.0018409056,0.99678624,0.000033603417,0.00031239694,0.00043354192,0.000003248618,0.000019912024,0.0000010038674,0.00056927395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996847,0.00008409104,0.00003730905,0.000031125055,0.00013725161,0.000025563173],"domain_scores_gemma":[0.9988808,0.00065719907,0.0002442952,0.000018952089,0.00015583076,0.00004286114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006834649,0.0006969875,0.0009307146,0.004185359,0.0003984956,0.0014493846,0.00043843326,0.0011205834,0.005553729],"category_scores_gemma":[0.0019431378,0.00023800306,0.00035511365,0.0040147696,0.000699105,0.0013576904,0.0006753332,0.0011513162,0.00088517007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110019035,0.00007465113,0.0009258968,0.03072438,0.00015109178,0.00030264255,0.00057966035,0.00013570297,0.00073817413,0.0027983254,0.06547413,0.8979854],"study_design_scores_gemma":[0.000023817953,0.00009014279,0.006777873,0.025400609,0.00034928235,0.0018296444,0.0007069862,0.00005417708,0.00037846106,0.0006181268,0.96375006,0.00002066336],"about_ca_topic_score_codex":0.004163203,"about_ca_topic_score_gemma":0.009039459,"teacher_disagreement_score":0.005553729,"about_ca_system_score_codex":0.00073737133,"about_ca_system_score_gemma":0.0012292723,"threshold_uncertainty_score":0.018579066},"labels":[],"label_agreement":null},{"id":"W2067903360","doi":"10.2165/00023210-200923020-00002","title":"Current Considerations in the Treatment of Generalized Anxiety Disorder","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"START Clinic","funders":"H. Lundbeck A/S; AstraZeneca","keywords":"Escitalopram; Generalized anxiety disorder; Paroxetine; Venlafaxine; Psychiatry; Duloxetine; Sertraline; Major depressive disorder; Anxiety; Antidepressant; Psychology; Anxiety disorder; Psychopharmacology; Major depressive episode; Medicine; Mood","score_opus":0.09963729924192531,"score_gpt":0.4303686466600599,"score_spread":0.3307313474181346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067903360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006171222,0.99890006,0.00008015271,0.00035603627,0.00012363573,0.000003609351,0.000007072673,0.000004821194,0.00046291915],"genre_scores_gemma":[0.0006072943,0.9982078,0.000278572,0.00037772075,0.00021926049,0.0000072384705,0.000015884267,0.0000012638734,0.00028495386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999648,0.000081409795,0.00007131934,0.00006636608,0.00010468388,0.000028400167],"domain_scores_gemma":[0.99890447,0.000665256,0.0001229415,0.000029380197,0.00020256353,0.00007548255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640933,0.00089043844,0.0026307567,0.0017381286,0.00039752352,0.0014352349,0.0014944255,0.0015395522,0.0042309524],"category_scores_gemma":[0.0015227826,0.00033830456,0.00076160114,0.0020972018,0.0008880651,0.0017127402,0.0006168787,0.0037577408,0.0020812578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015127951,0.00014772454,0.00018431399,0.012109438,0.000083210994,0.00017096255,0.000042049607,0.00019832344,0.000560832,0.0019805674,0.018081648,0.9662897],"study_design_scores_gemma":[0.00020052664,0.00034558828,0.002866729,0.0114983,0.00054229784,0.00227405,0.00016660143,0.00024864936,0.00035662355,0.0040008146,0.977454,0.000045744142],"about_ca_topic_score_codex":0.0027980783,"about_ca_topic_score_gemma":0.008012445,"teacher_disagreement_score":0.0042309524,"about_ca_system_score_codex":0.00088527374,"about_ca_system_score_gemma":0.0017410591,"threshold_uncertainty_score":0.014153898},"labels":[],"label_agreement":null},{"id":"W2072202743","doi":"10.2165/11533130-000000000-00000","title":"Juvenile Parkinsonism","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai; Parkinson Society Canada; Merz Pharmaceuticals; Teva Pharmaceutical Industries","keywords":"Parkinsonism; Psychopharmacology; Neurology; Medicine; Juvenile; Psychiatry; Neuroscience; Psychology; Internal medicine; Biology; Genetics; Disease","score_opus":0.034179649571433275,"score_gpt":0.32810438152230426,"score_spread":0.293924731950871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072202743","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020413229,0.99588203,0.00014553922,0.00016644404,0.00033099455,0.000012162038,0.00003954855,0.000018209337,0.003201077],"genre_scores_gemma":[0.0026252777,0.9909411,0.00036672753,0.00045348532,0.0004431485,0.000016245585,0.00012327943,0.0000040684286,0.0050265663],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998652,0.000019026207,0.00002737376,0.000023985614,0.000044571203,0.00001977092],"domain_scores_gemma":[0.9998079,0.000051129995,0.000064708125,0.000007647357,0.000043101947,0.000025486477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002588444,0.001148104,0.0016715173,0.0022380245,0.00034316044,0.0006972991,0.0005603742,0.0007467997,0.0069209123],"category_scores_gemma":[0.00043560256,0.00023422112,0.0004389332,0.001554065,0.000382797,0.000783129,0.00067619875,0.0011611333,0.003526641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001275921,0.000071514405,0.0001811292,0.009713075,0.00008270751,0.0005480432,0.00002494907,0.00010188704,0.0013970378,0.0007012374,0.049459197,0.93759155],"study_design_scores_gemma":[0.00009375456,0.00017359853,0.0016554364,0.0036709863,0.00030662323,0.0059668133,0.00004327622,0.00008196657,0.0006064465,0.0007747018,0.9866072,0.000019115163],"about_ca_topic_score_codex":0.0027373326,"about_ca_topic_score_gemma":0.009470783,"teacher_disagreement_score":0.0069209123,"about_ca_system_score_codex":0.00053420867,"about_ca_system_score_gemma":0.0011571374,"threshold_uncertainty_score":0.023152709},"labels":[],"label_agreement":null},{"id":"W2073820341","doi":"10.2165/00023210-200216080-00003","title":"Telepsychiatry","year":2002,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine","funders":"","keywords":"Telepsychiatry; Telemedicine; Videoconferencing; Modalities; Medicine; Medical education; Telehealth; Interpersonal communication; The Internet; Psychology; Multimedia; Health care; Computer science; World Wide Web","score_opus":0.07704153654559204,"score_gpt":0.41233227808422324,"score_spread":0.3352907415386312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073820341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054050284,0.96896577,0.000332255,0.0013064449,0.0016310366,0.00005219058,0.0001296315,0.000075823664,0.026966257],"genre_scores_gemma":[0.007449355,0.95964617,0.0008196616,0.0030268407,0.0012350823,0.000091022586,0.000272651,0.000013296372,0.02744588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963915,0.00008920724,0.000052172112,0.000070400085,0.00010353602,0.000045449764],"domain_scores_gemma":[0.99934715,0.00025038474,0.00015893702,0.000034499997,0.00012078349,0.00008821326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048827747,0.0009334552,0.0011518986,0.0024609214,0.00039249912,0.0009156072,0.00069902,0.0013096356,0.057204332],"category_scores_gemma":[0.0018462436,0.00026155464,0.00051925785,0.0026452597,0.0003486272,0.0010215738,0.0011281263,0.0012416076,0.014082755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061805215,0.000068127876,0.00018839687,0.0063055656,0.000038025482,0.00012246562,0.000025208374,0.000043828837,0.000235303,0.0006648711,0.06563645,0.92660993],"study_design_scores_gemma":[0.00020774381,0.00018473188,0.0044825384,0.009724925,0.00028817408,0.0025158003,0.00009871929,0.00007237489,0.00041074495,0.000739906,0.98125917,0.00001521076],"about_ca_topic_score_codex":0.0017084554,"about_ca_topic_score_gemma":0.0049771355,"teacher_disagreement_score":0.057204332,"about_ca_system_score_codex":0.0007958232,"about_ca_system_score_gemma":0.0019684527,"threshold_uncertainty_score":0.19136757},"labels":[],"label_agreement":null},{"id":"W2074119907","doi":"10.1007/s40263-014-0196-9","title":"QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"QT interval; Prolongation; Medicine; Torsades de pointes; Long QT syndrome; Ziprasidone; Escitalopram; Anesthesia; Intensive care medicine; Pharmacology; Internal medicine; Antipsychotic; Psychiatry; Schizophrenia (object-oriented programming); Antidepressant","score_opus":0.02742319594895679,"score_gpt":0.317847807261046,"score_spread":0.2904246113120892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074119907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009915717,0.9995548,0.00003974191,0.000057485817,0.000049104383,0.000004118214,0.000021231106,0.0000023515724,0.00017190957],"genre_scores_gemma":[0.00063535443,0.99890745,0.00011643711,0.00010173284,0.00010728859,0.000005031064,0.00003011608,6.329785e-7,0.0000959562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997085,0.000040654886,0.00009798281,0.00005474795,0.0000809272,0.000017164757],"domain_scores_gemma":[0.9991365,0.0004691816,0.000245782,0.000013843846,0.00010702212,0.00002755484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056273834,0.0009781683,0.002418752,0.0030582717,0.00021721964,0.0009693063,0.0009465682,0.0009989319,0.0036128312],"category_scores_gemma":[0.001638963,0.00031543418,0.0012352237,0.0028793404,0.00030576347,0.0011552557,0.00071010477,0.0010564654,0.0005714603],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024373493,0.00008958156,0.0007212204,0.09241679,0.00079340115,0.0005278411,0.000081207436,0.00033102612,0.0011048056,0.00068344176,0.01683619,0.8861707],"study_design_scores_gemma":[0.00038108922,0.00072628737,0.011453308,0.059824813,0.007607174,0.012396268,0.0003169771,0.00048529345,0.0009321811,0.0023449664,0.90336496,0.00016676476],"about_ca_topic_score_codex":0.0014125064,"about_ca_topic_score_gemma":0.0033038978,"teacher_disagreement_score":0.0036128312,"about_ca_system_score_codex":0.0003352606,"about_ca_system_score_gemma":0.0011217566,"threshold_uncertainty_score":0.012086153},"labels":[],"label_agreement":null},{"id":"W2074289679","doi":"10.2165/11533280-000000000-00000","title":"The Association between Conventional Antidepressants and the Metabolic Syndrome","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Metabolic syndrome; Medicine; Psychopharmacology; Disease; Abdominal obesity; Antidepressant; Type 2 Diabetes Mellitus; Diabetes mellitus; Major depressive disorder; Type 2 diabetes; Bioinformatics; Obesity; Internal medicine; Psychiatry; Endocrinology; Mood; Biology","score_opus":0.02977379898294423,"score_gpt":0.36987220265307574,"score_spread":0.3400984036701315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074289679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007885478,0.9995053,0.000035125333,0.00009943217,0.0000663963,0.0000013589455,0.000012083503,0.0000017857348,0.00019973912],"genre_scores_gemma":[0.00059970893,0.9989819,0.00008993635,0.0001140367,0.0001107282,0.0000016543104,0.00001626506,4.378151e-7,0.0000853497],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997873,0.000038014103,0.00005162793,0.00003975179,0.00007127808,0.000012147012],"domain_scores_gemma":[0.9991654,0.0005018491,0.00018030895,0.000015385893,0.00010522294,0.000031834952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056220434,0.0008620836,0.0019730031,0.0021979786,0.00016782196,0.00074211665,0.00085246516,0.0010384752,0.0027666998],"category_scores_gemma":[0.0011404114,0.00030347324,0.0008496516,0.0027955035,0.0003990664,0.000794275,0.0005491433,0.0013723896,0.0007111263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019804947,0.000056442477,0.00076962647,0.03817468,0.0008704783,0.0002980589,0.000030516572,0.00026660814,0.0007333626,0.00096292904,0.016652446,0.94098675],"study_design_scores_gemma":[0.0002879558,0.0003259188,0.01649824,0.035854317,0.0064707277,0.0054912823,0.00020734408,0.0005076267,0.00081222237,0.0034274787,0.9300156,0.00010127159],"about_ca_topic_score_codex":0.002977019,"about_ca_topic_score_gemma":0.007623952,"teacher_disagreement_score":0.002977019,"about_ca_system_score_codex":0.00047145516,"about_ca_system_score_gemma":0.0008633878,"threshold_uncertainty_score":0.009255528},"labels":[],"label_agreement":null},{"id":"W2076034178","doi":"10.2165/00023210-200822060-00003","title":"Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain","year":2008,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Diet and metabolism studies","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Psychopharmacology; Antipsychotic; Atypical antipsychotic; Medicine; Clozapine; Neurology; Psychiatry; Schizophrenia (object-oriented programming); Risperidone; Bipolar disorder; Psychology; Pharmacology; Mood","score_opus":0.08652114572492818,"score_gpt":0.3905713029207254,"score_spread":0.3040501571957972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076034178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019383378,0.9992261,0.00006891381,0.00007552285,0.0000606456,0.0000038715157,0.000012454408,0.000003829836,0.0003547836],"genre_scores_gemma":[0.0013574305,0.99798477,0.00023221789,0.00014829918,0.00008225952,0.0000055921855,0.000021779608,0.0000010381882,0.00016658627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998388,0.0000310623,0.000045988163,0.000027942595,0.000044489723,0.000011727949],"domain_scores_gemma":[0.9996567,0.00019154682,0.00008998895,0.0000073167575,0.000038676648,0.000015703206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044575924,0.0008681589,0.0021563147,0.0019357548,0.00015748026,0.0006080406,0.00073170976,0.0007173773,0.002410708],"category_scores_gemma":[0.00078503805,0.00023931466,0.0008131407,0.0017223655,0.00028667419,0.00061862497,0.0003911009,0.0010114103,0.0005621867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038271863,0.00010829913,0.000298269,0.032476194,0.0005427395,0.0003550081,0.00002962643,0.00020142435,0.0010365397,0.0004936312,0.007429833,0.9566458],"study_design_scores_gemma":[0.00088386476,0.0011582051,0.011069255,0.038950514,0.006469796,0.008876936,0.0002542968,0.0005400448,0.0020601253,0.0019717645,0.92766464,0.000100544064],"about_ca_topic_score_codex":0.0011626568,"about_ca_topic_score_gemma":0.003375212,"teacher_disagreement_score":0.002410708,"about_ca_system_score_codex":0.0003416644,"about_ca_system_score_gemma":0.00052510237,"threshold_uncertainty_score":0.008064628},"labels":[],"label_agreement":null},{"id":"W2077234386","doi":"10.2165/00023210-200418090-00003","title":"What are the Treatment Options for Patients with Severe Alzheimer???s Disease?","year":2004,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Donepezil; Rivastigmine; Galantamine; Memantine; Medicine; Alzheimer's disease; Disease; Clinical trial; Dementia; Psychology; Internal medicine","score_opus":0.05913915693612195,"score_gpt":0.34566652089798316,"score_spread":0.28652736396186124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077234386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000107392705,0.9978935,0.0000723964,0.00088219036,0.00014736448,0.000003337989,0.00001588175,0.0000044717312,0.000873426],"genre_scores_gemma":[0.0008234065,0.99768126,0.00019822476,0.0005906264,0.00023438454,0.000006580652,0.000017780558,7.0755823e-7,0.0004469887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998528,0.000034029825,0.000027129905,0.000021255022,0.000047317015,0.000017386254],"domain_scores_gemma":[0.9996662,0.00017847933,0.00007059146,0.000007124644,0.000051114363,0.000026487907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000565754,0.00079689693,0.002552336,0.001272438,0.0002906786,0.000993617,0.0007946721,0.00163451,0.004584804],"category_scores_gemma":[0.0009307718,0.00024853842,0.00067974086,0.0013171058,0.00038764736,0.0015072734,0.0003476191,0.0017335865,0.0017775866],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001846075,0.00008100772,0.00027902215,0.010837592,0.00014516897,0.00029216352,0.000032386513,0.00026609885,0.00065041916,0.0015683357,0.027972056,0.95769113],"study_design_scores_gemma":[0.00023511703,0.00033629884,0.0036081271,0.013928483,0.00067010877,0.0051510506,0.00024201085,0.00032089648,0.00059554004,0.0050298506,0.9698275,0.000055038618],"about_ca_topic_score_codex":0.0017722787,"about_ca_topic_score_gemma":0.005136523,"teacher_disagreement_score":0.004584804,"about_ca_system_score_codex":0.00048762184,"about_ca_system_score_gemma":0.00076185813,"threshold_uncertainty_score":0.015337765},"labels":[],"label_agreement":null},{"id":"W2084441956","doi":"10.2165/11592230-000000000-00000","title":"Transdermal Rivastigmine","year":2011,"lang":"pl","type":"review","venue":"CNS Drugs","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Western University","funders":"H. Lundbeck A/S; Exelon Corporation; Novartis Pharmaceuticals Corporation","keywords":"Rivastigmine; Transdermal patch; Transdermal; Medicine; Adverse effect; Nausea; Dermatology; Anesthesia; Skin patch; Pharmacology; Internal medicine; Dementia; Disease; Donepezil","score_opus":0.0857148668066361,"score_gpt":0.34183602177969635,"score_spread":0.25612115497306026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084441956","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027851923,0.9971226,0.00028666845,0.00026770454,0.0002196132,0.000012472311,0.000042861655,0.000019532828,0.0017501229],"genre_scores_gemma":[0.0015202522,0.99530774,0.00036517344,0.00030867336,0.00019831352,0.000018626588,0.00006637884,0.0000033142856,0.0022115465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998952,0.00001751355,0.000024628962,0.000019497184,0.00003234959,0.000010789982],"domain_scores_gemma":[0.99983644,0.00007147579,0.000043433534,0.0000069292005,0.000028869192,0.000012868421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036021828,0.0011727996,0.0015546157,0.0017304529,0.00016489037,0.0006335956,0.0006480668,0.00092147145,0.0050333426],"category_scores_gemma":[0.000534488,0.0002640701,0.0004801057,0.0012093323,0.00034047107,0.001141185,0.0005041651,0.0012994312,0.0028519076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023814688,0.00007285184,0.00008712333,0.010878045,0.0001089075,0.0002573322,0.00002238569,0.0001891721,0.0031009756,0.0006174515,0.022904245,0.96152353],"study_design_scores_gemma":[0.00018972371,0.00034364947,0.00095042196,0.0025796704,0.00044442335,0.0030193403,0.000038210994,0.00015177218,0.0018289541,0.0006792405,0.9897522,0.000022379649],"about_ca_topic_score_codex":0.0007882738,"about_ca_topic_score_gemma":0.0018590832,"teacher_disagreement_score":0.0050333426,"about_ca_system_score_codex":0.00043313636,"about_ca_system_score_gemma":0.0006532441,"threshold_uncertainty_score":0.016838193},"labels":[],"label_agreement":null},{"id":"W2084487135","doi":"10.2165/00023210-200721120-00003","title":"Recommendations for the Use of Pharmacological Smoking Cessation Strategies in Pregnant Women","year":2007,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Varenicline; Bupropion; Medicine; Smoking cessation; Nicotine replacement therapy; Pregnancy; Pharmacotherapy; Psychiatry; Obstetrics","score_opus":0.29853549716316513,"score_gpt":0.4485880852321022,"score_spread":0.15005258806893707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084487135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020018633,0.9882301,0.0008807363,0.006698765,0.0010310248,0.00008492306,0.000140314,0.000043243526,0.0026906424],"genre_scores_gemma":[0.0007979949,0.9910149,0.0034365028,0.0027206684,0.0003717787,0.00011423709,0.00015255692,0.000004314565,0.0013870737],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992555,0.000211868,0.00019519666,0.000072639785,0.00022517084,0.00003963445],"domain_scores_gemma":[0.99834394,0.0007791271,0.0003238001,0.000028072809,0.0004271863,0.00009786624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001747389,0.001062609,0.002287529,0.0028981033,0.00044470097,0.0009971628,0.0021524879,0.002838219,0.006539569],"category_scores_gemma":[0.0035307778,0.00044469332,0.0015822863,0.0018335694,0.00044506375,0.0012773509,0.000745981,0.0034631044,0.002517156],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009783324,0.00020507012,0.00031973922,0.021862436,0.00018915036,0.000295248,0.00006187601,0.00026392718,0.00054469355,0.0014831292,0.07068995,0.90398693],"study_design_scores_gemma":[0.00025231438,0.00016145207,0.0039612087,0.07395616,0.0012532091,0.001682427,0.0002328227,0.00032225595,0.00048823495,0.0033665216,0.9142625,0.000060965172],"about_ca_topic_score_codex":0.006811405,"about_ca_topic_score_gemma":0.014793538,"teacher_disagreement_score":0.006811405,"about_ca_system_score_codex":0.0011804596,"about_ca_system_score_gemma":0.0037326277,"threshold_uncertainty_score":0.02187711},"labels":[],"label_agreement":null},{"id":"W2086306474","doi":"10.2165/11631310-000000000-00000","title":"Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder","year":2012,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Risperidone; Depot; Olanzapine; Treatment of bipolar disorder; Bipolar disorder; Medicine; Antipsychotic; Extrapyramidal symptoms; Fluphenazine; Psychiatry; Mania; Bipolar I disorder; Paliperidone; Schizophrenia (object-oriented programming); Atypical antipsychotic; Haloperidol; Pharmacology; Internal medicine; Mood; Dopamine","score_opus":0.059190963956804406,"score_gpt":0.34792862736692887,"score_spread":0.28873766341012447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086306474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013993165,0.99917525,0.00007068845,0.000064143875,0.00006712514,0.0000039590564,0.000016366057,0.000004813213,0.0004577352],"genre_scores_gemma":[0.0008222514,0.9984084,0.00021067978,0.00011331911,0.000071948176,0.0000041464123,0.000026087491,0.0000011518653,0.000342051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998399,0.000026797841,0.000033302967,0.000024393848,0.00006338812,0.000012224774],"domain_scores_gemma":[0.99963963,0.00018377451,0.000088616456,0.000007244085,0.00005367401,0.000027103772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050048396,0.0008234309,0.0015551116,0.002009836,0.00023443806,0.0006561174,0.00094344304,0.0007047283,0.0039398414],"category_scores_gemma":[0.00062666886,0.00024427893,0.0006394321,0.0020338625,0.00034323716,0.00076194457,0.0004973794,0.0014706049,0.0010618597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013526346,0.00008759515,0.00014762291,0.022031087,0.00017739533,0.00015466558,0.000038040325,0.00014618509,0.0010382835,0.000681313,0.012510207,0.9628524],"study_design_scores_gemma":[0.0002152866,0.00036189312,0.0033068308,0.012881689,0.0012957938,0.0034684914,0.00012547943,0.00024635933,0.0008719333,0.0013611687,0.97581303,0.000051963205],"about_ca_topic_score_codex":0.0020104235,"about_ca_topic_score_gemma":0.00698382,"teacher_disagreement_score":0.0039398414,"about_ca_system_score_codex":0.0004403321,"about_ca_system_score_gemma":0.00076788815,"threshold_uncertainty_score":0.013180077},"labels":[],"label_agreement":null},{"id":"W2090314549","doi":"10.1007/s40263-014-0190-2","title":"Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date","year":2014,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Micronutrient; Attention deficit hyperactivity disorder; Psychopharmacology; Randomized controlled trial; Psychiatry; Medicine; Broad spectrum; Intensive care medicine; Surgery","score_opus":0.07538574041162764,"score_gpt":0.37931202038508316,"score_spread":0.3039262799734555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090314549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008067102,0.99951637,0.000037290036,0.00009501735,0.00003199951,0.0000057637003,0.000017586419,0.0000025892043,0.0002127345],"genre_scores_gemma":[0.00082146545,0.9986639,0.00019900197,0.0001548015,0.000037854028,0.000006979123,0.000019760882,6.363724e-7,0.0000954851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972564,0.000052348878,0.00006516725,0.0000539297,0.00008308044,0.000019762392],"domain_scores_gemma":[0.9992668,0.00046437673,0.0001396325,0.000012160296,0.00008884119,0.00002822951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008934405,0.0010145342,0.0030544025,0.0020061773,0.00030274503,0.0010763495,0.0012807089,0.001249291,0.0042221867],"category_scores_gemma":[0.0014108985,0.0003402978,0.0013982354,0.0020109604,0.00048064004,0.0009903541,0.00059262326,0.0017981526,0.0007454168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046751523,0.0001840797,0.00035141627,0.12244365,0.0012391956,0.0002281947,0.00004936196,0.0003763775,0.0012446918,0.0017084687,0.0120995995,0.85960734],"study_design_scores_gemma":[0.0008193697,0.00078996504,0.005278398,0.10633746,0.01197096,0.002891008,0.00026909367,0.00048955175,0.0018429358,0.003747579,0.8654695,0.00009414554],"about_ca_topic_score_codex":0.002621229,"about_ca_topic_score_gemma":0.0083498815,"teacher_disagreement_score":0.0042221867,"about_ca_system_score_codex":0.0006489389,"about_ca_system_score_gemma":0.0015791323,"threshold_uncertainty_score":0.014124632},"labels":[],"label_agreement":null},{"id":"W2092504356","doi":"10.1007/s40263-013-0097-3","title":"Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression","year":2013,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Moclobemide; Tranylcypromine; Phenelzine; Psychiatry; Depression (economics); Atypical depression; Monoamine oxidase inhibitor; PsycINFO; Medicine; Mood; Monoamine oxidase; Psychology; MEDLINE; Antidepressant; Anxiety; Chemistry","score_opus":0.04994602142880084,"score_gpt":0.36116447529369905,"score_spread":0.3112184538648982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092504356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073799405,0.9993882,0.000046534667,0.000088036686,0.00006677235,0.000003227267,0.000012913857,0.0000038201265,0.00031669324],"genre_scores_gemma":[0.0004982857,0.99900514,0.0001129743,0.000116693074,0.000079246514,0.0000029072187,0.000016890845,6.596643e-7,0.00016730998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981767,0.000031497937,0.000038035236,0.000032568405,0.00006520596,0.000015130209],"domain_scores_gemma":[0.9994973,0.00027955478,0.0000940534,0.0000098012715,0.00008201919,0.000037309674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006358954,0.0007960947,0.0020524862,0.0019704762,0.0002296052,0.00084244844,0.0011006796,0.00089686323,0.00455141],"category_scores_gemma":[0.000823208,0.00027738808,0.00075469655,0.0022605194,0.00036569545,0.0008920446,0.00048753378,0.0016581274,0.0012842941],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021341267,0.00009575851,0.00014114249,0.032172546,0.00026989082,0.000116587165,0.000034491575,0.00023214225,0.0010370837,0.0009344264,0.0135113355,0.9512412],"study_design_scores_gemma":[0.00027702472,0.00048806288,0.0033091123,0.020621626,0.0020553959,0.0018390603,0.00013309497,0.00032946083,0.0007504793,0.0020565053,0.96808827,0.00005191482],"about_ca_topic_score_codex":0.0021292323,"about_ca_topic_score_gemma":0.0060588913,"teacher_disagreement_score":0.00455141,"about_ca_system_score_codex":0.00045549712,"about_ca_system_score_gemma":0.00096674875,"threshold_uncertainty_score":0.0152260065},"labels":[],"label_agreement":null},{"id":"W2095273611","doi":"10.2165/00023210-200923060-00004","title":"Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy","year":2009,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Child and Family Research Institute","keywords":"Pregnancy; Medicine; Depression (economics); Low birth weight; Psychopharmacology; Pediatrics; Adverse effect; Antidepressant; Psychiatry; Obstetrics; Medical prescription; Sertraline; Internal medicine; Anxiety; Pharmacology","score_opus":0.03129358299483017,"score_gpt":0.34310695860110213,"score_spread":0.311813375606272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095273611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022584332,0.9990344,0.00007368454,0.000085861175,0.000056240333,0.0000041352223,0.000027865342,0.0000040823356,0.0004878816],"genre_scores_gemma":[0.002024927,0.9973079,0.00015159024,0.00013540495,0.00008667453,0.000004919995,0.000033406897,0.0000010420154,0.00025413258],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99968386,0.000062843115,0.00008308355,0.0000412589,0.00011199898,0.000016922093],"domain_scores_gemma":[0.9988845,0.0006443985,0.00029169512,0.000017413302,0.00012923514,0.000032707627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000891582,0.000714481,0.0021115066,0.0019269327,0.00015666326,0.0006496849,0.00094263884,0.0010073886,0.0031724838],"category_scores_gemma":[0.0018737769,0.0002844667,0.00079984614,0.0016356481,0.00025525235,0.000615456,0.0003188225,0.0010527475,0.00075439166],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026074916,0.00007252574,0.00036517586,0.04019045,0.0004614585,0.0002651829,0.000041758078,0.0003691573,0.0012856324,0.00060093997,0.011925621,0.9441613],"study_design_scores_gemma":[0.00049909553,0.001209527,0.008472366,0.033367842,0.004466546,0.006006965,0.00018475889,0.0006553402,0.0023737897,0.0016646167,0.9410232,0.00007602155],"about_ca_topic_score_codex":0.0020320457,"about_ca_topic_score_gemma":0.0041352543,"teacher_disagreement_score":0.0031724838,"about_ca_system_score_codex":0.0004550571,"about_ca_system_score_gemma":0.00077260076,"threshold_uncertainty_score":0.010613024},"labels":[],"label_agreement":null},{"id":"W2135586697","doi":"10.1007/s40263-015-0291-6","title":"Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial","year":2015,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Evening; Placebo; Attention deficit hyperactivity disorder; Guanfacine; Randomized controlled trial; Morning; Rating scale; Population; Medicine; Psychiatry; Clinical trial; Pediatrics; Psychology; Internal medicine; Developmental psychology","score_opus":0.01570401413637458,"score_gpt":0.28776217564195755,"score_spread":0.272058161505583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135586697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8693817,0.10051579,0.001931678,0.003036,0.0030592966,0.014690878,0.0027702805,0.0002878144,0.004326463],"genre_scores_gemma":[0.95748055,0.024331488,0.0028889824,0.0022331672,0.0016175366,0.008424153,0.0012111745,0.000045922097,0.0017670466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954333,0.0029684522,0.0005510413,0.00047472247,0.00029240054,0.00028007347],"domain_scores_gemma":[0.99492943,0.0026080005,0.0013169808,0.0003395539,0.0003458926,0.00046024853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074723577,0.0011859485,0.0058309897,0.00056614215,0.0005554058,0.0014820829,0.0012884077,0.003421395,0.007668211],"category_scores_gemma":[0.0075763767,0.00062359957,0.0041775717,0.0008599656,0.0016504782,0.0014353935,0.00044967557,0.0022150993,0.0006742599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97986513,0.0013624827,0.0005976556,0.00231915,0.0035060325,0.000027468086,0.000040302417,0.00010219696,0.0005918222,0.00005787006,0.00035107517,0.011178773],"study_design_scores_gemma":[0.9743051,0.021258935,0.0015802355,0.00017042148,0.0020061322,0.000013041725,0.00002390544,0.00010107553,0.00010223821,0.00006334193,0.00036462484,0.000011040947],"about_ca_topic_score_codex":0.0019444228,"about_ca_topic_score_gemma":0.003415303,"teacher_disagreement_score":0.007668211,"about_ca_system_score_codex":0.0010882532,"about_ca_system_score_gemma":0.0015067926,"threshold_uncertainty_score":0.03951806},"labels":[],"label_agreement":null},{"id":"W2227626307","doi":"10.1007/s40263-015-0288-1","title":"The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"National Institute of Mental Health; National Institutes of Health; Bristol-Myers Squibb","keywords":"Hypoactive sexual desire disorder; Sexual desire; Libido; Sexual function; Female sexual dysfunction; Sexual dysfunction; Psychiatry; Medicine; Distress; Psychology; Psychosocial; Clinical psychology; Human sexuality; Internal medicine","score_opus":0.3786873442893229,"score_gpt":0.42366875460578396,"score_spread":0.04498141031646108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227626307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007160892,0.9995202,0.000030052963,0.000077212026,0.000033051514,0.0000035307637,0.000015874464,0.0000017186936,0.00024681212],"genre_scores_gemma":[0.00043691898,0.99925774,0.000076766984,0.00006719666,0.000032787477,0.0000031150519,0.00001236731,3.7581415e-7,0.00011272314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998404,0.000031274583,0.00003353302,0.000027688433,0.000053674044,0.000013492823],"domain_scores_gemma":[0.999607,0.0002444376,0.00007054514,0.000008048686,0.000050049002,0.000019937908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006057073,0.00076499226,0.002194214,0.0020341866,0.00025759471,0.0011050076,0.00090909755,0.00083813834,0.0047800993],"category_scores_gemma":[0.00083234557,0.00028447862,0.00077038235,0.001942498,0.00049081247,0.0010974497,0.0006194982,0.0014582992,0.000921464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002391499,0.000110282,0.00027153327,0.06623624,0.00034335887,0.00022121717,0.00006854465,0.00028963477,0.0014470406,0.0028841,0.012459313,0.91542965],"study_design_scores_gemma":[0.00014685518,0.00033018633,0.0028606507,0.026763326,0.0013435209,0.002470152,0.00024154068,0.00020191047,0.00078381906,0.003628899,0.96117127,0.000057902907],"about_ca_topic_score_codex":0.0020378307,"about_ca_topic_score_gemma":0.00598221,"teacher_disagreement_score":0.0047800993,"about_ca_system_score_codex":0.00048846577,"about_ca_system_score_gemma":0.0013402317,"threshold_uncertainty_score":0.015991092},"labels":[],"label_agreement":null},{"id":"W2251665514","doi":"10.1007/s40263-015-0295-2","title":"The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Mental Health & Substance Use Services; University of British Columbia","funders":"Institute of Health Services and Policy Research; Canadian Institutes of Health Research","keywords":"Medicine; Pharmacokinetics; Tolerability; Medical physics; Intensive care medicine; Clinical trial; Clinical pharmacology; Pharmacology; Adverse effect; Internal medicine","score_opus":0.18668574639683075,"score_gpt":0.4065359293962108,"score_spread":0.21985018299938006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2251665514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010348605,0.998548,0.000106714346,0.00032875314,0.0002246109,0.0000042643783,0.000066545545,0.0000041522717,0.00061343634],"genre_scores_gemma":[0.0010837099,0.997474,0.00024232894,0.00040654276,0.0002756079,0.000007826697,0.00007915033,0.0000021205556,0.00042861616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999526,0.000107462474,0.00010480036,0.00007197474,0.0001682376,0.000021498747],"domain_scores_gemma":[0.99772006,0.0013475758,0.00050656317,0.000049852104,0.00031073592,0.000065205066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015107486,0.00062545907,0.0021638111,0.0014727658,0.00015467736,0.0017183569,0.00072723906,0.000950759,0.004938135],"category_scores_gemma":[0.0032672489,0.0002603872,0.0010097389,0.0022957036,0.00030808419,0.0012579509,0.0005124647,0.0020348132,0.0015925461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002767644,0.000037241494,0.00029442963,0.03212807,0.00040683613,0.000079640435,0.000044792752,0.00029813132,0.00096474506,0.0017901916,0.027463602,0.9362155],"study_design_scores_gemma":[0.00015306464,0.0003463126,0.004502919,0.02527163,0.0022779752,0.0013513428,0.00008405707,0.0003809902,0.00096806366,0.0027138654,0.9618902,0.000059619033],"about_ca_topic_score_codex":0.0025352861,"about_ca_topic_score_gemma":0.0058275023,"teacher_disagreement_score":0.004938135,"about_ca_system_score_codex":0.0008823007,"about_ca_system_score_gemma":0.0025546944,"threshold_uncertainty_score":0.016519666},"labels":[],"label_agreement":null},{"id":"W2275911658","doi":"10.1007/s40263-016-0310-2","title":"The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective","year":2016,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Substance Abuse Treatment and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"","keywords":"Nalmefene; Psychosocial; Medicine; Environmental health; Population; Public health; Cost effectiveness; Psychiatry; Naltrexone; Risk analysis (engineering); Internal medicine","score_opus":0.030771094258223962,"score_gpt":0.2995111677444613,"score_spread":0.26874007348623735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275911658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6873371,0.19833316,0.0020583437,0.06858719,0.0013580446,0.00020442938,0.0073702214,0.00005076294,0.034700748],"genre_scores_gemma":[0.98134357,0.015052726,0.0005448181,0.0012899011,0.00029938546,0.000038630955,0.0006052441,0.00000681791,0.00081892795],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99686795,0.0020522757,0.00022214455,0.00012786103,0.0004375702,0.000292252],"domain_scores_gemma":[0.99552816,0.0026399451,0.00091660616,0.000059469676,0.00042733722,0.00042837567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017171279,0.00044922443,0.0009342435,0.0011648312,0.00028413843,0.0018576187,0.00047333247,0.0019011273,0.0071588666],"category_scores_gemma":[0.011831844,0.00030072784,0.0024902485,0.0010228729,0.00058035884,0.0014836313,0.00096116523,0.0018207429,0.00027611395],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069279075,0.0014023422,0.16722326,0.01641719,0.022273123,0.0041491305,0.0008612314,0.08353927,0.003598296,0.029540332,0.03723058,0.5644861],"study_design_scores_gemma":[0.016078554,0.024135431,0.70409614,0.01813625,0.031650905,0.011407231,0.006711154,0.08618649,0.0023832952,0.030530429,0.067963324,0.00072073576],"about_ca_topic_score_codex":0.024672335,"about_ca_topic_score_gemma":0.03216256,"teacher_disagreement_score":0.024672335,"about_ca_system_score_codex":0.0075578527,"about_ca_system_score_gemma":0.0024411771,"threshold_uncertainty_score":0.054836333},"labels":[],"label_agreement":null},{"id":"W2291484568","doi":"10.1007/s40263-015-0293-4","title":"Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies","year":2015,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Cabergoline; Internal medicine; valvular heart disease; Hazard ratio; Cohort study; Pergolide; Cohort; Heart failure; Observational study; Dopamine agonist; Confidence interval; Dopamine","score_opus":0.07807149264030631,"score_gpt":0.33521396006356047,"score_spread":0.25714246742325414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291484568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040837303,0.99523574,0.00008693457,0.00005091161,0.00003514196,0.00003287969,0.00037512078,0.0000029268786,0.000096610216],"genre_scores_gemma":[0.065337956,0.9330511,0.0006037861,0.00027209334,0.000078604644,0.00008351237,0.000484498,0.0000036108404,0.000084785366],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977041,0.00049062463,0.0010939409,0.00032646724,0.0003094301,0.00007540997],"domain_scores_gemma":[0.9902947,0.0065541733,0.002455162,0.00015342925,0.00044734534,0.00009533874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029981092,0.0009678201,0.00537396,0.0028669746,0.00032028364,0.001306516,0.0010938357,0.0012412162,0.0021978773],"category_scores_gemma":[0.01260148,0.00086134375,0.011425053,0.0044455826,0.0003724688,0.0010711394,0.00087273255,0.0012062048,0.00012683411],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019074568,0.000060663784,0.030478314,0.7115635,0.1975938,0.0002709276,0.0001918804,0.00033572136,0.0004150012,0.0002201198,0.0015424254,0.05542013],"study_design_scores_gemma":[0.0010027505,0.00044348193,0.08256108,0.11961845,0.78264815,0.0012143196,0.0003794767,0.0002722685,0.00029323046,0.0005899638,0.010850743,0.000126145],"about_ca_topic_score_codex":0.005289158,"about_ca_topic_score_gemma":0.0162722,"teacher_disagreement_score":0.00537396,"about_ca_system_score_codex":0.0007860474,"about_ca_system_score_gemma":0.0016378757,"threshold_uncertainty_score":0.01585573},"labels":[],"label_agreement":null},{"id":"W2328547247","doi":"10.2165/11587900-000000000-00000","title":"The Pharmacology of New Antiepileptic Drugs","year":2011,"lang":"en","type":"editorial","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Agenzia Italiana del Farmaco, Ministero della Salute; Valeant Pharmaceuticals International; Eisai; Upsher-Smith; Johnson and Johnson; Pfizer","keywords":"Psychopharmacology; Antiepileptic drug; Medicine; Pharmacology; Clinical pharmacology; Epilepsy; Psychiatry","score_opus":0.018903417531976822,"score_gpt":0.3340876267090464,"score_spread":0.3151842091770696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328547247","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036139183,0.059671026,0.0001569554,0.033283602,0.90472436,0.00001668491,0.000035231118,0.0000436699,0.0020323347],"genre_scores_gemma":[0.0003779076,0.031818137,0.00014810057,0.025079463,0.9353273,0.00001923431,0.00002583165,0.000015038557,0.0071889693],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448746,0.0013020076,0.00079941924,0.00037244422,0.002724647,0.00031400687],"domain_scores_gemma":[0.98528606,0.0064608892,0.0012879487,0.00042132178,0.0049072066,0.0016367475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006783257,0.0040953136,0.0051305564,0.0038786102,0.002399028,0.006316962,0.004331027,0.017672578,0.006589765],"category_scores_gemma":[0.014359372,0.0016488652,0.0028856776,0.0020918716,0.0027490922,0.0047978237,0.0017871327,0.023418093,0.006934825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006882026,0.000018218137,0.00002282492,0.0005671519,0.00004082594,0.00013060351,0.000010716694,0.00003238585,0.00007899,0.0003154461,0.9857993,0.012914757],"study_design_scores_gemma":[0.00011476898,0.000046078236,0.000261501,0.00069464976,0.00013920528,0.0004801932,0.00002474082,0.00013428838,0.00009673258,0.00077336497,0.99721503,0.000019441193],"about_ca_topic_score_codex":0.0023829287,"about_ca_topic_score_gemma":0.009387366,"teacher_disagreement_score":0.017672578,"about_ca_system_score_codex":0.0037848533,"about_ca_system_score_gemma":0.0033414473,"threshold_uncertainty_score":0.03587377},"labels":[],"label_agreement":null},{"id":"W2344267538","doi":"10.1007/s40263-016-0334-7","title":"The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Occupational Therapy Practice and Research","field":"Health Professions","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; Centre for Movement Disorders; University of British Columbia","funders":"","keywords":"Meta-analysis; Medicine; Randomized controlled trial; Placebo; Major depressive disorder; Systematic review; Psychiatry; MEDLINE; Internal medicine; Mood; Alternative medicine; Pathology","score_opus":0.11877144229701035,"score_gpt":0.5124727009310429,"score_spread":0.39370125863403255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344267538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055724373,0.993529,0.0002236086,0.00007452905,0.00010456474,0.00015221814,0.00020718315,0.0000112335265,0.00012519535],"genre_scores_gemma":[0.1205879,0.8759946,0.0016049503,0.000660588,0.00019938558,0.0003211171,0.00037743535,0.0000116937335,0.00024227776],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962345,0.001350734,0.0013305057,0.00049311505,0.00043938903,0.0001518356],"domain_scores_gemma":[0.9912811,0.0062367925,0.0017012468,0.00021983804,0.00041780877,0.00014318155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058844653,0.0022879012,0.017112557,0.0030952885,0.000571636,0.0022805918,0.0020415694,0.0022542044,0.003357322],"category_scores_gemma":[0.016178241,0.0013236823,0.021551691,0.0037655837,0.00073733367,0.0016489335,0.0013119839,0.0022672347,0.0001910256],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008033078,0.00008281265,0.0030990618,0.46884942,0.49342766,0.00013183012,0.00010720003,0.00043384396,0.00038633202,0.00009717763,0.0005679996,0.02478351],"study_design_scores_gemma":[0.0025727153,0.00043645137,0.0041991677,0.019064356,0.9716845,0.00009302326,0.00006679339,0.00013328705,0.00012117014,0.00013616278,0.0014621702,0.000030215328],"about_ca_topic_score_codex":0.0059195957,"about_ca_topic_score_gemma":0.017584872,"teacher_disagreement_score":0.017112557,"about_ca_system_score_codex":0.0017903432,"about_ca_system_score_gemma":0.0021129942,"threshold_uncertainty_score":0.03112042},"labels":[],"label_agreement":null},{"id":"W2345643776","doi":"10.1007/s40263-016-0338-3","title":"Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"B.C. Women's Hospital & Health Centre; University of British Columbia","funders":"","keywords":"Psychopharmacology; Serotonin Uptake Inhibitors; Medicine; Reuptake inhibitor; Serotonin; Citalopram; Pregnancy; Pharmacology; Psychiatry; Fluoxetine; Internal medicine; Biology","score_opus":0.06956686618572296,"score_gpt":0.4006472551019375,"score_spread":0.33108038891621455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345643776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001074838,0.9996309,0.000025837304,0.000077387485,0.000026019938,0.0000053298154,0.000027436101,0.0000012094943,0.00009820787],"genre_scores_gemma":[0.0008911402,0.9988035,0.00009758373,0.00011605773,0.00003714005,0.0000052388923,0.000016911514,4.247732e-7,0.000032082928],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99906725,0.00017369472,0.0003515046,0.00012121752,0.00025344163,0.000032983775],"domain_scores_gemma":[0.9957814,0.0029666102,0.0008651811,0.000038641036,0.00028600998,0.00006226212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002056281,0.0009218187,0.0036464478,0.003181068,0.00024626407,0.0012480422,0.0013297372,0.0015119914,0.0035057152],"category_scores_gemma":[0.0049309963,0.0005015145,0.0022908496,0.0031684043,0.00045396073,0.0012707326,0.00069058884,0.0012505816,0.0003427774],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004956776,0.000093018956,0.0009342092,0.351446,0.0024193872,0.00025741794,0.00011331148,0.0003803775,0.0007462777,0.0008455805,0.0076646004,0.63460416],"study_design_scores_gemma":[0.0006458925,0.0011905804,0.012379746,0.38453633,0.029806327,0.0040742536,0.00060263457,0.0006037203,0.0012526221,0.0028023575,0.5619506,0.0001549618],"about_ca_topic_score_codex":0.0025584726,"about_ca_topic_score_gemma":0.006757335,"teacher_disagreement_score":0.0036464478,"about_ca_system_score_codex":0.0007011631,"about_ca_system_score_gemma":0.002092903,"threshold_uncertainty_score":0.01172775},"labels":[],"label_agreement":null},{"id":"W2531324366","doi":"10.1007/s40263-016-0386-8","title":"Novel Levodopa Formulations for Parkinson’s Disease","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Levodopa; Carbidopa; Entacapone; Prodrug; Pharmacology; Bioavailability; Medicine; Parkinson's disease; Dosage form; Chemistry; Internal medicine; Disease","score_opus":0.06355281078969582,"score_gpt":0.3509963170510967,"score_spread":0.28744350626140086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531324366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030849353,0.99780923,0.00015544995,0.00015674822,0.00012878432,0.000012996859,0.00003333618,0.000010241161,0.0013847039],"genre_scores_gemma":[0.0020676255,0.9957516,0.0004238319,0.00022836665,0.00014410928,0.000015488702,0.000045723275,0.0000027096823,0.0013205679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987817,0.000019028284,0.000028655182,0.000019119474,0.000041291485,0.000013863587],"domain_scores_gemma":[0.9998288,0.00007063971,0.00005039637,0.0000041361786,0.00003162519,0.000014375737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039917786,0.0011393786,0.001706992,0.002234285,0.00020670726,0.00079258555,0.00069621176,0.0009371008,0.005432552],"category_scores_gemma":[0.00048090285,0.00033625533,0.00057058403,0.0012864445,0.00032658706,0.0011214915,0.00063464633,0.0017105484,0.0015478462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022487165,0.00013199782,0.00008855687,0.02069212,0.00014431697,0.00024275568,0.000046425914,0.00021202989,0.0027042127,0.0011880071,0.015108239,0.9592165],"study_design_scores_gemma":[0.00023627293,0.000451175,0.0010473859,0.0072234524,0.00076724804,0.0023127813,0.00008176634,0.00026151407,0.0017017184,0.0016183354,0.9842609,0.000037329402],"about_ca_topic_score_codex":0.0007941006,"about_ca_topic_score_gemma":0.002916711,"teacher_disagreement_score":0.005432552,"about_ca_system_score_codex":0.00035525757,"about_ca_system_score_gemma":0.0006714365,"threshold_uncertainty_score":0.018173695},"labels":[],"label_agreement":null},{"id":"W2535539542","doi":"10.1007/s40263-016-0385-9","title":"Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies","year":2016,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Pharmacogenetics; Antidepressant; Neuroimaging; Medicine; Pharmacology; Psychology; Psychiatry; Biology; Genetics; Gene; Anxiety","score_opus":0.03917798352743512,"score_gpt":0.3908195862422717,"score_spread":0.3516416027148366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535539542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087993605,0.99893147,0.00016228347,0.0003866774,0.0000869371,0.000003884737,0.000013821313,0.0000036758634,0.00032317967],"genre_scores_gemma":[0.0010547875,0.9976173,0.00044826415,0.00042233607,0.00023401284,0.0000068679583,0.000027567863,0.0000011558872,0.0001876167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997131,0.000082203245,0.000053282434,0.00005383494,0.0000765816,0.00002095304],"domain_scores_gemma":[0.99901235,0.00061016233,0.00014616149,0.000023587987,0.00017268922,0.000035036097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013699614,0.0008537426,0.0022144238,0.0014806625,0.00014490091,0.0012848111,0.0010917863,0.0013393718,0.0025304193],"category_scores_gemma":[0.00181563,0.00030096679,0.00085890386,0.0014568523,0.00049152994,0.0011618608,0.0006900254,0.0019103067,0.0008090209],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018715109,0.00010404176,0.00062643003,0.018979387,0.0004067794,0.00017726664,0.00003483879,0.0004459612,0.0015368717,0.0036744762,0.015493296,0.95833343],"study_design_scores_gemma":[0.00020561133,0.0003636391,0.0046603945,0.01974836,0.0019005676,0.0024190883,0.00012853986,0.00077007356,0.0012023625,0.009073502,0.9594527,0.00007517425],"about_ca_topic_score_codex":0.0014429945,"about_ca_topic_score_gemma":0.0035137082,"teacher_disagreement_score":0.0025304193,"about_ca_system_score_codex":0.0006870637,"about_ca_system_score_gemma":0.0013833803,"threshold_uncertainty_score":0.008465111},"labels":[],"label_agreement":null},{"id":"W2596957891","doi":"10.1007/s40263-017-0418-z","title":"Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; National Institutes of Health; Pfizer","keywords":"Antidepressant; Major depressive disorder; Psychopharmacology; Monoamine neurotransmitter; Psychiatry; Medicine; microRNA; Reuptake inhibitor; Psychology; Bioinformatics; Pharmacology; Internal medicine; Receptor; Serotonin; Biology; Mood; Anxiety","score_opus":0.07909037364567921,"score_gpt":0.37371710061954705,"score_spread":0.2946267269738678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596957891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038850828,0.99615,0.0010258369,0.0005990778,0.00042805623,0.000009927058,0.000044192206,0.000022215938,0.0013321349],"genre_scores_gemma":[0.0066887154,0.9875317,0.0024305903,0.0010353241,0.00084218534,0.000044209894,0.00012521222,0.000010757316,0.0012912535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965715,0.000074472344,0.000047250138,0.00007591945,0.000118086085,0.000027212795],"domain_scores_gemma":[0.99935097,0.00042469328,0.00007096751,0.000018512557,0.0001065249,0.000028367182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009818568,0.0009753658,0.0017941975,0.0012501862,0.00020699247,0.0012169668,0.00095572736,0.0015123031,0.0017763798],"category_scores_gemma":[0.0014991331,0.00029798885,0.0006759314,0.0009485549,0.00074542745,0.00090897933,0.00069583923,0.002147361,0.0010451081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017092176,0.000074543896,0.0008459845,0.004849653,0.00015024413,0.00042452975,0.00005004578,0.0005141285,0.0076161623,0.004334376,0.014410835,0.9665586],"study_design_scores_gemma":[0.0001144482,0.00037716923,0.0038860894,0.0030773338,0.0005853634,0.004344128,0.00014215111,0.0015076672,0.010806044,0.009127334,0.96593326,0.00009894809],"about_ca_topic_score_codex":0.00055797765,"about_ca_topic_score_gemma":0.0012464444,"teacher_disagreement_score":0.0017941975,"about_ca_system_score_codex":0.00055695086,"about_ca_system_score_gemma":0.0007774408,"threshold_uncertainty_score":0.0059425235},"labels":[],"label_agreement":null},{"id":"W2599168029","doi":"10.1007/s40263-017-0427-y","title":"Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations","year":2017,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Queen's University Belfast","keywords":"Dementia; Medicine; Intensive care medicine; Health care; MEDLINE; Antibiotics; Psychiatry; Disease; Internal medicine","score_opus":0.09171518263481573,"score_gpt":0.3899917614172138,"score_spread":0.2982765787823981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599168029","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0134070255,0.4416259,0.001123893,0.5308453,0.00518937,0.000055337572,0.0005456932,0.000087905864,0.0071196184],"genre_scores_gemma":[0.16330908,0.7001374,0.010813154,0.10129791,0.020249031,0.00024225016,0.0010958582,0.000042855183,0.00281245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996503,0.0011152169,0.00095103966,0.0003796457,0.00073557405,0.00031552097],"domain_scores_gemma":[0.9683894,0.015891401,0.0038789304,0.0004466972,0.007880502,0.003513185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067868293,0.00066762586,0.0025427928,0.0015674521,0.0014403193,0.005819096,0.0022614263,0.0057972115,0.005939802],"category_scores_gemma":[0.027818324,0.00049956527,0.0017204563,0.0022541187,0.0014899855,0.007170069,0.0017855495,0.007408244,0.001103024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008264895,0.0017128153,0.14214508,0.007890128,0.00097211776,0.0013697584,0.0012451124,0.00076330634,0.0003158455,0.007756828,0.17881256,0.6561899],"study_design_scores_gemma":[0.0014376607,0.0023682343,0.23507832,0.09994143,0.0049372884,0.0051025795,0.032969937,0.006394937,0.0007387732,0.06216982,0.54816145,0.00069944176],"about_ca_topic_score_codex":0.012195374,"about_ca_topic_score_gemma":0.042256612,"teacher_disagreement_score":0.012195374,"about_ca_system_score_codex":0.0024185886,"about_ca_system_score_gemma":0.010225869,"threshold_uncertainty_score":0.035892606},"labels":[],"label_agreement":null},{"id":"W2607002700","doi":"10.1007/s40263-017-0439-7","title":"Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Lamotrigine; Medicine; In utero; Pregnancy; Pediatrics; Odds ratio; Carbamazepine; Population; Obstetrics; Epilepsy; Internal medicine; Fetus; Psychiatry","score_opus":0.17209415557151952,"score_gpt":0.4562765213663113,"score_spread":0.2841823657947918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607002700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021249533,0.7761901,0.0017349194,0.05598084,0.14705686,0.001542124,0.012828027,0.0002656983,0.0022764462],"genre_scores_gemma":[0.06003719,0.70437735,0.007927242,0.14672565,0.052280653,0.004544948,0.0070266165,0.0004896724,0.016590623],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98711675,0.00306984,0.006798965,0.00086466724,0.0017993333,0.00035046687],"domain_scores_gemma":[0.9529317,0.029993294,0.008800674,0.0011638902,0.006587727,0.00052278896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017636612,0.0026078287,0.006672628,0.007461696,0.0007432632,0.00246911,0.00245432,0.004086633,0.02702965],"category_scores_gemma":[0.11608116,0.001984975,0.009027562,0.0077368123,0.001053089,0.003079939,0.0020985573,0.00364232,0.003114434],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017071167,0.000041324303,0.002483376,0.5988343,0.043489475,0.0012409688,0.00038048992,0.00018306053,0.00029188674,0.0006852046,0.31737354,0.03328931],"study_design_scores_gemma":[0.006813883,0.00031456302,0.0106983865,0.314958,0.34711173,0.0016474876,0.00081220537,0.0003680611,0.0006107517,0.002642102,0.31369123,0.00033163902],"about_ca_topic_score_codex":0.008510301,"about_ca_topic_score_gemma":0.02590698,"teacher_disagreement_score":0.02702965,"about_ca_system_score_codex":0.00289639,"about_ca_system_score_gemma":0.007690467,"threshold_uncertainty_score":0.09327245},"labels":[],"label_agreement":null},{"id":"W2621146233","doi":"10.1007/s40263-017-0440-1","title":"A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; York University; University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Psychopharmacology; Medicine; Neurology; Adjunctive treatment; Neurosurgery; Intensive care medicine; Psychiatry; Internal medicine","score_opus":0.08613565472166292,"score_gpt":0.3917450842540957,"score_spread":0.3056094295324328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621146233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000881288,0.99938023,0.00004580219,0.00006887273,0.00007937325,0.0000048925695,0.000022478405,0.0000028374031,0.0003073139],"genre_scores_gemma":[0.0004436232,0.9990233,0.00015983814,0.00012510533,0.00009525021,0.0000043401915,0.00002017879,6.3273444e-7,0.0001277285],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996117,0.000057197332,0.00012344848,0.000059954586,0.000128348,0.000019465962],"domain_scores_gemma":[0.99899954,0.00063175504,0.00018359398,0.00001413112,0.00013516292,0.000035775727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059167674,0.00087967113,0.0017637174,0.0043298285,0.00035925873,0.0010678341,0.001037346,0.0010083978,0.004845888],"category_scores_gemma":[0.0015935996,0.0003357444,0.0011925385,0.0034240119,0.00038941466,0.0012621183,0.0006422918,0.0014345435,0.00077933964],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013842406,0.0001250165,0.00034415277,0.111677885,0.00046155925,0.00035771795,0.000087303546,0.00024150292,0.0013670945,0.0011759007,0.017839702,0.8661838],"study_design_scores_gemma":[0.00011580072,0.00044190363,0.0043271156,0.06659351,0.0026895078,0.005559363,0.00021051755,0.00027163766,0.001007978,0.0016153529,0.9170855,0.000081747145],"about_ca_topic_score_codex":0.0018035156,"about_ca_topic_score_gemma":0.0048179124,"teacher_disagreement_score":0.004845888,"about_ca_system_score_codex":0.00042908083,"about_ca_system_score_gemma":0.0014303575,"threshold_uncertainty_score":0.016211092},"labels":[],"label_agreement":null},{"id":"W2736248910","doi":"10.1007/s40263-017-0453-9","title":"Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cardiovascular Syncope and Autonomic Disorders","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Orthostatic vital signs; Baroreflex; Pure autonomic failure; Supine position; Blood pressure; Anesthesia; Cardiology; Midodrine; Internal medicine; Heart rate","score_opus":0.10340174153467674,"score_gpt":0.35388748833352446,"score_spread":0.2504857467988477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736248910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013124743,0.9991315,0.00012752287,0.00015037695,0.0001105619,0.000003064692,0.00000662089,0.0000050194244,0.0003340276],"genre_scores_gemma":[0.0022494628,0.9961881,0.00036522312,0.0004682539,0.0004744997,0.0000072452403,0.000029952147,0.0000020721332,0.0002152244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997019,0.0000570536,0.000077282355,0.00005252767,0.00008654932,0.000024738265],"domain_scores_gemma":[0.99952364,0.0002784842,0.0000996281,0.000008524867,0.000058730995,0.00003102202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045936936,0.0008878342,0.0019007492,0.0021334835,0.0002691959,0.0011920569,0.001001982,0.0012790535,0.001892179],"category_scores_gemma":[0.0014007064,0.00027840975,0.00090504455,0.0010239879,0.00040357347,0.0012123644,0.00070685474,0.0021863233,0.00063202664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012591084,0.000102861035,0.0006681952,0.02430415,0.00038224162,0.0017399391,0.000069808186,0.00033353365,0.00095681974,0.0008188785,0.017053934,0.95344365],"study_design_scores_gemma":[0.0003548956,0.00058385474,0.008071215,0.04122155,0.0028679883,0.039486174,0.00035561217,0.0009378859,0.0013311208,0.003702812,0.90093195,0.00015508707],"about_ca_topic_score_codex":0.00083696115,"about_ca_topic_score_gemma":0.0021580125,"teacher_disagreement_score":0.0021334835,"about_ca_system_score_codex":0.0003104524,"about_ca_system_score_gemma":0.00067467,"threshold_uncertainty_score":0.0063299537},"labels":[],"label_agreement":null},{"id":"W27800376","doi":"10.2165/00023210-200115030-00002","title":"Psychotic and Mood Disorders Associated with the Perimenopausal Period","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Stress Responses and Cortisol","field":"Neuroscience","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Psychopharmacology; Psychiatry; Mood disorders; Mood; Medicine; Neurology; Period (music); Psychosis; Psychology; Anxiety","score_opus":0.03430845675862346,"score_gpt":0.31247137427328087,"score_spread":0.2781629175146574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W27800376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012285615,0.9988003,0.000080929196,0.0001534677,0.0001556517,0.000003359493,0.000011149281,0.0000035283817,0.0006687467],"genre_scores_gemma":[0.0007518868,0.9981504,0.00012631924,0.00015194231,0.00029631608,0.000004054361,0.000018751718,7.9433505e-7,0.0004994584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998337,0.00003269509,0.00003183365,0.000036448208,0.00005139923,0.000013885623],"domain_scores_gemma":[0.9995035,0.00026626716,0.00009418468,0.000014083733,0.000079692974,0.000042356678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051723525,0.0010312028,0.001986438,0.0022238335,0.00034559306,0.0011186758,0.00083291996,0.0014296623,0.0026399386],"category_scores_gemma":[0.00088887056,0.00028924743,0.0003891391,0.0027573851,0.00060654467,0.0010588645,0.00054150115,0.0014290118,0.0012651875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012828367,0.00010057172,0.0006912972,0.010416031,0.000104476465,0.0008646577,0.00005781217,0.0003186755,0.00094296335,0.00088058296,0.018603563,0.9668911],"study_design_scores_gemma":[0.000059505383,0.00024417968,0.00889494,0.007437623,0.00040942736,0.011999263,0.00025903038,0.00022579568,0.000549123,0.0022092208,0.96766204,0.000049827304],"about_ca_topic_score_codex":0.0025092533,"about_ca_topic_score_gemma":0.008254979,"teacher_disagreement_score":0.0026399386,"about_ca_system_score_codex":0.00062759407,"about_ca_system_score_gemma":0.0011418913,"threshold_uncertainty_score":0.008831501},"labels":[],"label_agreement":null},{"id":"W2791111957","doi":"10.1007/s40263-018-0507-7","title":"Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Intracerebral and Subarachnoid Hemorrhage Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Reuptake inhibitor; Medicine; Serotonin Uptake Inhibitors; Reuptake; Serotonin; Serotonin reuptake inhibitor; Pharmacology; Internal medicine; Psychiatry; Fluoxetine","score_opus":0.05731548868257076,"score_gpt":0.3207594309603097,"score_spread":0.26344394227773893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791111957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018789867,0.99758565,0.000048539398,0.000073546464,0.000045675664,0.000040724393,0.00023616957,0.0000030631504,0.00008774023],"genre_scores_gemma":[0.018526716,0.9807272,0.00019084042,0.00023046965,0.000063416286,0.000056097724,0.00013859806,0.0000017540665,0.000064867854],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99827623,0.00036260948,0.00072389736,0.00024728198,0.00030208612,0.000087952234],"domain_scores_gemma":[0.99212635,0.0054678605,0.001747768,0.00008285178,0.0004751563,0.00009993851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001840807,0.0011202316,0.0054914146,0.004371502,0.00038645428,0.0015212353,0.0010364545,0.001677463,0.0030737503],"category_scores_gemma":[0.0119033735,0.00075519795,0.008404012,0.0063451324,0.00045399685,0.0011735064,0.0009538366,0.001117147,0.00016869088],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000758513,0.000036995167,0.0063785813,0.9003182,0.054643158,0.00028129775,0.00015311172,0.00018006265,0.00025240245,0.00014770178,0.0017812607,0.03506862],"study_design_scores_gemma":[0.00075425464,0.00041879926,0.034586776,0.37183264,0.57263094,0.001590548,0.00049575575,0.00022139768,0.00029985575,0.000443605,0.01659537,0.00013008014],"about_ca_topic_score_codex":0.011005435,"about_ca_topic_score_gemma":0.02660976,"teacher_disagreement_score":0.011005435,"about_ca_system_score_codex":0.0014112365,"about_ca_system_score_gemma":0.003968476,"threshold_uncertainty_score":0.021882772},"labels":[],"label_agreement":null},{"id":"W2791860867","doi":"10.1007/s40263-018-0490-z","title":"Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; St. Michael's Hospital; University Health Network","funders":"","keywords":"Modafinil; Major depressive disorder; Pharmacotherapy; Atomoxetine; Medicine; Psychiatry; Psychopharmacology; Psychological intervention; Clinical psychology; Psychology; Cognition; Methylphenidate; Attention deficit hyperactivity disorder","score_opus":0.07535872882892011,"score_gpt":0.32116784511316976,"score_spread":0.24580911628424965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791860867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003630274,0.99933237,0.000022223217,0.000106422085,0.000031628668,0.0000030153685,0.00001986423,0.000001139897,0.00012026161],"genre_scores_gemma":[0.0032397432,0.996326,0.000122003716,0.00013070664,0.0000728931,0.0000059774134,0.000031001404,3.902442e-7,0.000071195434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997683,0.000047935922,0.00006277625,0.000038032926,0.000065798784,0.000017159926],"domain_scores_gemma":[0.99942786,0.00034264135,0.000140037,0.0000069730086,0.00006299513,0.00001943586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007026008,0.0005574254,0.0017924178,0.0015234322,0.00017413458,0.0008195442,0.00068995473,0.0006622299,0.0017030833],"category_scores_gemma":[0.0012851525,0.00026432678,0.0010320034,0.00154257,0.00023484902,0.0006581612,0.00039577886,0.00090180367,0.00019394964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000339617,0.00010536347,0.0033966089,0.056788605,0.0012970073,0.00014394228,0.00009957439,0.00028615203,0.0004997763,0.00058408314,0.006941781,0.92951745],"study_design_scores_gemma":[0.00093175244,0.0018303638,0.15239812,0.16602427,0.015536503,0.009961647,0.0013104626,0.0012879403,0.0009540366,0.0045592436,0.6449358,0.00026993811],"about_ca_topic_score_codex":0.002734317,"about_ca_topic_score_gemma":0.0081517715,"teacher_disagreement_score":0.002734317,"about_ca_system_score_codex":0.00040894927,"about_ca_system_score_gemma":0.00077405217,"threshold_uncertainty_score":0.0056973696},"labels":[],"label_agreement":null},{"id":"W2803533112","doi":"10.1007/s40263-018-0526-4","title":"Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ceritinib; Anaplastic lymphoma kinase; Alectinib; Pembrolizumab; Atezolizumab; Lung cancer; Crizotinib; Nivolumab; Epidermal growth factor receptor; Radiation therapy; Oncology; Immunotherapy; Cancer; Cancer research; Internal medicine","score_opus":0.05160550864221264,"score_gpt":0.3612285686345384,"score_spread":0.30962305999232576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803533112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018032671,0.9988569,0.00011076251,0.00010456933,0.000072596755,0.000005696285,0.000015748179,0.000004401139,0.0006490028],"genre_scores_gemma":[0.0015363325,0.99738675,0.00018461738,0.00018929761,0.00010843299,0.000009453802,0.00003627616,0.0000012577485,0.00054746954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989927,0.000015815587,0.000016733,0.000019904332,0.00003616735,0.000012230187],"domain_scores_gemma":[0.99986374,0.00007095302,0.000028517423,0.000003494712,0.000024878129,0.000008338138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028999243,0.00060438213,0.0011938739,0.001196174,0.00014613975,0.0005982236,0.0005965317,0.0005814493,0.0025095935],"category_scores_gemma":[0.00040240315,0.00017854638,0.0005234837,0.0009935682,0.0002433463,0.0005961094,0.00035957445,0.0012868048,0.00084147847],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011837694,0.00009333537,0.00014578745,0.017098136,0.0001311706,0.00015590004,0.000030680447,0.00040603787,0.0027668711,0.0017614872,0.018607898,0.95868427],"study_design_scores_gemma":[0.000104788625,0.0003650901,0.0014666048,0.004713771,0.00046237113,0.002359671,0.000046385398,0.0002723581,0.0017780664,0.0012651831,0.9871377,0.000028018763],"about_ca_topic_score_codex":0.00091784284,"about_ca_topic_score_gemma":0.0024384602,"teacher_disagreement_score":0.0025095935,"about_ca_system_score_codex":0.0003562117,"about_ca_system_score_gemma":0.0005736989,"threshold_uncertainty_score":0.008395433},"labels":[],"label_agreement":null},{"id":"W2841591265","doi":"10.1007/s40263-018-0536-2","title":"Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Biogen","keywords":"Medicine; Multiple sclerosis; 4-Aminopyridine; Context (archaeology); Intensive care medicine; Clinical Practice; Clinical trial; Neurology; Clinical research; Approved drug; Drug; Physical therapy; Pharmacology; Internal medicine; Psychiatry; Potassium channel","score_opus":0.25025202403471297,"score_gpt":0.40428571449465667,"score_spread":0.1540336904599437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2841591265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008675524,0.9996321,0.000016653907,0.000065516644,0.000038774375,0.0000029342004,0.00001089618,0.0000018212645,0.00014452485],"genre_scores_gemma":[0.0009078807,0.9986928,0.00007594183,0.00013426221,0.00006628977,0.0000044473895,0.000014129894,5.7063664e-7,0.0001036511],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997156,0.000056581073,0.00007637123,0.00004719638,0.00008043748,0.000023725448],"domain_scores_gemma":[0.9991836,0.0005386349,0.00014047125,0.000012989292,0.000091785056,0.000032521253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010349158,0.0009670417,0.0031062416,0.0027512412,0.0002396327,0.001485153,0.0010566708,0.0015506742,0.0040675174],"category_scores_gemma":[0.0012967064,0.00035539188,0.0011833756,0.0025827116,0.00063307077,0.0012454801,0.00063089427,0.0020666164,0.000745329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062519865,0.0001718416,0.00026133066,0.10536505,0.0007752754,0.0002630073,0.00009465319,0.00031709022,0.0019040009,0.002122506,0.014299888,0.87380016],"study_design_scores_gemma":[0.0009879235,0.0011626858,0.005432196,0.05559529,0.0053234785,0.003158245,0.00029425125,0.0003909624,0.0017845599,0.00352641,0.92220694,0.00013695731],"about_ca_topic_score_codex":0.0015054495,"about_ca_topic_score_gemma":0.004363343,"teacher_disagreement_score":0.0040675174,"about_ca_system_score_codex":0.00047466488,"about_ca_system_score_gemma":0.0014393829,"threshold_uncertainty_score":0.013607204},"labels":[],"label_agreement":null},{"id":"W2885631557","doi":"10.1007/s40263-018-0559-8","title":"Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Tics; Discontinuation; Antipsychotic; Tourette syndrome; Psychiatry; Olanzapine; Pediatrics; Medicine; PsycINFO; Psychology; Schizophrenia (object-oriented programming); MEDLINE","score_opus":0.019711716712524797,"score_gpt":0.3369957751390928,"score_spread":0.317284058426568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885631557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006434488,0.9988825,0.000040888975,0.00006055269,0.000052164898,0.000051299277,0.00016098104,0.0000028762581,0.00010530306],"genre_scores_gemma":[0.0074782013,0.9917568,0.00021594054,0.00026864753,0.0000476245,0.000057107227,0.00011082514,0.0000017056419,0.00006312706],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985638,0.00028994156,0.0006207813,0.00019497784,0.0002502811,0.00008019331],"domain_scores_gemma":[0.9961164,0.0025425162,0.00097034965,0.000045229906,0.00024828146,0.00007710739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017534179,0.0012079414,0.005950076,0.0058232495,0.00041142074,0.001947085,0.0015077047,0.0016715107,0.0042320457],"category_scores_gemma":[0.008075762,0.00074455346,0.006855017,0.007097736,0.0005485556,0.0017059912,0.0013801752,0.0011529619,0.00020411515],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032546156,0.0000297918,0.0014716799,0.93761647,0.015148756,0.00020538333,0.00013767998,0.00011289972,0.00016205439,0.00015989474,0.0020564685,0.042573437],"study_design_scores_gemma":[0.0007644753,0.0003174253,0.01580956,0.6950718,0.24731798,0.0017348652,0.00054584304,0.00016993136,0.00017283157,0.00047368117,0.03750549,0.000116109346],"about_ca_topic_score_codex":0.0093797725,"about_ca_topic_score_gemma":0.03571109,"teacher_disagreement_score":0.0093797725,"about_ca_system_score_codex":0.001506566,"about_ca_system_score_gemma":0.004196023,"threshold_uncertainty_score":0.018650353},"labels":[],"label_agreement":null},{"id":"W2895953827","doi":"10.1007/s40263-018-0579-4","title":"From LBR-101 to Fremanezumab for Migraine","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Calcitonin gene-related peptide; Migraine; Chronic Migraine; Medicine; Calcitonin; Monoclonal antibody; Drug development; Pharmacology; In vivo; Receptor; Bioinformatics; Neuroscience; Antibody; Neuropeptide; Immunology; Drug; Internal medicine; Biology","score_opus":0.08518251319761845,"score_gpt":0.40393790446252364,"score_spread":0.3187553912649052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895953827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013436368,0.99926645,0.0000197219,0.00010415826,0.000080571124,0.000008664897,0.000033385248,0.0000025861168,0.00035007883],"genre_scores_gemma":[0.0020132556,0.9970741,0.000115323135,0.00039377107,0.0000973026,0.000014716072,0.00003694268,0.00000113149,0.00025351055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945575,0.00016218665,0.00017772132,0.00006680629,0.00010080747,0.000036684978],"domain_scores_gemma":[0.99871576,0.00082161656,0.00030170046,0.000020973062,0.00009828962,0.000041664032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013007437,0.0009840829,0.003358586,0.0048019527,0.0002571035,0.0014386347,0.001060945,0.0014274768,0.011771141],"category_scores_gemma":[0.003218752,0.00046668568,0.0023236212,0.0034388506,0.0005501211,0.0012614706,0.0010287149,0.0015893559,0.00091863767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096554734,0.000108170105,0.00030989968,0.33117625,0.0038370246,0.00031525985,0.00012676361,0.0002291179,0.00091159844,0.0012590578,0.018148605,0.6426127],"study_design_scores_gemma":[0.002312589,0.0013023712,0.005365648,0.24439229,0.033948205,0.002824028,0.00038028607,0.00017969996,0.0008863423,0.0018783455,0.7064291,0.00010100982],"about_ca_topic_score_codex":0.0019801767,"about_ca_topic_score_gemma":0.00809864,"teacher_disagreement_score":0.011771141,"about_ca_system_score_codex":0.00075584487,"about_ca_system_score_gemma":0.0015715596,"threshold_uncertainty_score":0.039378405},"labels":[],"label_agreement":null},{"id":"W2902232281","doi":"10.1007/s40263-018-0593-6","title":"Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Weston Brain Institute","keywords":"Neuroprotection; Neuroscience; Parkinson's disease; Disease; Medicine; Clinical trial; Neurology; Bioinformatics; Psychology; Internal medicine; Biology","score_opus":0.0666686767453187,"score_gpt":0.3375970176882603,"score_spread":0.2709283409429416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902232281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025199278,0.9989924,0.00006848773,0.00008400027,0.000070081056,0.0000058602704,0.000026407924,0.0000044851554,0.0004962962],"genre_scores_gemma":[0.0010042386,0.9983394,0.0001695182,0.00010299061,0.00006436947,0.0000065698196,0.000032198845,8.5864883e-7,0.000279847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987507,0.000018966393,0.00002800032,0.000019313155,0.000044855213,0.000013788361],"domain_scores_gemma":[0.99983025,0.000085110085,0.000039116618,0.000004052255,0.00002968118,0.000011777265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049575046,0.00084465486,0.0017797642,0.0018241083,0.00019419649,0.0008462685,0.00072016,0.00073252147,0.003868351],"category_scores_gemma":[0.0005461145,0.0002632501,0.0006794255,0.0015837009,0.0003172643,0.00085798046,0.0005606883,0.0015020773,0.0009903791],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027842904,0.00013676364,0.0001603717,0.041068003,0.00030130747,0.0002908468,0.00006409141,0.00036624103,0.0024565125,0.002053702,0.012004013,0.94081956],"study_design_scores_gemma":[0.000246371,0.00039819663,0.0017468339,0.0106303,0.0011296674,0.002301282,0.00012720296,0.00019397875,0.0014679644,0.0024322348,0.97927606,0.000049792452],"about_ca_topic_score_codex":0.00086754275,"about_ca_topic_score_gemma":0.001894274,"teacher_disagreement_score":0.003868351,"about_ca_system_score_codex":0.00027642658,"about_ca_system_score_gemma":0.0006108281,"threshold_uncertainty_score":0.012940884},"labels":[],"label_agreement":null},{"id":"W2902974546","doi":"10.1007/s40263-018-0588-3","title":"Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later","year":2018,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; University of Toronto","funders":"","keywords":"Tolerability; Psychopharmacology; Schizophrenia (object-oriented programming); Psychiatry; Antipsychotic; Psychology; Antipsychotic drug; Psychotherapist; Medicine; Pharmacology; Adverse effect","score_opus":0.13617126211709812,"score_gpt":0.48317644373907936,"score_spread":0.34700518162198124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902974546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001807627,0.99597114,0.00013565875,0.0025424063,0.0007936912,0.000003397161,0.000022485718,0.0000021323376,0.00034827692],"genre_scores_gemma":[0.0027102167,0.9910131,0.00033843334,0.0037323348,0.0017191292,0.000010674366,0.000030550724,0.0000048719294,0.00044071637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872977,0.00044970142,0.00023495934,0.0002016589,0.00032056202,0.00006342659],"domain_scores_gemma":[0.99533504,0.0033638992,0.00026384878,0.00010260099,0.0008371386,0.000097458666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004914338,0.0009770809,0.0021152555,0.001790207,0.00036411075,0.0031737355,0.00092086225,0.002054031,0.0024692041],"category_scores_gemma":[0.0067333337,0.00026495254,0.0011449667,0.0033530216,0.002398646,0.0046251346,0.0019064776,0.0043988116,0.00068866776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003112588,0.00012630103,0.0009828444,0.036635574,0.00041760548,0.00025660798,0.0013704619,0.0003360731,0.0009876312,0.028663043,0.051658515,0.8782541],"study_design_scores_gemma":[0.000056324647,0.00018304998,0.0043246998,0.030081926,0.0004766643,0.0010599885,0.0011315234,0.00016089193,0.00033704442,0.012404967,0.9496782,0.000104700164],"about_ca_topic_score_codex":0.005000678,"about_ca_topic_score_gemma":0.009114576,"teacher_disagreement_score":0.005000678,"about_ca_system_score_codex":0.001964238,"about_ca_system_score_gemma":0.004277733,"threshold_uncertainty_score":0.02598983},"labels":[],"label_agreement":null},{"id":"W2910495852","doi":"10.1007/s40263-018-0597-2","title":"Phytomedicines in the Treatment of Migraine","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary; Women and Children’s Health Research Institute; University of Alberta","funders":"","keywords":"Migraine; Psychopharmacology; Neurology; Medicine; Psychiatry; Psychology","score_opus":0.11595345186461525,"score_gpt":0.4122082481325315,"score_spread":0.29625479626791623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910495852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000089038425,0.9995913,0.000020885995,0.00003850806,0.00003868673,0.0000044949843,0.00001727912,0.0000019423535,0.00019791696],"genre_scores_gemma":[0.0007651215,0.9989222,0.000087389075,0.00007687496,0.000034781635,0.000004300313,0.00001542356,4.804691e-7,0.0000933582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997285,0.0000674147,0.000071625145,0.000042091637,0.000069931666,0.000020427653],"domain_scores_gemma":[0.99932325,0.0004832436,0.000106264015,0.000012153122,0.000052799667,0.000022359876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071633304,0.00092176505,0.0024501965,0.0038374823,0.00028073107,0.0009745725,0.0008084999,0.0010909983,0.0064254445],"category_scores_gemma":[0.0013548138,0.00032779644,0.0014176861,0.0035945436,0.00041394937,0.00072480226,0.00066970143,0.0011463882,0.00071429653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042369313,0.00012756781,0.00022022118,0.20566468,0.0013016982,0.00018653904,0.00007478042,0.00029946008,0.0011010371,0.0012949513,0.0076298336,0.78167546],"study_design_scores_gemma":[0.0007612444,0.00086250174,0.006164148,0.15377155,0.013680155,0.0023454295,0.00034368236,0.00030990836,0.0010797344,0.003035042,0.8175483,0.0000983136],"about_ca_topic_score_codex":0.0031619167,"about_ca_topic_score_gemma":0.008085217,"teacher_disagreement_score":0.0064254445,"about_ca_system_score_codex":0.0005302191,"about_ca_system_score_gemma":0.0010612023,"threshold_uncertainty_score":0.021495223},"labels":[],"label_agreement":null},{"id":"W2910561017","doi":"10.1007/s40263-018-0599-0","title":"Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"Royal Melbourne Hospital","keywords":"Schizophrenia (object-oriented programming); Psychosis; Psychiatry; Mood disorders; Dystonia; Neurology; Psychology; Disease; Cognition; Mood; Bipolar disorder; Medicine; Anxiety; Internal medicine","score_opus":0.029798970696599817,"score_gpt":0.3348153211590439,"score_spread":0.3050163504624441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910561017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007078317,0.99950993,0.000038094746,0.00008785484,0.00005797924,0.0000017873344,0.000010500651,0.000002489803,0.0002206207],"genre_scores_gemma":[0.0005574653,0.9988939,0.000121316756,0.00011452525,0.00015087635,0.00000328484,0.000021737811,5.2912094e-7,0.00013638214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998266,0.000027899809,0.00004170489,0.0000338625,0.000054124044,0.00001578751],"domain_scores_gemma":[0.99961996,0.00019262405,0.0000807891,0.000008326737,0.000065808345,0.000032447577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044392928,0.0010462143,0.0021366584,0.002380272,0.00023745252,0.0010072571,0.0009796754,0.0010369474,0.0023200589],"category_scores_gemma":[0.00079407677,0.00025007778,0.0006634757,0.0020482293,0.00045733686,0.0009170334,0.0006947698,0.0014142267,0.0007826501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019247505,0.00010518687,0.0004734969,0.020565327,0.00031198162,0.0005161301,0.000032596592,0.00036604624,0.0008338793,0.001201905,0.020834036,0.954567],"study_design_scores_gemma":[0.00019465866,0.00029610228,0.006274808,0.01776058,0.0017703255,0.008764632,0.00020248866,0.0004603391,0.0006794193,0.0036870157,0.95981133,0.00009822773],"about_ca_topic_score_codex":0.0018351567,"about_ca_topic_score_gemma":0.0044562467,"teacher_disagreement_score":0.002380272,"about_ca_system_score_codex":0.0005201599,"about_ca_system_score_gemma":0.0010807465,"threshold_uncertainty_score":0.007761359},"labels":[],"label_agreement":null},{"id":"W2920380976","doi":"10.1007/s40263-019-00618-2","title":"Expanding Role of NMDA Receptor Antagonists in the Management of Pain","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Anesthesia and Sedative Agents","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; St. Joseph's Hospital; St Joseph's Health Care","funders":"","keywords":"Dextromethorphan; Ketamine; NMDA receptor; Memantine; Medicine; Chronic pain; Pharmacology; Anesthesia; Intensive care medicine; Receptor; Psychiatry; Internal medicine","score_opus":0.0472936803371561,"score_gpt":0.3455623342468386,"score_spread":0.2982686539096825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920380976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009434013,0.9989729,0.000068908244,0.00017362267,0.00008495653,0.00000344374,0.000008894529,0.00000377624,0.00058907305],"genre_scores_gemma":[0.00048975856,0.9990663,0.00008643896,0.00012085415,0.00007573158,0.0000034814939,0.000010199369,6.732206e-7,0.00014665404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996809,0.00007281527,0.00006898378,0.000053279095,0.00010109207,0.000022970693],"domain_scores_gemma":[0.9993907,0.00037930865,0.000089235444,0.000014353796,0.00010101523,0.000025369625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007449463,0.00074088183,0.0012815838,0.0022505363,0.00025195384,0.00093033427,0.0007349534,0.00087707164,0.0038996357],"category_scores_gemma":[0.0010367018,0.00020281342,0.0008082006,0.0015347988,0.0004622448,0.0012146778,0.00066359044,0.0018015064,0.0012272368],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007969609,0.00006805764,0.00016694037,0.03347381,0.00014468291,0.00019399526,0.00008286933,0.0002624901,0.0013497125,0.0031447427,0.011552782,0.9494803],"study_design_scores_gemma":[0.000040768366,0.00025365793,0.0013834449,0.014117282,0.0003484037,0.0024021086,0.000105282124,0.0001545021,0.0007665002,0.00289319,0.9775079,0.000026995063],"about_ca_topic_score_codex":0.0010770572,"about_ca_topic_score_gemma":0.0024007575,"teacher_disagreement_score":0.0038996357,"about_ca_system_score_codex":0.0005956716,"about_ca_system_score_gemma":0.0010956994,"threshold_uncertainty_score":0.013045549},"labels":[],"label_agreement":null},{"id":"W2928038989","doi":"10.1007/s40263-019-00622-6","title":"The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury","year":2019,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; International Collaboration On Repair Discoveries; University of British Columbia","funders":"Canadian Institutes of Health Research; Wings for Life; Craig H. Neilsen Foundation","keywords":"Spinal cord injury; Pregabalin; Gabapentin; Medicine; Anesthesia; Anticonvulsant; Neurology; Spinal cord; Psychopharmacology; Epilepsy; Pharmacology; Psychiatry","score_opus":0.01473338062620074,"score_gpt":0.3675172022363786,"score_spread":0.3527838216101779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928038989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948304,0.003875375,0.000075278855,0.000048846014,0.000051047,0.000028738186,0.00008949686,0.0000076029755,0.0009933205],"genre_scores_gemma":[0.9949098,0.0031880722,0.00014166838,0.00004194008,0.00003814633,0.000017727834,0.00014219222,0.000003816705,0.0015165635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999897,0.00003129091,0.000009816269,0.000009404809,0.000012082281,0.000040437102],"domain_scores_gemma":[0.9998789,0.000040695028,0.000018280203,0.000010481252,0.000016766346,0.000034842975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020470237,0.0002574977,0.00051175745,0.00021893192,0.00027297813,0.00023919262,0.00026502553,0.0002486112,0.0027730654],"category_scores_gemma":[0.00041500395,0.00008425789,0.00027442668,0.00020849507,0.000350529,0.00022597023,0.00014617195,0.0004259114,0.00025335315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37455863,0.010092276,0.0028880497,0.0012172892,0.0004938242,0.00091478316,0.0002942559,0.00058923766,0.46144527,0.00042277828,0.001116725,0.14596684],"study_design_scores_gemma":[0.010565679,0.25280783,0.13099541,0.00020499121,0.0015800006,0.0014281033,0.00084264367,0.0020288655,0.5892335,0.00035766873,0.009870122,0.00008510528],"about_ca_topic_score_codex":0.0036983902,"about_ca_topic_score_gemma":0.009396779,"teacher_disagreement_score":0.0036983902,"about_ca_system_score_codex":0.00019994749,"about_ca_system_score_gemma":0.00052273826,"threshold_uncertainty_score":0.009276867},"labels":[],"label_agreement":null},{"id":"W2940332174","doi":"10.1007/s40263-019-00629-z","title":"Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia","funders":"","keywords":"Aripiprazole; Risperidone; Bipolar disorder; Paliperidone; Olanzapine; Medicine; Randomized controlled trial; Psychiatry; Quetiapine; Treatment of bipolar disorder; Cochrane Library; Antipsychotic; Bipolar I disorder; Atypical antipsychotic; Mood; Pediatrics; Schizophrenia (object-oriented programming); Internal medicine; Mania","score_opus":0.05585145500879804,"score_gpt":0.3455361583013354,"score_spread":0.28968470329253737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940332174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037034965,0.9991578,0.000050095972,0.0000621971,0.000057472465,0.000044102366,0.00012810207,0.0000037596171,0.00012609884],"genre_scores_gemma":[0.003622854,0.995756,0.00017813504,0.00022676711,0.000037635,0.00004105268,0.00006756099,0.0000013833601,0.00006861682],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9988771,0.0002942618,0.00040045867,0.00012666776,0.00023812824,0.00006340244],"domain_scores_gemma":[0.9963349,0.0025154424,0.0007904928,0.000038222177,0.00023870576,0.00008213168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019286539,0.0010801959,0.0054498333,0.003770463,0.00038187666,0.0014336365,0.0013554598,0.001303739,0.005096464],"category_scores_gemma":[0.006845065,0.00052567426,0.0056141904,0.0047869436,0.00046217712,0.0011868321,0.0008762797,0.0011170502,0.00029835157],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004755395,0.00003400155,0.0005087571,0.9076287,0.012543664,0.0001175065,0.000086340064,0.00013436133,0.00022426176,0.0002019025,0.0033926552,0.074652284],"study_design_scores_gemma":[0.0012181316,0.0004656224,0.007451983,0.73907214,0.206256,0.0007862854,0.00027167052,0.00018721173,0.00026453155,0.0005135757,0.043431286,0.00008148484],"about_ca_topic_score_codex":0.010267551,"about_ca_topic_score_gemma":0.036421,"teacher_disagreement_score":0.010267551,"about_ca_system_score_codex":0.0016913747,"about_ca_system_score_gemma":0.004241011,"threshold_uncertainty_score":0.020415604},"labels":[],"label_agreement":null},{"id":"W2942949442","doi":"10.1007/s40263-019-00636-0","title":"Authors’ Reply to Diener: “Phytomedicines in the Treatment of Migraine”","year":2019,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary; Women and Children’s Health Research Institute; University of Alberta","funders":"","keywords":"Diener; Migraine; Medicine; Psychopharmacology; Neurology; Psychiatry; Psychology; Psychotherapist","score_opus":0.034174075225902795,"score_gpt":0.31575787617181605,"score_spread":0.2815838009459133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942949442","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029238174,0.002549581,0.00003550614,0.96873415,0.027268326,0.00000863083,0.00006793214,0.000010725315,0.0010327788],"genre_scores_gemma":[0.002167707,0.0011355926,0.00006972151,0.95671195,0.03727884,0.00002130608,0.000021718184,0.000008418682,0.0025847568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996287,0.0014173182,0.00068192236,0.00045948534,0.0007064475,0.0004478054],"domain_scores_gemma":[0.988284,0.0076821325,0.0009977925,0.00022990057,0.0016665255,0.0011396299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003388165,0.00073060533,0.0019067761,0.0010010193,0.0032402263,0.003186904,0.001573396,0.050305583,0.0056687063],"category_scores_gemma":[0.026562108,0.00078701356,0.0012095119,0.0010419437,0.0024330055,0.0029800015,0.0013930213,0.027118897,0.0040833587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021094384,0.000033041662,0.00056602224,0.00013675967,0.000033478555,0.0016150653,0.0001920323,0.00003072461,0.00012923696,0.0013866997,0.989995,0.0056709885],"study_design_scores_gemma":[0.0002769771,0.0001276188,0.0019477155,0.0007801698,0.00009552038,0.0025624956,0.0007705535,0.00023085432,0.0003546223,0.005271081,0.98747474,0.00010756978],"about_ca_topic_score_codex":0.004784284,"about_ca_topic_score_gemma":0.006652475,"teacher_disagreement_score":0.050305583,"about_ca_system_score_codex":0.00301004,"about_ca_system_score_gemma":0.0036235733,"threshold_uncertainty_score":0.02183944},"labels":[],"label_agreement":null},{"id":"W2946911722","doi":"10.1007/s40263-019-00641-3","title":"Methylene Blue in the Treatment of Neuropsychiatric Disorders","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Methylene blue; Antidepressant; Anxiolytic; Bipolar disorder; Neuroprotection; Pharmacology; Medicine; Psychiatry; Mania; Psychology; Neuroscience; Lithium (medication); Anxiety; Chemistry","score_opus":0.05658665457901436,"score_gpt":0.3316590149100579,"score_spread":0.27507236033104354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946911722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007999814,0.9989047,0.00006955371,0.0001046848,0.00012844046,0.000003275822,0.000010715715,0.0000050972626,0.0006934162],"genre_scores_gemma":[0.00066739606,0.99825746,0.00015241011,0.00014640806,0.00015586588,0.0000046632063,0.000020442309,0.0000013247064,0.00059411646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998703,0.000026831798,0.000018891064,0.000023916506,0.00004497828,0.00001514631],"domain_scores_gemma":[0.9997967,0.00011088088,0.00003282472,0.000005475912,0.00003302788,0.000021183472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004211895,0.0009135733,0.0014149178,0.0020208152,0.00022127625,0.000813926,0.0009698887,0.0010411994,0.00408714],"category_scores_gemma":[0.0005203012,0.00023019464,0.00044021563,0.0015613292,0.0004751789,0.00072436035,0.00059956673,0.0018372325,0.0018028034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014914549,0.00009509176,0.0000930467,0.013823716,0.00009513802,0.00022192563,0.000033882254,0.00036750024,0.001792856,0.0020413545,0.022334445,0.958952],"study_design_scores_gemma":[0.00009485817,0.00022345937,0.00093282893,0.005425891,0.00027812197,0.0016716786,0.0000519328,0.00016510411,0.0005703189,0.0017403681,0.9888198,0.000025576936],"about_ca_topic_score_codex":0.0018415547,"about_ca_topic_score_gemma":0.0043707574,"teacher_disagreement_score":0.00408714,"about_ca_system_score_codex":0.0004910656,"about_ca_system_score_gemma":0.0007952861,"threshold_uncertainty_score":0.013672888},"labels":[],"label_agreement":null},{"id":"W2948421871","doi":"10.1007/s40263-019-00643-1","title":"Endolysosome and Autolysosome Dysfunction in Alzheimer’s Disease: Where Intracellular and Extracellular Meet","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alzheimer Nederland; ZonMw; EU Joint Programme – Neurodegenerative Disease Research; Weston Brain Institute; Alzheimer's Association","keywords":"Proteostasis; Intracellular; Lysosome; Endosome; Autophagy; Extracellular; Cell biology; Neuroscience; Disease; Biology; Secretion; Medicine; Pathology; Genetics; Biochemistry","score_opus":0.037134919561475375,"score_gpt":0.3097020473000599,"score_spread":0.27256712773858455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948421871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009638521,0.9985328,0.0000700738,0.00014656791,0.00014915127,0.000002559468,0.000011409404,0.000005511232,0.0009854147],"genre_scores_gemma":[0.00064262695,0.9983082,0.000118685035,0.0001245379,0.00008395195,0.0000033948277,0.000024276103,0.0000010063987,0.00069321657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998807,0.000020344183,0.000018706478,0.000018192077,0.000047970258,0.000014171531],"domain_scores_gemma":[0.99988997,0.00003855356,0.000023213694,0.0000039724705,0.000030286414,0.000013926031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025406166,0.00071841,0.0010928524,0.0022501156,0.0002918221,0.00084114505,0.0005163638,0.0009810032,0.0031086653],"category_scores_gemma":[0.0003125398,0.00016687205,0.00040547812,0.0024289745,0.00038419705,0.0011466711,0.0006432897,0.0011642849,0.0018439648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082408355,0.000059746737,0.00019843024,0.023585191,0.000096906224,0.0003686586,0.000104461535,0.00027890352,0.0031073522,0.0055287667,0.033281226,0.93330795],"study_design_scores_gemma":[0.000010747966,0.00007904353,0.0011814671,0.0052250163,0.000094963834,0.0024349594,0.00009474221,0.00006575073,0.00049423106,0.0028868038,0.987417,0.000015228201],"about_ca_topic_score_codex":0.0008549226,"about_ca_topic_score_gemma":0.0017503118,"teacher_disagreement_score":0.0031086653,"about_ca_system_score_codex":0.00051403465,"about_ca_system_score_gemma":0.0009512219,"threshold_uncertainty_score":0.010399461},"labels":[],"label_agreement":null},{"id":"W2963057845","doi":"10.1007/s40263-019-00651-1","title":"Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets","year":2019,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"European Commission","keywords":"Amantadine; Pharmacokinetics; Renal function; Medicine; Pharmacology; Dosing; Creatinine; Population; Urology; Oral administration; Internal medicine","score_opus":0.005505265742242169,"score_gpt":0.24411152707068612,"score_spread":0.23860626132844395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963057845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965833,0.0013574089,0.0012546284,0.000041538733,0.000010386644,0.00002197381,0.00007348371,0.00003247345,0.00062494935],"genre_scores_gemma":[0.9990565,0.00027486985,0.0004369935,0.00002741265,0.0000043140776,0.0000066101984,0.000045879402,0.000004601829,0.00014285758],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999705,0.00010415777,0.000020619531,0.000040056682,0.00009929169,0.000030909217],"domain_scores_gemma":[0.9993594,0.00027217576,0.00018797371,0.000049357353,0.00008011527,0.00005095157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005875197,0.0001755821,0.00038099725,0.00011516617,0.000110668676,0.00039455737,0.00017642035,0.00018799808,0.00086551864],"category_scores_gemma":[0.001781048,0.00009245304,0.00042131435,0.00012850853,0.00012763838,0.00025867787,0.00014810839,0.00030200614,0.00015975037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04706346,0.0023215197,0.2346575,0.0008495286,0.001310866,0.0021791903,0.00048331157,0.025542492,0.4305845,0.00051058,0.0011653213,0.25333184],"study_design_scores_gemma":[0.0008531113,0.022765651,0.7193298,0.00008780499,0.0010409311,0.004863952,0.00019433259,0.083460614,0.15974349,0.00037994917,0.007180483,0.000099909994],"about_ca_topic_score_codex":0.0015765077,"about_ca_topic_score_gemma":0.0010490014,"teacher_disagreement_score":0.0015765077,"about_ca_system_score_codex":0.00032002054,"about_ca_system_score_gemma":0.00040945775,"threshold_uncertainty_score":0.0031346083},"labels":[],"label_agreement":null},{"id":"W2968219865","doi":"10.1007/s40263-019-00657-9","title":"Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Genome British Columbia; University of British Columbia Hospital","funders":"Alberta Prion Research Institute; Canadian Institutes of Health Research; Consortium canadien en neurodégénérescence associée au vieillissement; Fondation Brain Canada","keywords":"Proteotoxicity; Frontotemporal lobar degeneration; Neurodegeneration; Protein aggregation; Disease; Neuroscience; Biology; Frontotemporal dementia; Medicine; Pathology; Dementia; Cell biology","score_opus":0.057841898429623166,"score_gpt":0.38011929955339896,"score_spread":0.3222774011237758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968219865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010314796,0.998803,0.00011227165,0.00012704657,0.00010254037,0.0000047312637,0.000014060649,0.000008714417,0.00072447385],"genre_scores_gemma":[0.00057163264,0.998629,0.00020653625,0.00014840355,0.000090506415,0.0000063991006,0.00002183746,0.0000013135718,0.00032429217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981457,0.000034111636,0.000030876952,0.000031583084,0.000067371526,0.000021584798],"domain_scores_gemma":[0.99968815,0.00016884132,0.00003925081,0.00000851374,0.00007247903,0.000022799035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006850923,0.00086997193,0.0014241176,0.0024065191,0.00024389935,0.0009405464,0.00067579554,0.0010568907,0.0038711524],"category_scores_gemma":[0.0005634769,0.00024378192,0.00061145885,0.0020899891,0.00036309494,0.0012682328,0.00060788647,0.0018291998,0.001708497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091415306,0.000109440174,0.00012391609,0.029226026,0.00011540901,0.00017427736,0.000064726424,0.00033507476,0.0032688135,0.0038324827,0.015336422,0.94732195],"study_design_scores_gemma":[0.000034829656,0.00020936734,0.00079228205,0.005202924,0.00026669842,0.0010760515,0.000066200926,0.00012045679,0.0008744371,0.0022771421,0.9890588,0.000020862399],"about_ca_topic_score_codex":0.000873148,"about_ca_topic_score_gemma":0.0017425299,"teacher_disagreement_score":0.0038711524,"about_ca_system_score_codex":0.00053237315,"about_ca_system_score_gemma":0.00089919707,"threshold_uncertainty_score":0.012950242},"labels":[],"label_agreement":null},{"id":"W2986981536","doi":"10.1007/s40263-019-00682-8","title":"Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm","year":2019,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"Ministry of Science and Technology, Taiwan","keywords":"Discontinuation; Antipsychotic; Schizophrenia (object-oriented programming); Medicine; Psychosis; Psychiatry; Dosing; Psychology; Algorithm; Internal medicine; Computer science","score_opus":0.034362615392149326,"score_gpt":0.35708397992175117,"score_spread":0.3227213645296019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986981536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014353854,0.8173166,0.14061278,0.01275569,0.00081128906,0.0016219438,0.0011586795,0.000988316,0.010380886],"genre_scores_gemma":[0.19962785,0.4852428,0.3018475,0.0068092723,0.00081203796,0.0013406462,0.0015655702,0.0001309286,0.0026234249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894315,0.00036129958,0.00024006376,0.00019550258,0.00021864995,0.00004134906],"domain_scores_gemma":[0.998979,0.0006422767,0.00017534896,0.000021689983,0.00015206452,0.000029727322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001891312,0.0015436808,0.0032942444,0.0021976745,0.00029942903,0.0014027221,0.0021213787,0.0011916846,0.0027364579],"category_scores_gemma":[0.0041770837,0.00044577752,0.0032379527,0.0009998588,0.0004498591,0.0011252816,0.0006004783,0.003175966,0.0006312486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011489542,0.0004043808,0.0022021853,0.0131141385,0.0017809783,0.00018493607,0.00008930703,0.022945954,0.0009798314,0.008645135,0.010749999,0.9377542],"study_design_scores_gemma":[0.012929058,0.007861916,0.030380601,0.07308174,0.039704107,0.009570073,0.0007304315,0.35074046,0.008774759,0.18181312,0.28352517,0.0008885253],"about_ca_topic_score_codex":0.003344585,"about_ca_topic_score_gemma":0.005611385,"teacher_disagreement_score":0.003344585,"about_ca_system_score_codex":0.001914058,"about_ca_system_score_gemma":0.0024196035,"threshold_uncertainty_score":0.013887525},"labels":[],"label_agreement":null},{"id":"W2998920613","doi":"10.1007/s40263-020-00700-0","title":"Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Biogen","keywords":"Tolerability; Dimethyl fumarate; Medicine; Adverse effect; Nausea; Internal medicine; Gastroenterology; Multiple sclerosis; Diarrhea; Abdominal pain; Immunology","score_opus":0.07551401859164208,"score_gpt":0.3057251555602757,"score_spread":0.2302111369686336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998920613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967811,0.0020638697,0.0002096253,0.000100445504,0.000040378196,0.00024131867,0.00017578604,0.000040539788,0.00034691015],"genre_scores_gemma":[0.9969631,0.00096482685,0.0005883818,0.0002349301,0.00011895657,0.00021340934,0.00038981636,0.000012798809,0.00051383284],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99947745,0.00028436477,0.000043947293,0.000076703276,0.000055660275,0.00006190267],"domain_scores_gemma":[0.99916315,0.000219738,0.00026748216,0.000063699306,0.000059187834,0.00022671472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018333469,0.0009923801,0.0025775712,0.00028405094,0.00025800566,0.0005902453,0.0005236751,0.00082545064,0.0024915033],"category_scores_gemma":[0.0011496219,0.00044378542,0.0014377752,0.0003041206,0.0005353148,0.0007377744,0.00024592856,0.0015170758,0.00038406265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8748635,0.017478371,0.0037945744,0.0009120294,0.0018697197,0.00014276092,0.00014872421,0.0006189919,0.046153277,0.000057072928,0.0005611348,0.053399697],"study_design_scores_gemma":[0.4426227,0.53111637,0.018486075,0.000028815275,0.0010205507,0.00023488878,0.000042949414,0.0007281423,0.0048034876,0.000046367968,0.00084095687,0.000028627865],"about_ca_topic_score_codex":0.0004239743,"about_ca_topic_score_gemma":0.0012727682,"teacher_disagreement_score":0.0025775712,"about_ca_system_score_codex":0.0004244375,"about_ca_system_score_gemma":0.00049928064,"threshold_uncertainty_score":0.009695768},"labels":[],"label_agreement":null},{"id":"W3013166411","doi":"10.1007/s40263-020-00713-9","title":"Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Meta-analysis; Medication adherence; Antipsychotic; Confidence interval; Schizophrenia (object-oriented programming); Internal medicine; Regimen; MEDLINE; Psychiatry","score_opus":0.11520425710561334,"score_gpt":0.3935842397463182,"score_spread":0.27837998264070485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013166411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009544343,0.9892575,0.00036965546,0.000100583966,0.00012609511,0.00015406637,0.00026919562,0.000018145449,0.00016039769],"genre_scores_gemma":[0.22181591,0.7737462,0.0022826612,0.00069759047,0.00017757191,0.0004621207,0.0004906183,0.000017495175,0.00030979665],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99476457,0.0021678875,0.001690647,0.0005927059,0.00057649607,0.00020774055],"domain_scores_gemma":[0.99260485,0.0050183996,0.0015411098,0.0002808109,0.0004286568,0.0001261573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008150415,0.0022673383,0.014870759,0.003145595,0.0004704128,0.0023660576,0.0017766951,0.002316297,0.0025001264],"category_scores_gemma":[0.017336613,0.0014965457,0.02859028,0.004694398,0.0006164502,0.0017529082,0.0015955019,0.0022229087,0.00018303869],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033362058,0.0000700003,0.0065624123,0.2690357,0.6973472,0.00009356004,0.000103583945,0.0004105625,0.00019794574,0.000087453984,0.00042905618,0.022326319],"study_design_scores_gemma":[0.0010866186,0.00024236813,0.0064912783,0.014475238,0.9763773,0.00006378979,0.000056438035,0.00018298955,0.0000795771,0.00009955262,0.0008163937,0.000028491962],"about_ca_topic_score_codex":0.008776279,"about_ca_topic_score_gemma":0.021856008,"teacher_disagreement_score":0.014870759,"about_ca_system_score_codex":0.0019460503,"about_ca_system_score_gemma":0.0024390207,"threshold_uncertainty_score":0.043103993},"labels":[],"label_agreement":null},{"id":"W3031692871","doi":"10.1007/s40263-020-00737-1","title":"Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Institute of Aging; Institute of Nutrition, Metabolism and Diabetes; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Neuroinflammation; Senile plaques; Immune system; Neurodegeneration; Dementia; Immunology; Alzheimer's disease; Disease; Amyloid (mycology); Inflammation; Biochemistry of Alzheimer's disease; Biology; Innate immune system; Neuroscience; Medicine; Amyloid precursor protein; Pathology","score_opus":0.08595807630187191,"score_gpt":0.3982246360576957,"score_spread":0.3122665597558238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031692871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006568666,0.9991179,0.00007082589,0.000100814534,0.000108662534,0.0000052631704,0.000013558893,0.000005034937,0.0005121865],"genre_scores_gemma":[0.00051049487,0.99878496,0.00014516346,0.00014426211,0.000094750896,0.0000065797503,0.000017540327,8.149775e-7,0.00029555024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998357,0.000030667423,0.00002854982,0.000024576442,0.0000595884,0.000020779848],"domain_scores_gemma":[0.9997291,0.00013765649,0.000053177246,0.0000063677276,0.000052681808,0.000021018905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069151516,0.001211015,0.002004077,0.0024522615,0.0002301492,0.0012419281,0.00085689337,0.001403842,0.0048280307],"category_scores_gemma":[0.000731341,0.00033801308,0.00072949607,0.0020164647,0.00045083763,0.0011858067,0.00061211776,0.002350892,0.0018565633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020294312,0.00012814546,0.00008614757,0.034345917,0.00017554875,0.00016428849,0.000049338887,0.00040449496,0.0022798488,0.0032238034,0.021703059,0.93723655],"study_design_scores_gemma":[0.00017267896,0.0004502953,0.0009353013,0.01291728,0.00089215545,0.0010664184,0.00006716938,0.0002429395,0.0008361996,0.002854282,0.9795297,0.000035648223],"about_ca_topic_score_codex":0.0015415002,"about_ca_topic_score_gemma":0.0035675382,"teacher_disagreement_score":0.0048280307,"about_ca_system_score_codex":0.0006062429,"about_ca_system_score_gemma":0.0011753495,"threshold_uncertainty_score":0.016151369},"labels":[],"label_agreement":null},{"id":"W3036420635","doi":"10.1007/s40263-020-00743-3","title":"Methadone for Pain Management: A Pharmacotherapeutic Review","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; St Joseph's Health Care; London Health Sciences Centre; St. Joseph's Hospital","funders":"","keywords":"Methadone; Medicine; Cancer pain; Opioid; Chronic pain; Analgesic; Intensive care medicine; Addiction; Morphine; Anesthesia; Psychiatry; Cancer; Internal medicine","score_opus":0.06837846230751701,"score_gpt":0.39302345922953075,"score_spread":0.32464499692201376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036420635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042991138,0.9995303,0.000030551062,0.00008495563,0.000091770686,0.000006031411,0.00001927048,0.000003240504,0.000190852],"genre_scores_gemma":[0.0002666711,0.9991742,0.0000961338,0.00021702301,0.00007886437,0.0000061989344,0.000017056918,8.2752547e-7,0.0001430076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996729,0.0000661799,0.00007813844,0.00005903105,0.00009327914,0.000030406003],"domain_scores_gemma":[0.9991609,0.00045289643,0.00018010037,0.000015987333,0.00012970337,0.000060408278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097015436,0.0013589088,0.0030923823,0.00434364,0.00029758032,0.0015347857,0.0012797347,0.0016134061,0.007059787],"category_scores_gemma":[0.0015337637,0.00054708833,0.0012174753,0.004303816,0.0005151697,0.0018060216,0.0011636879,0.002387425,0.0015690991],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030022298,0.00017118822,0.00017788167,0.13666078,0.0006814468,0.00016188898,0.00008541655,0.00033391433,0.0013537578,0.0014242786,0.033960436,0.8246888],"study_design_scores_gemma":[0.00036378694,0.0004737699,0.0026499035,0.06928167,0.0038626068,0.0014332123,0.00014025778,0.00029361673,0.0004758771,0.001147004,0.9198024,0.00007590167],"about_ca_topic_score_codex":0.002345645,"about_ca_topic_score_gemma":0.008068015,"teacher_disagreement_score":0.007059787,"about_ca_system_score_codex":0.00081643654,"about_ca_system_score_gemma":0.0022356533,"threshold_uncertainty_score":0.023617327},"labels":[],"label_agreement":null},{"id":"W3037461942","doi":"10.1007/s40263-020-00744-2","title":"Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Jazz Pharmaceuticals","keywords":"Cataplexy; Narcolepsy; Epworth Sleepiness Scale; Placebo; Subgroup analysis; Excessive daytime sleepiness; Psychology; Modafinil; Anesthesia; Internal medicine; Medicine; Sleep disorder; Confidence interval; Psychiatry; Polysomnography; Insomnia","score_opus":0.06475190533656593,"score_gpt":0.3432362906212195,"score_spread":0.2784843852846536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037461942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93782485,0.051823135,0.0013203891,0.00090902933,0.0016481797,0.0032871363,0.0010850928,0.0001714233,0.0019307039],"genre_scores_gemma":[0.98393667,0.009236941,0.0010931194,0.00085530285,0.0006116615,0.0022411286,0.0006009978,0.000023840528,0.0014003488],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988152,0.0005827537,0.00018737321,0.00017902277,0.00009768859,0.00013799785],"domain_scores_gemma":[0.998852,0.00054044166,0.0002823948,0.00008004344,0.000084200365,0.00016082331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025089453,0.00174774,0.0056649907,0.0007047888,0.00045772412,0.0013934253,0.0009130334,0.0018402595,0.003945804],"category_scores_gemma":[0.0032434498,0.00070304424,0.005838463,0.0005737282,0.0008998013,0.0010433198,0.0005170674,0.0025871203,0.00041005109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96607023,0.000707719,0.0007768653,0.0034919356,0.01511182,0.000044469678,0.00006429286,0.00019407245,0.0015852193,0.00009020458,0.0004154348,0.011447825],"study_design_scores_gemma":[0.96482474,0.017833717,0.003439335,0.00022125509,0.012226397,0.00003328524,0.000062542575,0.00036625654,0.00030655687,0.00017405824,0.0004826348,0.000029181434],"about_ca_topic_score_codex":0.0017019177,"about_ca_topic_score_gemma":0.004679781,"teacher_disagreement_score":0.0056649907,"about_ca_system_score_codex":0.0009483267,"about_ca_system_score_gemma":0.0010059376,"threshold_uncertainty_score":0.013268709},"labels":[],"label_agreement":null},{"id":"W3045363217","doi":"10.1007/s40263-020-00749-x","title":"Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study","year":2020,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Bayer HealthCare; Teva Pharmaceutical Industries; Biogen; Celgene; Sanofi","keywords":"Alemtuzumab; Medicine; Multiple sclerosis; Neurology; Interferon beta-1a; Internal medicine; Post-hoc analysis; Clinical trial; Interferon beta; Psychiatry","score_opus":0.017180481804925214,"score_gpt":0.2825230293991739,"score_spread":0.2653425475942487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045363217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986583,0.0006959451,0.00005756411,0.000021635944,0.000013228626,0.000056818964,0.00028817347,0.000005002279,0.00020339448],"genre_scores_gemma":[0.9987716,0.000094222945,0.000062885236,0.00003127006,0.000032453296,0.000056210636,0.0007650211,0.000003437108,0.00018276344],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99765646,0.0011388101,0.00015159667,0.0005320432,0.00021665946,0.0003043006],"domain_scores_gemma":[0.9961605,0.0012905602,0.0009923032,0.000526665,0.0003873823,0.00064260047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051091635,0.00091115665,0.0020422973,0.0005218113,0.00043669494,0.0012473684,0.0008758878,0.00074925687,0.0016171596],"category_scores_gemma":[0.0044200146,0.00029370337,0.0029323534,0.00051038194,0.00055092265,0.0008273701,0.0008995476,0.0012915038,0.00023312162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5806978,0.001590658,0.3908722,0.00033633513,0.011693942,0.00023227684,0.00030742583,0.0011429513,0.0023034576,0.00010064299,0.00088333106,0.009838945],"study_design_scores_gemma":[0.028298298,0.055013254,0.90117365,0.00006277588,0.009468743,0.00030013028,0.0002145405,0.0028584946,0.0010381424,0.00017616966,0.0013388606,0.000057048193],"about_ca_topic_score_codex":0.0011466001,"about_ca_topic_score_gemma":0.0012504195,"teacher_disagreement_score":0.0051091635,"about_ca_system_score_codex":0.0005353094,"about_ca_system_score_gemma":0.0006317132,"threshold_uncertainty_score":0.027020156},"labels":[],"label_agreement":null},{"id":"W3048893740","doi":"10.1007/s40263-020-00754-0","title":"Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update","year":2020,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; University Health Network","funders":"","keywords":"Dopaminergic; Parkinson's disease; Psychopharmacology; Medicine; Neurology; Neuroscience; Physical medicine and rehabilitation; Apomorphine; Motor control; Disease; Psychology; Dopamine; Psychiatry; Internal medicine","score_opus":0.030008998222642153,"score_gpt":0.32352673857504793,"score_spread":0.2935177403524058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048893740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007928921,0.9992594,0.000050991093,0.00009390224,0.0001130561,0.0000051706356,0.000024926721,0.000005219008,0.00036809614],"genre_scores_gemma":[0.0004174087,0.99886334,0.00013859525,0.00019875284,0.000118903685,0.000005932633,0.000030291896,0.0000010178511,0.00022571336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999811,0.000033826178,0.000043549975,0.000029033565,0.00006304152,0.000019675223],"domain_scores_gemma":[0.99950945,0.00026854812,0.000095534786,0.000008488976,0.00008410734,0.00003377118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071938284,0.0011141909,0.0021826532,0.0023620706,0.00020404314,0.0011845896,0.0009870421,0.0012056528,0.0059901257],"category_scores_gemma":[0.00085105374,0.00033365074,0.0010160862,0.0021090466,0.00036086616,0.0012967755,0.0006705339,0.0019052186,0.0015675714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030426795,0.00014137958,0.00016659523,0.04771954,0.00031706007,0.00022289738,0.000043705724,0.00026009238,0.0012784183,0.0010046699,0.02832279,0.9202186],"study_design_scores_gemma":[0.00040989014,0.00048210257,0.0022372894,0.018691363,0.001954878,0.0020943917,0.000086813016,0.0002806812,0.00042897987,0.0013358076,0.97194654,0.000051397303],"about_ca_topic_score_codex":0.0016058038,"about_ca_topic_score_gemma":0.005315817,"teacher_disagreement_score":0.0059901257,"about_ca_system_score_codex":0.00047710468,"about_ca_system_score_gemma":0.0011027944,"threshold_uncertainty_score":0.020038962},"labels":[],"label_agreement":null},{"id":"W3134827765","doi":"10.1007/s40263-021-00801-4","title":"Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Gambling Behavior and Treatments","field":"Psychology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bibliothèque et Archives nationales du Québec; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Centre de Santé et de Services Sociaux de la Vieille-Capitale; Centre Hospitalier Universitaire de Sherbrooke; Université Laval; Institut Universitaire en Santé Mentale de Québec","funders":"","keywords":"Aripiprazole; Psychiatry; Psychology; Odds ratio; Population; Nested case-control study; Confidence interval; Psychosis; Comorbidity; Medicine; Clinical psychology; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.06074770325621788,"score_gpt":0.3763586047743851,"score_spread":0.31561090151816723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134827765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997147,0.000052085474,0.000054604527,0.000016603108,0.0000040188143,0.00002037826,0.000029179406,0.0000017469714,0.000106690575],"genre_scores_gemma":[0.99957365,0.00005833291,0.000075058684,0.000027021126,0.0000068518657,0.00001256091,0.000056548655,0.000001771135,0.00018819126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903226,0.00031902935,0.00006738388,0.00023677901,0.00014274925,0.00020178616],"domain_scores_gemma":[0.99893254,0.00026131017,0.00025184074,0.00012861872,0.00011792838,0.00030778497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008662885,0.0006071094,0.0007333317,0.0010375679,0.0031583195,0.0012094238,0.0008048912,0.0009763253,0.0015555049],"category_scores_gemma":[0.0021292048,0.00093751465,0.00095139415,0.00079472584,0.0010009196,0.000626318,0.0007956666,0.0015763502,0.00023913241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030001362,0.0072906716,0.97806245,0.000045757384,0.00035327172,0.0032337832,0.0021089176,0.000055205575,0.0029051388,0.00014680186,0.00024458565,0.002553161],"study_design_scores_gemma":[0.00034531692,0.0020901093,0.99185234,0.000016296386,0.00025349823,0.0025404033,0.0019297556,0.00054564985,0.00016832935,0.000067985005,0.00016231174,0.000028009203],"about_ca_topic_score_codex":0.035139084,"about_ca_topic_score_gemma":0.05652262,"teacher_disagreement_score":0.035139084,"about_ca_system_score_codex":0.0013325296,"about_ca_system_score_gemma":0.0010568524,"threshold_uncertainty_score":0.0698691},"labels":[],"label_agreement":null},{"id":"W3134994261","doi":"10.1007/s40263-021-00793-1","title":"Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; McMaster University; BC Mental Health & Substance Use Services; St. Joseph’s Healthcare Hamilton; University of British Columbia; University of Toronto; TRIUMF; University of British Columbia Hospital","funders":"Canadian Institutes of Health Research; Ontario Brain Institute","keywords":"Escitalopram; Aripiprazole; Major depressive disorder; Neurocognitive; Psychology; Psychiatry; Cognition; Adjunctive treatment; Bipolar disorder; Psychomotor learning; Medicine; Internal medicine; Schizophrenia (object-oriented programming); Anxiety","score_opus":0.014135780871600319,"score_gpt":0.2788517343189797,"score_spread":0.26471595344737936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134994261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96310747,0.008233935,0.00021217206,0.0018782269,0.00020648687,0.0008177711,0.019954268,0.000034322835,0.0055555184],"genre_scores_gemma":[0.9767139,0.0032580155,0.00092688785,0.00089859247,0.000179886,0.0003849881,0.016602898,0.000013907972,0.0010209734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971439,0.00042330602,0.00023043122,0.00034261832,0.0012787306,0.0005809904],"domain_scores_gemma":[0.993816,0.0006758946,0.0012263337,0.0002730434,0.002791,0.0012177763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004127834,0.0009123842,0.0019020061,0.0009433909,0.0016625617,0.0016977919,0.0016563556,0.0010428866,0.0011759485],"category_scores_gemma":[0.008547757,0.0003812503,0.0022041774,0.0025922293,0.00057154393,0.0008002826,0.0012558564,0.0016388631,0.00019953499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037954092,0.004143828,0.8339063,0.00082376134,0.006185055,0.00012564102,0.00032116848,0.0010281141,0.0003718072,0.00033343333,0.023853585,0.09095324],"study_design_scores_gemma":[0.002240935,0.0009369051,0.99310267,0.0001569942,0.0016492684,0.000032863205,0.00011590497,0.00044490345,0.0000553601,0.00011647597,0.0011091603,0.000038475835],"about_ca_topic_score_codex":0.7626466,"about_ca_topic_score_gemma":0.8542749,"teacher_disagreement_score":0.23735338,"about_ca_system_score_codex":0.01741663,"about_ca_system_score_gemma":0.025464471,"threshold_uncertainty_score":0.4775024},"labels":[],"label_agreement":null},{"id":"W3147565333","doi":"10.1007/s40263-021-00798-w","title":"Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Fingolimod; Sphingosine-1-phosphate receptor; S1PR1; Sphingosine-1-phosphate; Sphingosine kinase; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Pharmacology; Immune system; Medicine; Receptor; Sphingosine; Functional selectivity; Immunology; Neuroscience; Biology; G protein-coupled receptor; Cancer research; Internal medicine","score_opus":0.05276628998028735,"score_gpt":0.29557527165513836,"score_spread":0.24280898167485102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147565333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001185884,0.9975981,0.00023142679,0.00033229392,0.00044456174,0.000008107231,0.0000321611,0.000013950274,0.0012208833],"genre_scores_gemma":[0.00095637655,0.995908,0.00042787305,0.00042678718,0.00048550143,0.000016123753,0.00006560338,0.0000032448027,0.0017104178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998692,0.00002619467,0.000017037672,0.00002052223,0.000051125182,0.000015892552],"domain_scores_gemma":[0.9997993,0.00008208201,0.000038647722,0.0000077916975,0.000044849414,0.000027364387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054335827,0.0012060239,0.0013009909,0.00166291,0.00021037897,0.00074337405,0.0008797471,0.0010737823,0.004337849],"category_scores_gemma":[0.0006142424,0.00023755102,0.00042545912,0.0017216434,0.00040746978,0.0007999757,0.0005833727,0.002124203,0.002665845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021352593,0.00011303619,0.0000850857,0.0076009943,0.0000902934,0.00024798937,0.000022680812,0.00043163236,0.0032896742,0.003195434,0.06231178,0.92239785],"study_design_scores_gemma":[0.000093545816,0.00015448609,0.0005171885,0.0014218685,0.00017015345,0.0007908865,0.000017633789,0.00013292853,0.0007097802,0.0015485367,0.99442935,0.000013597505],"about_ca_topic_score_codex":0.0007547048,"about_ca_topic_score_gemma":0.002386384,"teacher_disagreement_score":0.004337849,"about_ca_system_score_codex":0.00049697654,"about_ca_system_score_gemma":0.0006886107,"threshold_uncertainty_score":0.014511526},"labels":[],"label_agreement":null},{"id":"W3156392683","doi":"10.1007/s40263-021-00808-x","title":"Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Takeda (Canada)","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Pharmacotherapy; Discontinuation; Medicine; Pediatrics; Attention deficit hyperactivity disorder; Comorbidity; Methylphenidate; Retrospective cohort study; Young adult; McNemar's test; Psychiatry; Internal medicine","score_opus":0.012183851937043863,"score_gpt":0.30060121251875166,"score_spread":0.2884173605817078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156392683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933873,0.00071971666,0.00010470837,0.00018438947,0.0000074431305,0.000028213743,0.005146618,0.0000064458927,0.00041522054],"genre_scores_gemma":[0.99421173,0.00050410937,0.00020617463,0.00012284066,0.000014556578,0.00004016794,0.004813336,0.000003988191,0.000083100385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975769,0.00056230824,0.00060387194,0.00047887742,0.0005500847,0.00022796483],"domain_scores_gemma":[0.9916672,0.0011989095,0.00555343,0.00036248946,0.0007191412,0.00049890287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001837452,0.00026873918,0.0006225342,0.002212003,0.0006949371,0.0013734363,0.00071309536,0.0005896723,0.0007739906],"category_scores_gemma":[0.005913252,0.0003618542,0.0011460198,0.0050875954,0.00027334483,0.0007655702,0.0012088519,0.0009742368,0.00016336779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007025273,0.000029841582,0.9982786,0.000021537544,0.00012829156,0.000053483294,0.00008648686,0.000038405513,0.000035409306,0.00001641529,0.0002538301,0.0009873819],"study_design_scores_gemma":[0.000008339734,0.00002158201,0.99891055,0.000028584182,0.00006961405,0.00015263657,0.00025431387,0.0003078037,0.000024871484,0.000010481971,0.00020755046,0.0000035826945],"about_ca_topic_score_codex":0.05759591,"about_ca_topic_score_gemma":0.07397363,"teacher_disagreement_score":0.05759591,"about_ca_system_score_codex":0.0013151699,"about_ca_system_score_gemma":0.0013237692,"threshold_uncertainty_score":0.114521325},"labels":[],"label_agreement":null},{"id":"W3156691689","doi":"10.1007/s40263-021-00803-2","title":"Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Queen's University; University of British Columbia; University of British Columbia Hospital","funders":"Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; H. Lundbeck A/S; Servier; Ontario Brain Institute","keywords":"Escitalopram; Aripiprazole; Quality of life (healthcare); Major depressive disorder; Clinical psychology; Psychology; Depression (economics); Psychiatry; Adjunctive treatment; Antidepressant; Medicine; Internal medicine; Anxiety; Schizophrenia (object-oriented programming); Mood; Psychotherapist","score_opus":0.007309110990366666,"score_gpt":0.24854670039845367,"score_spread":0.241237589408087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156691689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982816,0.00063301134,0.000044510543,0.00009261872,0.000017987075,0.000027114847,0.0004569463,0.0000022975264,0.0004438319],"genre_scores_gemma":[0.99892104,0.00021522085,0.00006863649,0.000059865986,0.000028319764,0.000023400855,0.00049307296,0.0000011959656,0.00018916311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991935,0.00027705202,0.00012468055,0.00011484347,0.00014110921,0.0001488013],"domain_scores_gemma":[0.9982589,0.00045872387,0.00074009073,0.00008572501,0.00018126848,0.0002753044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090738194,0.00032688485,0.00074411865,0.00042444275,0.0004599789,0.00091449555,0.0003319979,0.0005657869,0.001564566],"category_scores_gemma":[0.0031396092,0.00029416347,0.0014575148,0.00090842,0.0002414926,0.00063270313,0.0005398389,0.0009880385,0.0001937031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002822545,0.00040952078,0.99229974,0.00003994635,0.0006307999,0.000040051098,0.000052501426,0.000046327,0.00010104466,0.000010798334,0.00021209936,0.0033346266],"study_design_scores_gemma":[0.00026665267,0.0005852364,0.9982698,0.000009982415,0.0003187305,0.000061353865,0.00012260402,0.00018070328,0.000026540734,0.000014849773,0.00013667936,0.0000068457543],"about_ca_topic_score_codex":0.0054227654,"about_ca_topic_score_gemma":0.009237751,"teacher_disagreement_score":0.0054227654,"about_ca_system_score_codex":0.0006303501,"about_ca_system_score_gemma":0.0005245491,"threshold_uncertainty_score":0.010782421},"labels":[],"label_agreement":null},{"id":"W3164200337","doi":"10.1007/s40263-021-00814-z","title":"Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Purdue Pharma (Canada); University of Alberta","funders":"Purdue Pharma; Purdue University","keywords":"Pittsburgh Sleep Quality Index; Methylphenidate; Placebo; Stimulant; Clinical trial; Medicine; Adverse effect; Randomized controlled trial; Open label; Attention deficit hyperactivity disorder; Insomnia; Internal medicine; Anesthesia; Psychiatry; Sleep quality","score_opus":0.0375773965351871,"score_gpt":0.3543715755283068,"score_spread":0.3167941789931197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164200337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992249,0.0025798765,0.00036438397,0.00021235751,0.00024145069,0.0029427046,0.0005994839,0.00012518655,0.00068553374],"genre_scores_gemma":[0.9882067,0.0027543195,0.002526437,0.0004363127,0.00030998167,0.0030047765,0.0008675074,0.000025128504,0.0018689848],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995289,0.00018380255,0.000055804205,0.0001003633,0.000057555142,0.00007369817],"domain_scores_gemma":[0.99923515,0.00017414821,0.0001667875,0.00007688592,0.000080146885,0.00026694234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001555636,0.0014717991,0.0026558088,0.00051188207,0.00048724323,0.00073012436,0.0015665569,0.0017506017,0.0044130078],"category_scores_gemma":[0.0011980622,0.0007949432,0.0017468443,0.00043255006,0.0009580471,0.0010221165,0.00047323725,0.0025649532,0.00086779945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95804626,0.015085828,0.0004942586,0.0006401072,0.0004659911,0.000035129546,0.00006252034,0.00017726948,0.0053555286,0.000044598255,0.00030024617,0.019292302],"study_design_scores_gemma":[0.88576496,0.11043698,0.0021067297,0.000024280951,0.00024395114,0.00003282679,0.000021840262,0.00029015535,0.0008271529,0.000024527673,0.00021236927,0.000014200133],"about_ca_topic_score_codex":0.001956678,"about_ca_topic_score_gemma":0.0052784514,"teacher_disagreement_score":0.0044130078,"about_ca_system_score_codex":0.00071492,"about_ca_system_score_gemma":0.001413962,"threshold_uncertainty_score":0.014762998},"labels":[],"label_agreement":null},{"id":"W3185751141","doi":"10.1007/s40263-021-00840-x","title":"Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"EMD Serono; Teva Pharmaceutical Industries; Celgene; MedDay Pharmaceuticals; Biogen; Sanofi","keywords":"Medicine; Adverse effect; Multiple sclerosis; Incidence (geometry); Clinical Practice; Expanded Disability Status Scale; Physical therapy; Internal medicine; Psychiatry","score_opus":0.0465823873557548,"score_gpt":0.36075225756524093,"score_spread":0.3141698702094861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185751141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998069,0.0007970297,0.00008649073,0.00007754383,0.000007266567,0.00007028864,0.00049527036,0.000004326867,0.00039273044],"genre_scores_gemma":[0.9987821,0.00023461942,0.00013847195,0.000081495506,0.000019957892,0.000057964597,0.00059327536,0.0000017196861,0.00009036607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997359,0.0015197373,0.00029141965,0.00025442013,0.00047268844,0.00010267539],"domain_scores_gemma":[0.9922008,0.0020625046,0.003985504,0.00040038093,0.00074637256,0.0006044906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054345694,0.0004104827,0.0008658552,0.000454591,0.00026831395,0.000790706,0.00031308437,0.00058281916,0.0008969094],"category_scores_gemma":[0.007591368,0.0002152435,0.001044596,0.00075844704,0.00031053557,0.0005668678,0.0005165733,0.0006701413,0.00022779968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015527424,0.0008442758,0.96645534,0.00017421925,0.000932863,0.00007667012,0.00030124246,0.00016641583,0.00050554983,0.000014632901,0.0003354584,0.0146657955],"study_design_scores_gemma":[0.0018935511,0.006595155,0.98973024,0.000035708246,0.00036992593,0.00021786764,0.00012437269,0.00042100146,0.00014391837,0.000013955427,0.00043639253,0.000017949327],"about_ca_topic_score_codex":0.00072148436,"about_ca_topic_score_gemma":0.0010702927,"teacher_disagreement_score":0.0054345694,"about_ca_system_score_codex":0.00034972318,"about_ca_system_score_gemma":0.00033471262,"threshold_uncertainty_score":0.028741121},"labels":[],"label_agreement":null},{"id":"W3186046354","doi":"10.1007/s40263-021-00839-4","title":"Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Tuberous Sclerosis Complex Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Tuberous sclerosis; Subependymal giant cell astrocytoma; Tolerability; Everolimus; Medicine; Pediatrics; Internal medicine; Epilepsy; Surgery; Astrocytoma; Psychiatry; Glioma; Adverse effect","score_opus":0.06900239039779014,"score_gpt":0.2948978457487866,"score_spread":0.22589545535099642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186046354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995414,0.00010165955,0.000018730863,0.000029651728,0.0000012786045,0.000007848434,0.00014115793,7.483077e-7,0.00015747621],"genre_scores_gemma":[0.9996965,0.00006395805,0.000026804373,0.000040267732,0.0000028892457,0.000006963803,0.000114669754,5.474781e-7,0.00004737242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990295,0.0003359101,0.0001565826,0.0001350496,0.00017177401,0.00017119134],"domain_scores_gemma":[0.99773526,0.00037386513,0.0012776928,0.000071522845,0.00023079668,0.00031100598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010918754,0.00018476095,0.000418358,0.0006801637,0.00036006892,0.0007014234,0.00019920213,0.00052788656,0.000991292],"category_scores_gemma":[0.0029008053,0.0001961428,0.00063202094,0.0008684952,0.00031936128,0.0006226837,0.00045990216,0.0004927558,0.0002176245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009026173,0.0001032944,0.997626,0.00002229939,0.00006465521,0.0000791365,0.0005325211,0.000031361287,0.000105048006,0.000010235161,0.00007200124,0.0012632074],"study_design_scores_gemma":[0.00001148479,0.00045207667,0.9976453,0.000013719027,0.000031179326,0.00032272015,0.001099432,0.000117142954,0.000043207037,0.0000074074765,0.0002475106,0.000008865503],"about_ca_topic_score_codex":0.004191632,"about_ca_topic_score_gemma":0.0040203547,"teacher_disagreement_score":0.004191632,"about_ca_system_score_codex":0.00043694727,"about_ca_system_score_gemma":0.0003651038,"threshold_uncertainty_score":0.008334458},"labels":[],"label_agreement":null},{"id":"W3188896843","doi":"10.1007/s40263-021-00846-5","title":"Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; University of Alberta; University of Toronto; University Health Network","funders":"","keywords":"Adverse effect; Ketamine; Tolerability; Medicine; Intensive care medicine; Psychiatry; Major depressive disorder; Context (archaeology); Anxiety; Neurology; Mood; Internal medicine","score_opus":0.006728945509502953,"score_gpt":0.2747249285350123,"score_spread":0.26799598302550937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188896843","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030387167,0.9992112,0.0000785853,0.00006320796,0.000047438647,0.000007909065,0.000012954023,0.000004258373,0.00027062316],"genre_scores_gemma":[0.0023432272,0.996965,0.0003060959,0.0001327083,0.00007434066,0.000009403389,0.000024342711,0.0000010444734,0.0001438554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979645,0.000044989112,0.000049041508,0.000026545149,0.000066489476,0.000016537],"domain_scores_gemma":[0.99956244,0.0002314903,0.00012325631,0.0000072907014,0.000054899196,0.000020624102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005921126,0.00072527525,0.0018381551,0.0012720174,0.00014464514,0.0005956196,0.00094514166,0.00081434805,0.002364083],"category_scores_gemma":[0.0010969845,0.00022269794,0.00095108605,0.0008517048,0.00023532196,0.00047343626,0.00032465986,0.001334498,0.0004973564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038491676,0.00014867386,0.0002654833,0.04040981,0.0005872824,0.00014753811,0.000046315257,0.0003230705,0.0012863277,0.0005495876,0.006054283,0.9497967],"study_design_scores_gemma":[0.001984724,0.003390607,0.022478452,0.08113718,0.008719728,0.006540127,0.0003525312,0.0011882767,0.0036938435,0.0033131281,0.8670333,0.00016810297],"about_ca_topic_score_codex":0.0014462384,"about_ca_topic_score_gemma":0.0040439367,"teacher_disagreement_score":0.002364083,"about_ca_system_score_codex":0.00029807325,"about_ca_system_score_gemma":0.0005739455,"threshold_uncertainty_score":0.007908583},"labels":[],"label_agreement":null},{"id":"W3194250079","doi":"10.1007/s40263-021-00854-5","title":"Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Olfactory and Sensory Function Studies","field":"Neuroscience","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Physicians' Services Incorporated Foundation","keywords":"Frontotemporal dementia; Dementia; Neurology; Psychosis; Psychiatry; Psychopharmacology; Psychology; Cognition; Personality changes; Medicine; Disease; Neuropsychiatry; Clinical psychology; Internal medicine","score_opus":0.18773797303704354,"score_gpt":0.3700846432395017,"score_spread":0.18234667020245815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194250079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007354175,0.9993594,0.000057056084,0.00006369287,0.00006436277,0.000004290227,0.000012662581,0.0000044015437,0.00036053028],"genre_scores_gemma":[0.0008853777,0.99835867,0.00017019584,0.00016534489,0.00011962172,0.000007859598,0.000024259463,0.0000011177598,0.00026754584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998373,0.00003806952,0.000038117836,0.00002912468,0.000042012034,0.000015462661],"domain_scores_gemma":[0.9996631,0.0002069681,0.00006232875,0.000007257843,0.000039898314,0.000020412452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005834155,0.0012934086,0.002480675,0.002466468,0.00020715002,0.000995331,0.0010298765,0.0012510045,0.0036781488],"category_scores_gemma":[0.00086372055,0.0003204284,0.0008603832,0.0019318481,0.00039901581,0.0008287841,0.0005683218,0.0017835388,0.001114367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002482467,0.00011454573,0.00013774185,0.035135806,0.00037183956,0.00036006328,0.000033800385,0.0003834069,0.001111085,0.000984124,0.016444365,0.94467497],"study_design_scores_gemma":[0.00051452307,0.00059017114,0.0034664953,0.02585051,0.002908396,0.004573346,0.00012393785,0.0005288164,0.0011003258,0.0025669516,0.95769584,0.000080635444],"about_ca_topic_score_codex":0.0016016039,"about_ca_topic_score_gemma":0.0040874546,"teacher_disagreement_score":0.0036781488,"about_ca_system_score_codex":0.0005282238,"about_ca_system_score_gemma":0.0007473215,"threshold_uncertainty_score":0.012304604},"labels":[],"label_agreement":null},{"id":"W3200887443","doi":"10.1007/s40263-021-00860-7","title":"Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts","year":2021,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Université de Montréal; Centre Hospitalier de l’Université de Montréal; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; Agence Nationale de la Recherche","keywords":"Fingolimod; Medicine; Natalizumab; Expanded Disability Status Scale; Multiple sclerosis; Internal medicine; Confidence interval; Cohort; Hazard ratio; Disease; Immunology","score_opus":0.03640744322808392,"score_gpt":0.2720628795888382,"score_spread":0.23565543636075426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200887443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284816,0.0059888586,0.00011720261,0.00010382833,0.00004676782,0.000058586636,0.0004135541,0.000007014018,0.0004160709],"genre_scores_gemma":[0.9979963,0.0009561489,0.00009653115,0.00011567951,0.00005357898,0.000057673053,0.0005521124,0.0000063597827,0.00016568317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877065,0.0004135448,0.00017928421,0.0002939707,0.00010578091,0.00023677482],"domain_scores_gemma":[0.9990502,0.0003119015,0.000290872,0.0001656743,0.00007057184,0.00011078352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016442233,0.0012936834,0.0026775035,0.0007791021,0.00048403934,0.0013007263,0.0006026952,0.00083948474,0.0012343957],"category_scores_gemma":[0.002611004,0.00048605032,0.005887816,0.0011679867,0.00038580975,0.0007106863,0.0007688994,0.001154484,0.00015753598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30361876,0.0007543779,0.57355124,0.0011905559,0.0841523,0.0007992447,0.00076571637,0.00086428353,0.0074276887,0.00028291548,0.0014516228,0.02514128],"study_design_scores_gemma":[0.024788532,0.00742895,0.8894153,0.0002272304,0.07183719,0.00070638856,0.0013566056,0.0008581189,0.0009982579,0.0005200443,0.001769003,0.00009434255],"about_ca_topic_score_codex":0.003527422,"about_ca_topic_score_gemma":0.006143144,"teacher_disagreement_score":0.003527422,"about_ca_system_score_codex":0.00058709935,"about_ca_system_score_gemma":0.0006791879,"threshold_uncertainty_score":0.008695602},"labels":[],"label_agreement":null},{"id":"W3213007658","doi":"10.1007/s40263-021-00877-y","title":"Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Psilocybin; Serotonergic; Neuroscience; Neurochemical; Antidepressant; Monoaminergic; Psychology; Hallucinogen; Pharmacology; Psychopharmacology; Serotonin; Medicine; Receptor; Psychiatry; Hippocampus; Internal medicine","score_opus":0.0834527158822608,"score_gpt":0.42685967313502526,"score_spread":0.3434069572527645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213007658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008838069,0.99930465,0.000044242828,0.00013806943,0.00005726927,0.0000020662671,0.0000108047325,0.0000022578486,0.00035223406],"genre_scores_gemma":[0.0006178145,0.99893063,0.000082034945,0.00008372293,0.00006592152,0.0000030892327,0.000013808113,4.3904484e-7,0.00020245064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991524,0.000016550106,0.00001192992,0.000018756233,0.000027084548,0.000010496267],"domain_scores_gemma":[0.99985325,0.00007386318,0.000026044125,0.0000045475044,0.00002656474,0.000015669071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040691392,0.0007883061,0.0012404319,0.0012790863,0.00021084203,0.00081550586,0.0008116029,0.0008181444,0.0036421951],"category_scores_gemma":[0.00041827204,0.00022072355,0.00039603724,0.001378557,0.0005361706,0.0008644011,0.0004800146,0.0015561908,0.001176845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024714624,0.0001545543,0.00020648305,0.014028073,0.00012760956,0.00023888987,0.000044938035,0.00042570868,0.0032296611,0.003968893,0.017363457,0.9599646],"study_design_scores_gemma":[0.00014684122,0.00035960236,0.0032218352,0.0057912758,0.00036230494,0.0017070478,0.000109454886,0.0002451922,0.0011923999,0.005552215,0.98127097,0.000040760824],"about_ca_topic_score_codex":0.0012728136,"about_ca_topic_score_gemma":0.00294002,"teacher_disagreement_score":0.0036421951,"about_ca_system_score_codex":0.0005867427,"about_ca_system_score_gemma":0.00081180834,"threshold_uncertainty_score":0.0121843815},"labels":[],"label_agreement":null},{"id":"W3215276948","doi":"10.1007/s40263-021-00879-w","title":"Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Technische Universität München","keywords":"Cannabidiol; Neuropathic pain; Medicine; Cannabis; Chronic pain; Pregabalin; Gabapentin; Dronabinol; Tetrahydrocannabinol; Duloxetine; Population; Psychiatry; Pharmacology; Cannabinoid; Internal medicine; Alternative medicine","score_opus":0.02875298202892851,"score_gpt":0.3593217910969135,"score_spread":0.33056880906798497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215276948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006092935,0.99230146,0.00011177489,0.0019834172,0.0008434142,0.00005177266,0.0004123107,0.0000058075575,0.003680795],"genre_scores_gemma":[0.024234852,0.9632041,0.0011610471,0.0069165644,0.0016623946,0.0001660269,0.00056963466,0.000017063885,0.0020683724],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9951593,0.0018384504,0.0011698738,0.00040738302,0.001283602,0.00014143065],"domain_scores_gemma":[0.9854709,0.011193353,0.0020793322,0.00023438086,0.00083868764,0.00018341407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026608494,0.00058664824,0.0014208069,0.0056063323,0.0006830534,0.0020054928,0.0006830768,0.0018227728,0.016918356],"category_scores_gemma":[0.013768663,0.00025117458,0.002322926,0.0049420027,0.0014900138,0.0016829115,0.0012468154,0.0018524297,0.00092769874],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007962438,0.00010743126,0.0020461385,0.3429354,0.0021874434,0.00033322177,0.0011924052,0.00023950395,0.0005883327,0.031447846,0.04839801,0.5697281],"study_design_scores_gemma":[0.00024901898,0.00018233573,0.010830774,0.23612162,0.003134791,0.000989441,0.0007110318,0.00009574372,0.00033938047,0.009639372,0.7376325,0.000074046635],"about_ca_topic_score_codex":0.008979478,"about_ca_topic_score_gemma":0.019700218,"teacher_disagreement_score":0.016918356,"about_ca_system_score_codex":0.0020910834,"about_ca_system_score_gemma":0.005000464,"threshold_uncertainty_score":0.05659753},"labels":[],"label_agreement":null},{"id":"W3217624600","doi":"10.1007/s40263-021-00876-z","title":"Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials","year":2021,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal; Jewish General Hospital; Montreal Heart Institute","funders":"","keywords":"Randomized controlled trial; Neurocognitive; Medicine; Cognition; Systematic review; Meta-analysis; MEDLINE; Cochrane Library; Pediatrics; Clinical psychology; Psychology; Psychiatry; Internal medicine","score_opus":0.04656544141655883,"score_gpt":0.41076723611627863,"score_spread":0.3642017946997198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217624600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008651883,0.99837613,0.00010165391,0.00010000397,0.000078472614,0.00016885821,0.00020871678,0.000008078261,0.0000928951],"genre_scores_gemma":[0.014106453,0.98413867,0.0006641639,0.00047808015,0.000077347344,0.0002676753,0.00016141524,0.000005850364,0.00010028657],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953046,0.0014153003,0.0019253407,0.0005562557,0.00062925485,0.0001693002],"domain_scores_gemma":[0.98581475,0.010037062,0.003036634,0.00022548396,0.00069093506,0.00019515108],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00703671,0.0021860453,0.014402736,0.0047652572,0.0006153223,0.0026963188,0.002243549,0.0024411262,0.0056902813],"category_scores_gemma":[0.026870927,0.0012812751,0.013653413,0.0062141237,0.0009875958,0.0017502868,0.0016170833,0.0018819011,0.00030033218],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014777499,0.000032110664,0.0007270425,0.9151492,0.0574305,0.00006195001,0.000068286325,0.000109878856,0.00016451959,0.000103506805,0.0009905222,0.02368486],"study_design_scores_gemma":[0.0037740355,0.00052060554,0.0052027577,0.37259728,0.60621923,0.00024006655,0.00017272573,0.00012829082,0.00022991245,0.00045810928,0.010388128,0.00006897794],"about_ca_topic_score_codex":0.009537825,"about_ca_topic_score_gemma":0.027955389,"teacher_disagreement_score":0.98559725,"about_ca_system_score_codex":0.0028825938,"about_ca_system_score_gemma":0.005681469,"threshold_uncertainty_score":0.03721416},"labels":[],"label_agreement":null},{"id":"W328786158","doi":"10.2165/11533120-000000000-00000","title":"For What Diagnoses Are Psychotropic Medications Being Prescribed?","year":2010,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"Substance Abuse and Mental Health Services Administration; Centers for Disease Control and Prevention; Australian Government; U.S. Department of Health and Human Services","keywords":"Psychiatry; Anxiety; Medicine; Psychotropic drug; Mood; Psychopharmacology; Antidepressant; Anti-Anxiety Agents; Mood disorders; Depression (economics); Drug; Medical prescription; Pharmacology","score_opus":0.013481992939070238,"score_gpt":0.3088238816607857,"score_spread":0.29534188872171546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W328786158","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24141787,0.11454346,0.011405867,0.44481313,0.0066461074,0.00048070258,0.0071250903,0.00039354136,0.17317417],"genre_scores_gemma":[0.8060256,0.08163881,0.01845588,0.06441072,0.004955489,0.00026531238,0.002021619,0.00014936892,0.022077171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987544,0.00043055075,0.00021856403,0.00013850958,0.00028323615,0.00017474903],"domain_scores_gemma":[0.9950688,0.0017313763,0.0015002099,0.00017743955,0.0009775291,0.00054466457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014914925,0.00026090757,0.00082486955,0.0010031224,0.0010850716,0.0013794742,0.0005831673,0.002489988,0.010793096],"category_scores_gemma":[0.013227639,0.0001802506,0.0012480018,0.0009579915,0.00070856954,0.0021046505,0.00034530804,0.0016496652,0.0035163353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008398069,0.0005957765,0.32035267,0.0014800717,0.0003841189,0.0031728474,0.0014426848,0.000367654,0.0014068494,0.0054269996,0.092005216,0.5725253],"study_design_scores_gemma":[0.00041988186,0.0009453426,0.5156818,0.013343004,0.001632686,0.048439182,0.015963212,0.0031320436,0.0046943463,0.030779947,0.36465156,0.00031693076],"about_ca_topic_score_codex":0.0056554717,"about_ca_topic_score_gemma":0.016414931,"teacher_disagreement_score":0.010793096,"about_ca_system_score_codex":0.0012957823,"about_ca_system_score_gemma":0.0022593925,"threshold_uncertainty_score":0.036106467},"labels":[],"label_agreement":null},{"id":"W33860922","doi":"10.1007/s40263-021-00803-2","title":"A critical appraisal of the added value of BiPV in atria","year":2006,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Building Energy and Comfort Optimization","field":"Engineering","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; Servier; Ontario Brain Institute","keywords":"Building-integrated photovoltaics; Glazing; Photovoltaic system; Architectural engineering; Atrium (architecture); Desk; Photovoltaics; Engineering; Mechanical engineering; Civil engineering; Electrical engineering","score_opus":0.003950654662513969,"score_gpt":0.21833486385308926,"score_spread":0.2143842091905753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W33860922","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046067946,0.81137043,0.00328547,0.085849665,0.01695759,0.006793349,0.0061741457,0.00013769085,0.023363799],"genre_scores_gemma":[0.45680878,0.42436647,0.016506078,0.04963667,0.0319598,0.006654614,0.004113086,0.00018965494,0.009764922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98712593,0.0097736735,0.00118665,0.00037395424,0.0013536623,0.00018617127],"domain_scores_gemma":[0.9314261,0.056357995,0.003873199,0.0018057326,0.0052638166,0.0012731064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0242931,0.0013083016,0.004893477,0.0016445387,0.00053724565,0.0027314667,0.002176256,0.0041613486,0.013488698],"category_scores_gemma":[0.055885687,0.00039149818,0.0040075,0.0017210043,0.0019128906,0.0020157192,0.00071627914,0.00509694,0.001424165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27610213,0.0005107378,0.0017186082,0.07612955,0.010200524,0.0006080955,0.00027634314,0.0021756126,0.0031904497,0.007306154,0.04539551,0.57638633],"study_design_scores_gemma":[0.19965959,0.08971819,0.027256124,0.14486992,0.08437426,0.0013559621,0.0015257848,0.0052448427,0.007991059,0.025837751,0.41161206,0.00055438996],"about_ca_topic_score_codex":0.002026061,"about_ca_topic_score_gemma":0.0049379854,"teacher_disagreement_score":0.0242931,"about_ca_system_score_codex":0.0035069627,"about_ca_system_score_gemma":0.0045471587,"threshold_uncertainty_score":0.12847573},"labels":[],"label_agreement":null},{"id":"W38310539","doi":"10.2165/00023210-200115010-00004","title":"Glutamate Receptors and Nociception","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Metabotropic glutamate receptor; Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 5; Ionotropic effect; Glutamate receptor; Metabotropic glutamate receptor 1; Metabotropic glutamate receptor 6; Kainate receptor; Metabotropic glutamate receptor 7; Metabotropic glutamate receptor 8; Pharmacology; Nociception; Neuroscience; Metabotropic receptor; Chemistry; Receptor; Biology; AMPA receptor; Biochemistry","score_opus":0.04115513688786963,"score_gpt":0.34376611217775704,"score_spread":0.3026109752898874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W38310539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000113914226,0.99735236,0.00018533286,0.00022240366,0.0004562115,0.000008351905,0.000016730077,0.000009745556,0.0016349633],"genre_scores_gemma":[0.0005250374,0.99708706,0.00019978979,0.00018269007,0.0002934704,0.000009285415,0.00002317915,0.0000012613414,0.0016781893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998103,0.000031400472,0.00003753223,0.00002576747,0.00007505469,0.000019951685],"domain_scores_gemma":[0.9998085,0.000070896895,0.000043353444,0.000009209853,0.000049938022,0.000018124563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056295266,0.0016483378,0.0023107808,0.002323713,0.00034379718,0.0010665734,0.0011584465,0.0014149258,0.005375015],"category_scores_gemma":[0.00060643477,0.00035934246,0.000445378,0.0032567203,0.00062504935,0.0020672982,0.0007047286,0.0015904111,0.00390446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018449196,0.00009407572,0.00010270061,0.01270272,0.00007303186,0.00033927307,0.000043162952,0.00033289267,0.0025582106,0.002120647,0.04226903,0.9391798],"study_design_scores_gemma":[0.0000491959,0.00014225805,0.00062584,0.0026105565,0.00017775915,0.0020097008,0.0000586678,0.00009327305,0.00058107084,0.001737793,0.9918967,0.000017208868],"about_ca_topic_score_codex":0.0015620094,"about_ca_topic_score_gemma":0.003934895,"teacher_disagreement_score":0.005375015,"about_ca_system_score_codex":0.0006806873,"about_ca_system_score_gemma":0.0012842317,"threshold_uncertainty_score":0.017981231},"labels":[],"label_agreement":null},{"id":"W4206358361","doi":"10.1007/s40263-021-00883-0","title":"Pharmacological Management of Apathy in Dementia","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neurological Disorders and Treatments","field":"Neuroscience","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Ontario Brain Institute; Sunnybrook Health Science Centre","funders":"","keywords":"Apathy; Dementia; Rivastigmine; Memantine; Dementia with Lewy bodies; Frontotemporal dementia; Rotigotine; Galantamine; Psychiatry; Medicine; Vascular dementia; Psychology; Internal medicine; Parkinson's disease; Disease; Donepezil","score_opus":0.11569123049786068,"score_gpt":0.3665872304137719,"score_spread":0.2508959999159112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206358361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070368624,0.9991848,0.00007897751,0.0000932882,0.00008623619,0.000004969393,0.000011551849,0.0000044955523,0.00046523777],"genre_scores_gemma":[0.00075106334,0.9983261,0.00021410338,0.00019701755,0.00018547135,0.000008635601,0.00002487657,0.0000013778447,0.00029133973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998041,0.000039446568,0.00004550641,0.00003123476,0.000060154856,0.000019576824],"domain_scores_gemma":[0.9995864,0.00024453492,0.000080962236,0.000008641409,0.000053624753,0.000025858879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006171221,0.0012451053,0.0024770952,0.0025962293,0.0002509644,0.0011691232,0.001095333,0.001432214,0.0038933705],"category_scores_gemma":[0.0010357216,0.00035123713,0.00088066753,0.0019943244,0.0004662841,0.0009695108,0.00061778096,0.0024500485,0.0013695831],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002348978,0.00013841206,0.00011699352,0.02680365,0.00025555125,0.0002905806,0.000036110454,0.00033023418,0.00070535974,0.001032839,0.016218593,0.95383686],"study_design_scores_gemma":[0.0005499387,0.00062309566,0.0026517704,0.025084225,0.0018036087,0.004521529,0.00012891703,0.0004784841,0.000664745,0.0029815608,0.960438,0.00007405716],"about_ca_topic_score_codex":0.0013975871,"about_ca_topic_score_gemma":0.0034830717,"teacher_disagreement_score":0.0038933705,"about_ca_system_score_codex":0.0004703095,"about_ca_system_score_gemma":0.0007789736,"threshold_uncertainty_score":0.013024628},"labels":[],"label_agreement":null},{"id":"W4212826549","doi":"10.1007/s40263-022-00897-2","title":"Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Adler; START Clinic; Professional Engineers Ontario; Lakehead University; Grey Nuns Community Hospital; University of Calgary; Misericordia Community Hospital; NOSM University; Translational Research in Oncology; University of Saskatchewan; University of Alberta","funders":"","keywords":"Ketamine; Context (archaeology); Medicine; Addiction; Intensive care medicine; Psychiatry; Treatment-resistant depression; Depression (economics); Mood; Major depressive disorder","score_opus":0.02660666941866643,"score_gpt":0.3258086522865787,"score_spread":0.2992019828679123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212826549","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006599238,0.062468074,0.0025981597,0.92275655,0.005311568,0.00005631634,0.000028610857,0.000043191016,0.0060774977],"genre_scores_gemma":[0.021120194,0.2623683,0.02197242,0.64947075,0.03533261,0.0005827353,0.0001157035,0.000102672464,0.008934703],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877345,0.0063023996,0.0020991266,0.0009123909,0.0023961735,0.00055543287],"domain_scores_gemma":[0.9696577,0.020101521,0.0019443169,0.0009026121,0.0052775256,0.0021163954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01772493,0.0009183971,0.0015035629,0.001967474,0.0036062528,0.0068113343,0.004370886,0.021650262,0.006703397],"category_scores_gemma":[0.043370504,0.00069843204,0.002112007,0.0015313713,0.011785093,0.01584844,0.0049490705,0.025282733,0.0031529227],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010704032,0.00028278847,0.0031240922,0.0031912618,0.000058795395,0.008582938,0.0069729537,0.0005702684,0.0010583575,0.115611665,0.51710016,0.34333974],"study_design_scores_gemma":[0.00006849424,0.00016555867,0.0019690914,0.015172515,0.00004042814,0.010677351,0.0085050585,0.00049199874,0.00019925159,0.10688558,0.85570556,0.00011916468],"about_ca_topic_score_codex":0.0037012906,"about_ca_topic_score_gemma":0.010075262,"teacher_disagreement_score":0.021650262,"about_ca_system_score_codex":0.0036341718,"about_ca_system_score_gemma":0.01263861,"threshold_uncertainty_score":0.09373951},"labels":[],"label_agreement":null},{"id":"W4214636256","doi":"10.1007/s40263-022-00903-7","title":"Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Substantia nigra; Pars compacta; Medicine; Immunization; Parkinson's disease; Disease; Neurotoxicity; Neurology; Neuroscience; Dopaminergic; Vaccination; Immunology; Dopamine; Antibody; Pathology; Biology; Internal medicine; Psychiatry; Toxicity","score_opus":0.01075353122992427,"score_gpt":0.2653492891887223,"score_spread":0.254595757958798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214636256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.781739,0.15465625,0.019896522,0.0038875844,0.002220724,0.00058311905,0.00043299064,0.00062529265,0.03595855],"genre_scores_gemma":[0.95174533,0.028113326,0.0071761035,0.0008930392,0.0003424068,0.00016882148,0.00025342478,0.000029862515,0.011277673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999032,0.000022761442,0.000005722725,0.000019313551,0.000024748273,0.0000241786],"domain_scores_gemma":[0.9999449,0.000014861476,0.000013282302,0.000005409812,0.000010399628,0.000011171813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025836358,0.0003308945,0.0004745771,0.0002792996,0.00016826468,0.00033007594,0.00021919614,0.0005343795,0.0041367565],"category_scores_gemma":[0.0002393231,0.00008955363,0.00046305664,0.00014841856,0.00021429887,0.00049229915,0.0002296098,0.0008048931,0.0006698157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038877835,0.002904225,0.0021366961,0.001292941,0.0003277386,0.0003876549,0.00011651672,0.0017930998,0.3110615,0.003333261,0.006953946,0.6658047],"study_design_scores_gemma":[0.007249517,0.09328213,0.07444644,0.001397679,0.001606183,0.009319321,0.00042580318,0.013669528,0.48009154,0.0114637045,0.30688575,0.0001623242],"about_ca_topic_score_codex":0.0008329866,"about_ca_topic_score_gemma":0.001604345,"teacher_disagreement_score":0.0041367565,"about_ca_system_score_codex":0.00023279001,"about_ca_system_score_gemma":0.00025125913,"threshold_uncertainty_score":0.013838887},"labels":[],"label_agreement":null},{"id":"W4232225695","doi":"10.2165/00023210-200620020-00008","title":"Augmenting Strategies in Clozapine-Resistant Schizophrenia","year":2006,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Clozapine; Psychopharmacology; Schizophrenia (object-oriented programming); Psychiatry; Medicine; Psychology; Pharmacology; Psychotherapist","score_opus":0.012831819847018061,"score_gpt":0.27935427258433976,"score_spread":0.26652245273732167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232225695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96495295,0.017074812,0.001268077,0.0021226553,0.00018041243,0.00018486455,0.00021294384,0.00017275794,0.013830578],"genre_scores_gemma":[0.97880334,0.013788792,0.0028981364,0.0004072897,0.000084953965,0.00010151846,0.00017508578,0.000013787305,0.0037271837],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99993896,0.000022214324,0.00000669838,0.0000069994526,0.000011901701,0.000013218143],"domain_scores_gemma":[0.99991155,0.00002223669,0.000022160393,0.0000069482635,0.000009245063,0.000027800186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013095248,0.00036453395,0.0004567674,0.00030415304,0.00027944264,0.00026329255,0.00035649978,0.00038265798,0.003321733],"category_scores_gemma":[0.00034545307,0.000050978768,0.00023810564,0.0002193038,0.00017715058,0.00019089069,0.00020852253,0.00047412087,0.0004965847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015929425,0.0053735473,0.0040221377,0.0014198739,0.00028916533,0.0018310773,0.0006722956,0.0010665404,0.097137675,0.0033169354,0.0050373,0.863904],"study_design_scores_gemma":[0.039496765,0.1564186,0.25655353,0.0030535872,0.0062263645,0.013483769,0.005045408,0.013831734,0.16466554,0.02430536,0.31656018,0.00035915873],"about_ca_topic_score_codex":0.0027427138,"about_ca_topic_score_gemma":0.010569407,"teacher_disagreement_score":0.003321733,"about_ca_system_score_codex":0.000317336,"about_ca_system_score_gemma":0.00041382667,"threshold_uncertainty_score":0.011112332},"labels":[],"label_agreement":null},{"id":"W4240725191","doi":"10.1007/s40263-017-0433-0","title":"Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis","year":2017,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Lamotrigine; Medicine; In utero; Pregnancy; Pediatrics; Odds ratio; Carbamazepine; Population; Obstetrics; Epilepsy; Internal medicine; Fetus; Psychiatry","score_opus":0.19486570779744306,"score_gpt":0.46526494203629903,"score_spread":0.270399234238856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240725191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056276377,0.9933107,0.0002843678,0.0000966974,0.00007727121,0.00011443242,0.00032800183,0.000010645568,0.00015022418],"genre_scores_gemma":[0.14228328,0.85396945,0.0014894917,0.00079369504,0.0001357979,0.00040457776,0.00054156175,0.000017817702,0.00036429957],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99654454,0.0011535474,0.0012921338,0.00046171725,0.00036793936,0.0001801649],"domain_scores_gemma":[0.99257433,0.0050747413,0.0015443979,0.0002534042,0.00044635776,0.00010680375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005441401,0.0023043982,0.0113508245,0.0036611194,0.00047299959,0.0022763687,0.0018261952,0.0020994723,0.0040519047],"category_scores_gemma":[0.018115923,0.0012998565,0.02427116,0.004958538,0.0005527138,0.0016049624,0.0015707584,0.0018923484,0.000287594],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021168224,0.00005144842,0.0053950073,0.40071175,0.5735449,0.00023179306,0.00012699045,0.00039180173,0.00026726277,0.00012684507,0.00060521206,0.016430145],"study_design_scores_gemma":[0.0005152363,0.00015586909,0.0040345863,0.017366555,0.97584414,0.00013264606,0.00007242637,0.00008772094,0.00008581819,0.00012917873,0.0015498041,0.000026079137],"about_ca_topic_score_codex":0.008193969,"about_ca_topic_score_gemma":0.023873497,"teacher_disagreement_score":0.0113508245,"about_ca_system_score_codex":0.0017764245,"about_ca_system_score_gemma":0.0028465728,"threshold_uncertainty_score":0.028777182},"labels":[],"label_agreement":null},{"id":"W42654371","doi":"10.2165/11587820-000000000-00000","title":"Targeting Progressive Neuroaxonal Injury","year":2011,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; McGill University","funders":"National Institutes of Health; Health Canada; Multiple Sclerosis Society; Canadian Institutes of Health Research; Teva Pharmaceutical Industries; Sanofi","keywords":"Neurodegeneration; Medicine; Neuroprotection; Amyotrophic lateral sclerosis; Multiple sclerosis; Disease; Neurology; Neuroscience; Parkinson's disease; Inflammation; Degenerative disease; Pathology; Progressive supranuclear palsy; Immunology; Biology; Internal medicine","score_opus":0.04339443308181088,"score_gpt":0.33550784726540683,"score_spread":0.29211341418359593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W42654371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026420745,0.9964856,0.00032008672,0.00025431978,0.00025190137,0.000018934305,0.00004324292,0.000019346291,0.0023423529],"genre_scores_gemma":[0.001491439,0.99563074,0.00041055446,0.0002539926,0.00015348458,0.000021391857,0.000054588527,0.0000024352191,0.0019813161],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998969,0.000013372537,0.000018773855,0.000017915963,0.00003782212,0.000015145745],"domain_scores_gemma":[0.99984527,0.00005597572,0.00003959511,0.000005366276,0.00003686168,0.000017011465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039107108,0.0014832873,0.0019472666,0.0024531074,0.00026647077,0.00083266484,0.0007319807,0.001143967,0.004503195],"category_scores_gemma":[0.00042028565,0.0003498426,0.00045571863,0.0016882978,0.0004495605,0.0011027177,0.00061317434,0.0017742267,0.002290395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015989272,0.00012924301,0.00007947781,0.013486743,0.00009216872,0.00020744132,0.00003088449,0.00041430598,0.0032701662,0.001461498,0.02533835,0.9553297],"study_design_scores_gemma":[0.00011863327,0.00034196582,0.00081135397,0.0035219016,0.0004389228,0.0017792063,0.000048458438,0.00025345795,0.0015909025,0.0015067677,0.9895606,0.00002775149],"about_ca_topic_score_codex":0.0015421375,"about_ca_topic_score_gemma":0.0054376377,"teacher_disagreement_score":0.004503195,"about_ca_system_score_codex":0.00059755147,"about_ca_system_score_gemma":0.001032262,"threshold_uncertainty_score":0.015064657},"labels":[],"label_agreement":null},{"id":"W4283592028","doi":"10.1007/s40263-022-00930-4","title":"Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Milken Family Foundation; Milken Institute","keywords":"Medicine; Nasal administration; Intensive care medicine; Drug; Psychiatry; Pharmacology","score_opus":0.13988202627114982,"score_gpt":0.4464926226626209,"score_spread":0.3066105963914711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283592028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003742115,0.9944555,0.0007636841,0.0009784614,0.0003425076,0.000023454031,0.000028935994,0.000015916321,0.003017366],"genre_scores_gemma":[0.0012063347,0.9964025,0.0008256362,0.00042489372,0.00015988837,0.000021688598,0.00002490393,0.0000038324324,0.0009302853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996045,0.00007899486,0.00005122324,0.00007699616,0.0001539425,0.000034280096],"domain_scores_gemma":[0.9994168,0.000296145,0.00007474734,0.000022413,0.00015450391,0.000035458135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016778599,0.00080935325,0.0010242283,0.0017223704,0.00035782586,0.0016715665,0.0011343311,0.0015667209,0.002692567],"category_scores_gemma":[0.001121616,0.0003853251,0.00067085127,0.001190352,0.0011015849,0.0024277568,0.0006942423,0.0032926914,0.0019940587],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000861237,0.00020568016,0.0002859726,0.020505512,0.000083265644,0.00041817856,0.00017728508,0.0003869709,0.009887083,0.026611468,0.016829895,0.92452264],"study_design_scores_gemma":[0.000022880195,0.00028668472,0.00065026194,0.004300462,0.000082302475,0.0018705784,0.00012404592,0.00016552764,0.002329467,0.0035057832,0.98662347,0.000038512087],"about_ca_topic_score_codex":0.0013294789,"about_ca_topic_score_gemma":0.0027807518,"teacher_disagreement_score":0.002692567,"about_ca_system_score_codex":0.0007005485,"about_ca_system_score_gemma":0.0019453363,"threshold_uncertainty_score":0.009007573},"labels":[],"label_agreement":null},{"id":"W4283660569","doi":"10.1007/s40263-022-00932-2","title":"A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cilag; H. Lundbeck A/S; Mylan; Biogen; Sunovion; Medical Research Council; Sanofi; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Clozapine; Tolerability; Guideline; Schizophrenia (object-oriented programming); Checklist; Medicine; Intensive care medicine; Psychopharmacology; Psychiatry; Adverse effect; Psychology; Internal medicine","score_opus":0.014328500738093691,"score_gpt":0.2785911916347042,"score_spread":0.2642626908966105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283660569","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012764176,0.18085255,0.15065862,0.50097615,0.017524928,0.05845966,0.021474382,0.005149329,0.052140266],"genre_scores_gemma":[0.025072236,0.08732757,0.7511273,0.0781528,0.004089459,0.027440578,0.013687115,0.00030850372,0.012794401],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97590274,0.011062275,0.009521573,0.00055291754,0.0024501814,0.00051039824],"domain_scores_gemma":[0.9472088,0.016456457,0.0076719956,0.001420311,0.024820454,0.00242201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02045526,0.0020924648,0.00264135,0.008234968,0.0019068959,0.0024115546,0.0034351104,0.0064731,0.005335659],"category_scores_gemma":[0.058762316,0.0013813634,0.0037537087,0.004845628,0.0013573135,0.0038649712,0.002279632,0.0057316544,0.0037709863],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019247115,0.0005071668,0.0039179283,0.013557577,0.00033919842,0.0016935838,0.0014085331,0.0012945232,0.0015632908,0.0048298887,0.69855654,0.2721394],"study_design_scores_gemma":[0.0011278259,0.00062620646,0.024975507,0.068265535,0.0011954996,0.0043246606,0.0018414124,0.0031188151,0.0013806531,0.015587118,0.87707496,0.00048187183],"about_ca_topic_score_codex":0.011089588,"about_ca_topic_score_gemma":0.03528481,"teacher_disagreement_score":0.02045526,"about_ca_system_score_codex":0.0035708805,"about_ca_system_score_gemma":0.020919576,"threshold_uncertainty_score":0.10817903},"labels":[],"label_agreement":null},{"id":"W4286491536","doi":"10.1007/s40263-022-00937-x","title":"Antiseizure Drugs and Movement Disorders","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; Ontario Neurotrauma Foundation; University of Toronto; University Health Network","funders":"Department of Medicine, University of Toronto","keywords":"Lacosamide; Oxcarbazepine; Lamotrigine; Medicine; Movement disorders; Tiagabine; Carbamazepine; Levetiracetam; Zonisamide; Felbamate; Perampanel; Epilepsy; Gabapentin; Primidone; Topiramate; Pharmacology; Adverse effect; Psychiatry; Internal medicine","score_opus":0.034637669936816176,"score_gpt":0.35363422266236744,"score_spread":0.3189965527255513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286491536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000664547,0.9986885,0.000038430888,0.00012894894,0.00015695787,0.0000061710657,0.00002240487,0.0000050889716,0.0008870252],"genre_scores_gemma":[0.0005297611,0.99834216,0.00011265723,0.00021165679,0.0001694587,0.0000070123892,0.000029109762,9.5307604e-7,0.0005973263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979454,0.000037120568,0.000049098413,0.000029719857,0.0000673084,0.000022161392],"domain_scores_gemma":[0.9996345,0.00016772622,0.00010258306,0.000009930262,0.000058476493,0.000026664935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053924724,0.0011983572,0.0019136673,0.00381215,0.00024914675,0.0011104066,0.00070190144,0.0010483139,0.009023792],"category_scores_gemma":[0.0009134458,0.0003391936,0.0006492977,0.0034547693,0.0004206895,0.0012188031,0.00077227765,0.0014381539,0.0020706404],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001685462,0.000094646435,0.0001425385,0.039133262,0.00022375661,0.00013817848,0.000039792514,0.00018738779,0.00072274107,0.0014198998,0.033245094,0.9244842],"study_design_scores_gemma":[0.00016571664,0.00021070927,0.0015814505,0.017304216,0.0010163571,0.0012127854,0.000069534,0.00011613468,0.00027320936,0.0014356517,0.9765887,0.000025638403],"about_ca_topic_score_codex":0.0019642015,"about_ca_topic_score_gemma":0.006587422,"teacher_disagreement_score":0.009023792,"about_ca_system_score_codex":0.0006032889,"about_ca_system_score_gemma":0.0015332053,"threshold_uncertainty_score":0.030187547},"labels":[],"label_agreement":null},{"id":"W4292104378","doi":"10.1007/s40263-022-00947-9","title":"Correction to: Antiseizure Drugs and Movement Disorders","year":2022,"lang":"en","type":"erratum","venue":"CNS Drugs","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; Ontario Neurotrauma Foundation; University of Toronto; University Health Network","funders":"","keywords":"Psychopharmacology; Movement disorders; Neurology; Medicine; Psychology; Psychotherapist; Psychiatry; Neuroscience; Internal medicine","score_opus":0.00823056938266356,"score_gpt":0.28123803979069834,"score_spread":0.27300747040803475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292104378","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004446471,0.0010610712,0.00015120198,0.031048194,0.9631777,0.000016429505,0.0004686041,0.00009718915,0.0039351773],"genre_scores_gemma":[0.00406997,0.007403164,0.0018416223,0.11322347,0.5790677,0.00015797761,0.0013921964,0.0007411146,0.29210275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970572,0.00046701406,0.00052105763,0.00035975326,0.0012609602,0.00033404506],"domain_scores_gemma":[0.98240674,0.0048719365,0.00090931216,0.0010459503,0.009497651,0.0012684116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029592153,0.002442146,0.0024093438,0.004252628,0.003280082,0.0044560474,0.0027334043,0.0083652465,0.06758529],"category_scores_gemma":[0.035420783,0.0010656137,0.0018070793,0.0020990358,0.0019151615,0.0021291655,0.0019188639,0.011641335,0.044072177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013176311,0.0000031462748,0.000022342509,0.000046048128,0.0000035865585,0.00011508195,0.0000049216087,0.000013686543,0.00000688785,0.00024753402,0.99691415,0.0026095144],"study_design_scores_gemma":[0.00003966121,0.000009265641,0.00027588973,0.00023494847,0.00001866499,0.00040527745,0.000026861057,0.00009697034,0.000058357164,0.00071366667,0.9981066,0.000013734863],"about_ca_topic_score_codex":0.024025578,"about_ca_topic_score_gemma":0.034261856,"teacher_disagreement_score":0.06758529,"about_ca_system_score_codex":0.00405964,"about_ca_system_score_gemma":0.006063968,"threshold_uncertainty_score":0.22609532},"labels":[],"label_agreement":null},{"id":"W4293065740","doi":"10.1007/s40263-022-00946-w","title":"Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia","year":2022,"lang":"en","type":"erratum","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medical Research Council","keywords":"Clozapine; Guideline; Psychopharmacology; Schizophrenia (object-oriented programming); Checklist; Medicine; Psychiatry; MEDLINE; Psychology; Psychotherapist; Pathology; Political science","score_opus":0.013875041224964767,"score_gpt":0.28099551024642033,"score_spread":0.2671204690214556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293065740","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039157446,0.004337179,0.00454648,0.27325463,0.7026928,0.0002844405,0.0037589483,0.0014045158,0.009329501],"genre_scores_gemma":[0.014437801,0.024078203,0.058944505,0.3997716,0.21967404,0.0021380044,0.011758491,0.004269444,0.26492798],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895399,0.0029145845,0.0028163258,0.00046088055,0.0037917763,0.0004764744],"domain_scores_gemma":[0.91953045,0.019742126,0.004442326,0.0025051183,0.05186902,0.001910904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008269689,0.0015896994,0.001352769,0.002953055,0.0022780318,0.0035486778,0.0023435783,0.006879789,0.031900454],"category_scores_gemma":[0.120009236,0.00086183264,0.0018339254,0.0019655414,0.0016873643,0.0021040696,0.0017888467,0.011279041,0.034647502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013119275,0.000004436325,0.00003995542,0.000065702996,0.0000025719714,0.000088623834,0.000026731945,0.000022255193,0.000015534628,0.00023021061,0.99252784,0.006962945],"study_design_scores_gemma":[0.00004621469,0.0000261173,0.00050925394,0.0010193873,0.000023319235,0.00069631427,0.000103542494,0.00018641666,0.00015820871,0.0008897047,0.996302,0.000039353967],"about_ca_topic_score_codex":0.018464176,"about_ca_topic_score_gemma":0.030151086,"teacher_disagreement_score":0.031900454,"about_ca_system_score_codex":0.0035845188,"about_ca_system_score_gemma":0.012767118,"threshold_uncertainty_score":0.106717706},"labels":[],"label_agreement":null},{"id":"W4295449270","doi":"10.1007/s40263-022-00944-y","title":"A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"National Institute of Mental Health; Universität Zürich","keywords":"Research Domain Criteria; Psilocybin; Psychology; PsycINFO; Valence (chemistry); Clinical psychology; Cognitive psychology; Cognition; Psychiatry; MEDLINE; Hallucinogen; Chemistry","score_opus":0.2240884902956888,"score_gpt":0.5258268709130501,"score_spread":0.30173838061736136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295449270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064278007,0.75852364,0.021130577,0.024804445,0.0058156354,0.1511157,0.023810789,0.00095306715,0.007418224],"genre_scores_gemma":[0.041181177,0.53938836,0.10736482,0.022373917,0.0014783466,0.27074975,0.013855769,0.00037059115,0.0032372726],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.87281513,0.037271477,0.063988335,0.006345351,0.017456695,0.0021229177],"domain_scores_gemma":[0.7320733,0.15797243,0.052966602,0.006973104,0.045780975,0.004233627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.113999926,0.003869852,0.018356714,0.05867887,0.0038646427,0.010577069,0.008419006,0.006544444,0.01445766],"category_scores_gemma":[0.28094956,0.002519891,0.016004806,0.04258904,0.0042236946,0.011526966,0.0114494385,0.0036839058,0.0022211748],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002042948,0.00002232573,0.0009567151,0.9400991,0.0022498108,0.00012588747,0.00085202226,0.00016907376,0.00035971132,0.0015379646,0.006704247,0.04671884],"study_design_scores_gemma":[0.00034327168,0.00009696555,0.0012753992,0.9527845,0.009811239,0.00013210664,0.0007261408,0.00017409281,0.00025596525,0.0016420011,0.0327013,0.000056999903],"about_ca_topic_score_codex":0.007952133,"about_ca_topic_score_gemma":0.017498266,"teacher_disagreement_score":0.113999926,"about_ca_system_score_codex":0.0171741,"about_ca_system_score_gemma":0.07328497,"threshold_uncertainty_score":0.60289645},"labels":[],"label_agreement":null},{"id":"W4297238194","doi":"10.1007/s40263-022-00952-y","title":"Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research","year":2022,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Medicine; Nephrogenic diabetes insipidus; Kidney disease; Lithium (medication); Adverse effect; Comorbidity; PsycINFO; Internal medicine; Intensive care medicine; Observational study; Psychiatry; Randomized controlled trial; MEDLINE; Kidney","score_opus":0.0393036728831198,"score_gpt":0.3819230748082708,"score_spread":0.342619401925151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297238194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033385205,0.9993724,0.000019144754,0.00006709589,0.000031393185,0.000017040105,0.00010849282,0.0000011828122,0.000049410366],"genre_scores_gemma":[0.0037172318,0.9958675,0.00010077158,0.00017715573,0.000036296697,0.000020870051,0.0000518467,7.486922e-7,0.000027542534],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973054,0.00069041766,0.0010751172,0.00030379288,0.0005053106,0.00011998208],"domain_scores_gemma":[0.9882945,0.008167239,0.002691712,0.000106307336,0.00058745255,0.00015285121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033945728,0.0011755482,0.006733674,0.006597193,0.00042433696,0.0023040145,0.0011817158,0.0016952043,0.0039254217],"category_scores_gemma":[0.012096066,0.0007525338,0.006356245,0.009403147,0.0006252138,0.0014746821,0.0013589342,0.0010600585,0.00021172965],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036713295,0.000029277593,0.0016574148,0.9309691,0.017145963,0.00015869303,0.000114005634,0.00012828197,0.00021870981,0.00016218264,0.0022034121,0.046845865],"study_design_scores_gemma":[0.0005837673,0.00029615007,0.016392753,0.7302763,0.2090317,0.0010898254,0.00040975193,0.00013382174,0.0002410064,0.00046508352,0.04099773,0.00008211623],"about_ca_topic_score_codex":0.0087620625,"about_ca_topic_score_gemma":0.036033515,"teacher_disagreement_score":0.0087620625,"about_ca_system_score_codex":0.0017962732,"about_ca_system_score_gemma":0.0055750036,"threshold_uncertainty_score":0.017952442},"labels":[],"label_agreement":null},{"id":"W4306292918","doi":"10.1007/s40263-022-00956-8","title":"The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study","year":2022,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries","keywords":"Medicine; Chorea; Tolerability; Adverse effect; Somnolence; Huntington's disease; Akathisia; Pediatrics; Internal medicine; Anesthesia; Disease; Psychiatry","score_opus":0.059127159505417796,"score_gpt":0.3357942568526275,"score_spread":0.2766670973472097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306292918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982768,0.00043840514,0.00022034117,0.000041463274,0.000018879728,0.00047591244,0.00026109803,0.000023305101,0.0002436762],"genre_scores_gemma":[0.9971595,0.00046398956,0.00039474553,0.0001478571,0.00009207277,0.0004999743,0.0006776064,0.0000093019025,0.00055500196],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993598,0.0003529766,0.000043806343,0.000095488234,0.000080861704,0.0000670167],"domain_scores_gemma":[0.9982054,0.00041128264,0.00059335795,0.00021454143,0.00014335003,0.00043201086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025473589,0.00115002,0.0014409861,0.0003844612,0.00038773016,0.00055373786,0.0004593488,0.0008938258,0.0025207957],"category_scores_gemma":[0.0013459335,0.00030564834,0.0010473906,0.0003033173,0.00066714536,0.00074350124,0.0003049425,0.001708462,0.00042765017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8253413,0.050622225,0.021926675,0.0005275485,0.001273895,0.00027839807,0.00037808553,0.0008007991,0.04394211,0.00005834088,0.00084660616,0.05400395],"study_design_scores_gemma":[0.24506912,0.68144685,0.065537356,0.00003806113,0.00073638017,0.0003358156,0.00008348447,0.0010884982,0.004253682,0.00007214816,0.0013065442,0.000032128108],"about_ca_topic_score_codex":0.0006038207,"about_ca_topic_score_gemma":0.0012063473,"teacher_disagreement_score":0.0025473589,"about_ca_system_score_codex":0.00049821474,"about_ca_system_score_gemma":0.00085959694,"threshold_uncertainty_score":0.013471842},"labels":[],"label_agreement":null},{"id":"W4375859891","doi":"10.1007/s40263-023-01002-x","title":"Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis","year":2023,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Biogen","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Confidence interval; Nuclear medicine; Relative risk; Gastroenterology; Fingolimod; Immunology","score_opus":0.12092613490396055,"score_gpt":0.3234922728062846,"score_spread":0.20256613790232408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375859891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578569,0.020583922,0.009856895,0.0006465197,0.0012051446,0.00058923074,0.004073233,0.00014873214,0.0050394502],"genre_scores_gemma":[0.99462986,0.000632393,0.0024296585,0.00020183121,0.00008757225,0.00025889976,0.0006301484,0.000026733407,0.001102821],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97328806,0.01972926,0.0018371462,0.002657314,0.0011372709,0.0013510328],"domain_scores_gemma":[0.984315,0.0100564025,0.0022814418,0.0023417014,0.0006518049,0.00035359294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013191246,0.0012268913,0.0022848817,0.0008209825,0.000568555,0.0011091512,0.0019223583,0.0013472204,0.007088752],"category_scores_gemma":[0.036738385,0.00064564217,0.0070260265,0.0011782701,0.00050636125,0.0013346443,0.0016831701,0.0019769215,0.00038863384],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26589456,0.0011626225,0.28852585,0.0059738243,0.35115764,0.00066227454,0.0009335592,0.0035048076,0.0035825125,0.0045044953,0.004463078,0.06963483],"study_design_scores_gemma":[0.0473362,0.024989957,0.5863543,0.00088480586,0.29806337,0.0010512747,0.0013618427,0.012466023,0.0058613727,0.008520866,0.0128390165,0.00027089688],"about_ca_topic_score_codex":0.009135913,"about_ca_topic_score_gemma":0.008932254,"teacher_disagreement_score":0.013191246,"about_ca_system_score_codex":0.0007737483,"about_ca_system_score_gemma":0.0009741891,"threshold_uncertainty_score":0.069762826},"labels":[],"label_agreement":null},{"id":"W4378953505","doi":"10.1007/s40263-023-01010-x","title":"Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Pain Management and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medizinische Universität Graz","keywords":"Medicine; Phantom limb pain; Calcitonin; Phantom limb; Amputation; Analgesic; Regimen; Randomized controlled trial; MEDLINE; Observational study; Physical therapy; Internal medicine; Anesthesia; Surgery","score_opus":0.09207663435731953,"score_gpt":0.3865501423956726,"score_spread":0.29447350803835304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089772494,0.99794334,0.00009770754,0.00018387975,0.000090793765,0.00038501792,0.00018200441,0.000008273424,0.00021127563],"genre_scores_gemma":[0.014431134,0.98339844,0.0005224779,0.00051827205,0.000085847736,0.0007575871,0.00015734078,0.0000042824595,0.00012462014],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942048,0.0022763747,0.0018007297,0.0003871034,0.0011045812,0.00022637175],"domain_scores_gemma":[0.98085326,0.013509555,0.0034422236,0.0002121285,0.0017313599,0.00025152235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067220153,0.0014915088,0.009227204,0.00904371,0.00067373674,0.002446605,0.0020239584,0.0022599483,0.0048393114],"category_scores_gemma":[0.02648772,0.00085238676,0.0066991523,0.011670933,0.0009231344,0.0021288758,0.0012881652,0.0010616204,0.00031148177],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015108999,0.000012198024,0.00028057516,0.978228,0.004870563,0.000065812535,0.000088585366,0.00005994547,0.000088759574,0.000103898885,0.00072329753,0.015327214],"study_design_scores_gemma":[0.00046085587,0.00028330353,0.0025695567,0.91013396,0.075480476,0.00030626572,0.000241823,0.0001215654,0.00013575873,0.00023945054,0.009995083,0.00003205237],"about_ca_topic_score_codex":0.009098437,"about_ca_topic_score_gemma":0.024600716,"teacher_disagreement_score":0.009227204,"about_ca_system_score_codex":0.0042267037,"about_ca_system_score_gemma":0.012868549,"threshold_uncertainty_score":0.03554988},"labels":[],"label_agreement":null},{"id":"W4379114392","doi":"10.1007/s40263-023-01016-5","title":"BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Glioma; Targeted therapy; Clinical trial; Bioinformatics; Oncology; Internal medicine; Cancer research; Biology; Cancer","score_opus":0.046265265051207385,"score_gpt":0.3385630503462798,"score_spread":0.29229778529507244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379114392","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006249083,0.9992773,0.00004219636,0.00018166308,0.000092402865,0.0000025288714,0.00002032993,0.00000465956,0.00031649022],"genre_scores_gemma":[0.00048439138,0.998796,0.00009145165,0.00021900401,0.00013541999,0.0000037659697,0.000040164596,9.549335e-7,0.00022888275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979395,0.00003536235,0.000037600905,0.000040181923,0.000070799775,0.00002216789],"domain_scores_gemma":[0.999553,0.00023683062,0.0000867679,0.000009443736,0.00008280153,0.00003112232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006835479,0.0010511486,0.0021105502,0.0019607907,0.0001728319,0.0012126658,0.00094716996,0.001083049,0.003007624],"category_scores_gemma":[0.0011031505,0.00033334998,0.00085214956,0.001901806,0.00037934657,0.0010813825,0.0006215788,0.0020789544,0.0013572611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019337778,0.000059906393,0.00021074986,0.0187972,0.00023424927,0.000121510464,0.000023084232,0.00046119135,0.00087605586,0.0011771707,0.028017325,0.9498282],"study_design_scores_gemma":[0.00016640914,0.0003341282,0.0024392677,0.01568048,0.001321422,0.0016693416,0.00006906672,0.00035774885,0.00059678114,0.0027537781,0.9745574,0.000054233067],"about_ca_topic_score_codex":0.0013561836,"about_ca_topic_score_gemma":0.0036540765,"teacher_disagreement_score":0.003007624,"about_ca_system_score_codex":0.00078124064,"about_ca_system_score_gemma":0.0011967887,"threshold_uncertainty_score":0.010061502},"labels":[],"label_agreement":null},{"id":"W4385231015","doi":"10.1007/s40263-023-01028-1","title":"Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Paliperidone Palmitate; Paliperidone; Meta-analysis; Randomized controlled trial; Schizophrenia (object-oriented programming); Cochrane Library; Adverse effect; Positive and Negative Syndrome Scale; Discontinuation; Observational study; Internal medicine; Antipsychotic; Psychiatry; Psychosis","score_opus":0.08628787647540762,"score_gpt":0.3851335997236647,"score_spread":0.2988457232482571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385231015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050710714,0.99349,0.00029609594,0.00013202407,0.00011039854,0.00040354853,0.00027404906,0.000019253546,0.00020370938],"genre_scores_gemma":[0.14314559,0.85123926,0.0019985198,0.0009373839,0.00021898783,0.0015232126,0.00062850263,0.000025483818,0.00028301968],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99087876,0.0035496403,0.0033530968,0.0008326145,0.0011286814,0.00025720586],"domain_scores_gemma":[0.9830519,0.011336658,0.0036079658,0.0004141704,0.0013245139,0.00026474745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012813696,0.002566355,0.022510134,0.0061830436,0.0006852409,0.0032924067,0.0024450854,0.0026059984,0.0029381409],"category_scores_gemma":[0.02885931,0.001518555,0.03944177,0.005831451,0.0008877453,0.0022157116,0.0015403309,0.0021492294,0.00023783384],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002860715,0.000055871424,0.0016214744,0.5352273,0.44546053,0.00009996347,0.0000924936,0.00039329185,0.00021209342,0.00008295629,0.0003153585,0.013577942],"study_design_scores_gemma":[0.0009470202,0.00037060614,0.0021527724,0.036271702,0.95866936,0.000081193146,0.000049827107,0.00016531239,0.00013185687,0.000121651225,0.001011628,0.000027211527],"about_ca_topic_score_codex":0.0061896984,"about_ca_topic_score_gemma":0.01256944,"teacher_disagreement_score":0.022510134,"about_ca_system_score_codex":0.0034910087,"about_ca_system_score_gemma":0.00417831,"threshold_uncertainty_score":0.06776613},"labels":[],"label_agreement":null},{"id":"W4386019723","doi":"10.1007/s40263-023-01008-5","title":"Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Anxiety; Anxiolytic; Lysergic acid diethylamide; Psychology; Psychopharmacology; Clinical trial; Randomized controlled trial; Pharmacology; Medicine; Psychiatry; Serotonin; Receptor; Internal medicine","score_opus":0.34593529662441314,"score_gpt":0.5418382729961186,"score_spread":0.1959029763717055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386019723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012067181,0.9995807,0.000024251407,0.000044566,0.000029023056,0.0000034703053,0.0000136483,0.0000021803858,0.00018151144],"genre_scores_gemma":[0.00104701,0.99863917,0.00007972428,0.00007904489,0.00003340233,0.0000039222546,0.000015315996,5.3070505e-7,0.00010193011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998356,0.00003707829,0.00003162782,0.00003094564,0.000050391478,0.000014300997],"domain_scores_gemma":[0.9995148,0.0003048256,0.000087625565,0.000009471055,0.000053913187,0.000029405775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007275202,0.0009621525,0.0022844882,0.0016656971,0.00019270519,0.0009392685,0.0009887326,0.0009747062,0.004613582],"category_scores_gemma":[0.0009582128,0.00023340496,0.00096942583,0.0017352162,0.00041726942,0.00057335425,0.00043740048,0.0013994756,0.00076881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070018717,0.00018255592,0.00022975799,0.06807665,0.000772078,0.0002052549,0.00004462574,0.00035657495,0.0018216419,0.0012184476,0.0099022165,0.91648996],"study_design_scores_gemma":[0.0013500404,0.0019968883,0.0063072243,0.061812475,0.009101378,0.0036669497,0.00029342994,0.0004420257,0.002643625,0.0030913947,0.9091772,0.000117367556],"about_ca_topic_score_codex":0.0020800163,"about_ca_topic_score_gemma":0.0050877524,"teacher_disagreement_score":0.004613582,"about_ca_system_score_codex":0.00038578323,"about_ca_system_score_gemma":0.0010420748,"threshold_uncertainty_score":0.015433967},"labels":[],"label_agreement":null},{"id":"W4387326085","doi":"10.1007/s40263-023-01032-5","title":"Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University; Brain and Cognition Discovery Foundation; University Health Network","funders":"National Institute of Mental Health; National Institute on Aging","keywords":"Dextromethorphan; Bupropion; Medicine; Major depressive disorder; Internal medicine; Placebo; Adverse effect; Depression (economics); Randomized controlled trial; Meta-analysis; Rating scale; Hamilton Rating Scale for Depression; Psychiatry; Psychology; Smoking cessation; Alternative medicine","score_opus":0.2922463324314019,"score_gpt":0.533897522969662,"score_spread":0.24165119053826006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387326085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005673065,0.99890244,0.000073823074,0.00007318063,0.000052995674,0.000092695154,0.00012619254,0.000005149448,0.00010619872],"genre_scores_gemma":[0.009599049,0.9893567,0.00041973707,0.0002945524,0.000045152075,0.00010432501,0.00009991245,0.0000034856812,0.0000770985],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99752873,0.0008202516,0.00091361627,0.00023505735,0.00042202242,0.000080272395],"domain_scores_gemma":[0.99038374,0.0071761287,0.0017273049,0.00010928183,0.00045881423,0.00014472964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004759121,0.0012557576,0.008504972,0.0034526247,0.00039612915,0.0016688092,0.0016112783,0.0013509053,0.004387233],"category_scores_gemma":[0.015219793,0.0006490917,0.0070450045,0.0043465113,0.00070389494,0.0012410443,0.0010873828,0.0014147278,0.00024375567],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013102745,0.000033144774,0.00046005598,0.89560497,0.030764164,0.00006797144,0.000077668104,0.00017231356,0.0003126549,0.00019340802,0.0015250953,0.0694782],"study_design_scores_gemma":[0.004096788,0.0010442013,0.008570252,0.53775984,0.4145606,0.0005472578,0.0002678154,0.00029765468,0.000522614,0.00075478904,0.031472865,0.000105320076],"about_ca_topic_score_codex":0.0057002534,"about_ca_topic_score_gemma":0.02167073,"teacher_disagreement_score":0.008504972,"about_ca_system_score_codex":0.0017775089,"about_ca_system_score_gemma":0.00346254,"threshold_uncertainty_score":0.025168896},"labels":[],"label_agreement":null},{"id":"W4388725740","doi":"10.1007/s40263-023-01048-x","title":"Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; George & Fay Yee Centre for Healthcare Innovation; University of Manitoba","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Zonisamide; Internal medicine; Adverse effect; Psychiatry; Topiramate; Epilepsy","score_opus":0.07539284631828222,"score_gpt":0.366625635527805,"score_spread":0.2912327892095228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388725740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006343126,0.99229443,0.00036087763,0.00010014779,0.000118525364,0.00020600205,0.0003608026,0.000019871528,0.00019623945],"genre_scores_gemma":[0.17767411,0.8176621,0.0020030353,0.0009067449,0.00019424222,0.00048512535,0.00065487385,0.0000291224,0.00039069922],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9945786,0.0022349562,0.0017306322,0.00065149856,0.0005986863,0.00020556166],"domain_scores_gemma":[0.9913005,0.005958197,0.0018119086,0.00026686658,0.0005120768,0.00015047408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008751682,0.0026847366,0.018641667,0.003410156,0.0004953532,0.0026926398,0.0020791772,0.0021093495,0.0038357945],"category_scores_gemma":[0.01780228,0.0015766174,0.031441346,0.0044390685,0.0008311238,0.0016558621,0.0015115293,0.002153211,0.00028061334],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049358383,0.00003837996,0.0023663505,0.31881544,0.6599276,0.00008892974,0.0000738582,0.0004187997,0.00029881526,0.00009885468,0.0004636254,0.012473474],"study_design_scores_gemma":[0.0017019007,0.0002357118,0.0027670662,0.011152027,0.98264474,0.000058999816,0.000038054146,0.00010990372,0.00008643347,0.00012771407,0.0010541362,0.00002321091],"about_ca_topic_score_codex":0.0062785624,"about_ca_topic_score_gemma":0.017766362,"teacher_disagreement_score":0.018641667,"about_ca_system_score_codex":0.0021040447,"about_ca_system_score_gemma":0.0024445609,"threshold_uncertainty_score":0.04628384},"labels":[],"label_agreement":null},{"id":"W4388970634","doi":"10.1007/s40263-023-01044-1","title":"The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review","year":2023,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Research Domain Criteria; Psychology; Lysergic acid diethylamide; Mood; Happiness; Clinical psychology; Mental health; Psychiatry; Medicine; Psychotherapist","score_opus":0.13164598224215734,"score_gpt":0.48225955610918525,"score_spread":0.3506135738670279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388970634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003878003,0.9671244,0.0033616095,0.0027645146,0.0007292962,0.018217944,0.0021203498,0.00005254574,0.0017512783],"genre_scores_gemma":[0.08232337,0.8175276,0.023736574,0.007119284,0.00071665255,0.06517111,0.0025431782,0.000042888125,0.0008193355],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.912754,0.03166499,0.03969464,0.0035045652,0.011254657,0.0011271914],"domain_scores_gemma":[0.76208603,0.17192121,0.040847898,0.0045825406,0.019040931,0.0015214211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.073712595,0.0020564075,0.012741558,0.019913571,0.0016151645,0.0058970116,0.0040517338,0.004277095,0.005133531],"category_scores_gemma":[0.20676145,0.0013718767,0.010660027,0.012914581,0.0026326354,0.0048223725,0.004275,0.0019209794,0.00049309473],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018786486,0.000013092343,0.0006801131,0.9670115,0.004547141,0.00008825831,0.00036925904,0.00011019398,0.00019857136,0.00073985604,0.0008873389,0.025166834],"study_design_scores_gemma":[0.00032945964,0.00013106538,0.0019543068,0.95105356,0.031918745,0.00017443554,0.00037218822,0.0001426565,0.00025292826,0.0010774318,0.0125493985,0.000043821296],"about_ca_topic_score_codex":0.005962151,"about_ca_topic_score_gemma":0.014561223,"teacher_disagreement_score":0.073712595,"about_ca_system_score_codex":0.00948333,"about_ca_system_score_gemma":0.033485305,"threshold_uncertainty_score":0.3898341},"labels":[],"label_agreement":null},{"id":"W4388970721","doi":"10.1007/s40263-023-01053-0","title":"Context is a Critical for Psychoactive Drug Effects","year":2023,"lang":"en","type":"letter","venue":"CNS Drugs","topic":"Psychedelics and Drug Studies","field":"Psychology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Psychopharmacology; Context (archaeology); Drug; Psychoactive drug; Medicine; Pharmacology; Psychology; Psychiatry; Biology","score_opus":0.044034003831641515,"score_gpt":0.3884740242489851,"score_spread":0.34444002041734356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388970721","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030713395,0.001554317,0.000042554322,0.9842286,0.010649387,0.000005412384,0.00001104735,0.00000691832,0.0031945435],"genre_scores_gemma":[0.0045931106,0.0016891962,0.00015045215,0.9397456,0.048071265,0.000024820447,0.0000069573866,0.000011206802,0.0057074022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99558747,0.0016452959,0.0005086834,0.00057612255,0.0011043792,0.0005780546],"domain_scores_gemma":[0.9775,0.01450286,0.0011000996,0.0006518272,0.002214064,0.0040311874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006707249,0.00066226616,0.002121497,0.0007751919,0.008993301,0.0062464485,0.0018830567,0.05959812,0.009549752],"category_scores_gemma":[0.026489228,0.000684383,0.0014502275,0.00064572215,0.00813272,0.0058767437,0.0033039248,0.061654467,0.0039177868],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016249603,0.00010991204,0.001293419,0.00014580057,0.000043999647,0.004703012,0.000469043,0.00004494618,0.0002992738,0.013080783,0.9553825,0.024264796],"study_design_scores_gemma":[0.00023071704,0.000128176,0.00328634,0.000712574,0.00007158065,0.0045121787,0.0014522944,0.00018030882,0.00020122998,0.041038726,0.9481098,0.00007609612],"about_ca_topic_score_codex":0.010567811,"about_ca_topic_score_gemma":0.040096857,"teacher_disagreement_score":0.05959812,"about_ca_system_score_codex":0.006228419,"about_ca_system_score_gemma":0.01048309,"threshold_uncertainty_score":0.045190513},"labels":[],"label_agreement":null},{"id":"W4391810680","doi":"10.1007/s40263-024-01061-8","title":"Targeting Pannexin-1 Channels: Addressing the ‘Gap’ in Chronic Pain","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Pannexin; Chronic pain; Neuroscience; Medicine; Adenosine; Purinergic receptor; Ion channel; Mechanism (biology); Bioinformatics; Pharmacology; Biology; Cell biology; Gap junction; Internal medicine; Connexin; Intracellular; Receptor","score_opus":0.0690528701644024,"score_gpt":0.34761524076179967,"score_spread":0.2785623705973973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391810680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000106548134,0.9983571,0.00017904803,0.00044165924,0.00029186465,0.000004284118,0.000019121,0.000009195939,0.00059118605],"genre_scores_gemma":[0.0006289855,0.9980578,0.00019629308,0.00033659974,0.00019437844,0.0000062556837,0.0000280524,0.0000017919896,0.0005497943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998684,0.000022568001,0.000016740545,0.000023025716,0.00004934944,0.000019905272],"domain_scores_gemma":[0.99976534,0.00011928547,0.000029981085,0.0000062359354,0.000052315874,0.000026805503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006713642,0.00086989475,0.0014676005,0.0011749851,0.00021441413,0.0010711659,0.0009222567,0.001377589,0.0036603597],"category_scores_gemma":[0.00067888334,0.00023449215,0.0004953605,0.0011551386,0.0005785178,0.0014763317,0.0007047421,0.0026858551,0.0017179871],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019826318,0.000103574486,0.00010029931,0.015818533,0.00011925262,0.00019782332,0.000047001588,0.0005284838,0.0039545484,0.0067638797,0.05216916,0.9199991],"study_design_scores_gemma":[0.000073670184,0.00017850821,0.00046761328,0.0027575886,0.00016398341,0.0007784488,0.000040769755,0.00018335029,0.0007968356,0.002679879,0.99185914,0.000020132935],"about_ca_topic_score_codex":0.0009171749,"about_ca_topic_score_gemma":0.002650105,"teacher_disagreement_score":0.0036603597,"about_ca_system_score_codex":0.00064198,"about_ca_system_score_gemma":0.00077232736,"threshold_uncertainty_score":0.012245119},"labels":[],"label_agreement":null},{"id":"W4392283745","doi":"10.1007/s40263-024-01069-0","title":"The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medizinische Universität Graz","keywords":"Opioid; Medicine; Morphine; Agonist; Hyperalgesia; Buprenorphine; Anesthesia; Neuropathic pain; Sensitization; Chronic pain; Methadone; Pharmacology; Nociception; Internal medicine; Physical therapy; Receptor","score_opus":0.04020969767706196,"score_gpt":0.30014388552686616,"score_spread":0.2599341878498042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392283745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999062,0.00041161283,0.00012660366,0.000012248438,0.0000071876966,0.000047519035,0.00007486296,0.0000026612317,0.00025536426],"genre_scores_gemma":[0.9995172,0.00008344176,0.00013628321,0.000026775171,0.00000987429,0.000036197758,0.00007896943,0.0000013335874,0.00010987371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873084,0.0005166817,0.00016338828,0.00025611746,0.00022140359,0.000111557856],"domain_scores_gemma":[0.99727565,0.0011583943,0.0008021419,0.00018260983,0.00027024013,0.00031096055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001616509,0.00026164268,0.00050300587,0.0006609641,0.00042098996,0.00045805913,0.00020024838,0.0005810698,0.0025721767],"category_scores_gemma":[0.0024851782,0.00032935926,0.00051237555,0.000497524,0.00030436597,0.0004738087,0.00035641552,0.0005142189,0.0004051331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001101243,0.0004750014,0.99548537,0.000034830697,0.00017668575,0.000051401763,0.00015851564,0.000030492201,0.00055868394,0.000009795783,0.000036563713,0.0018814479],"study_design_scores_gemma":[0.00007145613,0.0040760925,0.9948388,0.0000072173775,0.00008565173,0.0002819611,0.00019239394,0.00011210591,0.00013273784,0.000012778981,0.00018280021,0.0000061248184],"about_ca_topic_score_codex":0.0003639362,"about_ca_topic_score_gemma":0.00047707194,"teacher_disagreement_score":0.0025721767,"about_ca_system_score_codex":0.0001607468,"about_ca_system_score_gemma":0.00018885345,"threshold_uncertainty_score":0.008604825},"labels":[],"label_agreement":null},{"id":"W4392954175","doi":"10.1007/s40263-024-01078-z","title":"An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Electroconvulsive Therapy Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brain and Cognition Discovery Foundation; University of Toronto","funders":"Neurocrine Biosciences; University of Kentucky","keywords":"Akathisia; Anticholinergic; Tardive dyskinesia; Medicine; Adverse effect; Movement disorders; Dyskinesia; Anticholinergic agents; Dystonia; Parkinsonism; Neurology; Intensive care medicine; Extrapyramidal symptoms; Psychiatry; Anesthesia; Pharmacology; Internal medicine; Schizophrenia (object-oriented programming); Antipsychotic; Disease; Parkinson's disease","score_opus":0.09967599939751602,"score_gpt":0.41015990142707126,"score_spread":0.3104839020295552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392954175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015667136,0.98969764,0.00015016503,0.0059995106,0.0016526276,0.000045269928,0.0002818934,0.000026021035,0.0019901623],"genre_scores_gemma":[0.0015297083,0.99094677,0.0006606276,0.0048152907,0.0011546876,0.00005588643,0.0003537859,0.000006804849,0.0004764847],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99780685,0.00060530915,0.0008050859,0.00015839675,0.0005192989,0.000105070656],"domain_scores_gemma":[0.98644537,0.007766003,0.0017878431,0.00017758434,0.0034450404,0.00037814706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038470805,0.0010653752,0.0030854195,0.0062072454,0.00057375664,0.0022574284,0.0023312354,0.002879157,0.009853066],"category_scores_gemma":[0.01501783,0.000570045,0.0032102342,0.0044551804,0.00053893635,0.0030258363,0.0014704277,0.004167954,0.0022788502],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026000798,0.00008105266,0.00066031516,0.11524537,0.0011118993,0.0003492512,0.00019078892,0.0002086668,0.000360965,0.0018592702,0.1656805,0.7139918],"study_design_scores_gemma":[0.00014743644,0.00016983737,0.0028262236,0.21572344,0.003853526,0.0011703952,0.00012315346,0.00009795782,0.0001364351,0.0015688818,0.7741332,0.00004946718],"about_ca_topic_score_codex":0.003874233,"about_ca_topic_score_gemma":0.012634624,"teacher_disagreement_score":0.009853066,"about_ca_system_score_codex":0.0018152446,"about_ca_system_score_gemma":0.004379637,"threshold_uncertainty_score":0.032961786},"labels":[],"label_agreement":null},{"id":"W4396705661","doi":"10.1007/s40263-024-01089-w","title":"Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Mental Health; Monash University","keywords":"Psychopharmacology; Schizophrenia (object-oriented programming); Adverse effect; Antipsychotic; Psychiatry; Medicine; Psychology; Internal medicine; Neurology; Clozapine","score_opus":0.026063628324950388,"score_gpt":0.314193143153479,"score_spread":0.2881295148285286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396705661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726236,0.0014914091,0.000084209496,0.000087750115,0.00001871973,0.000010307291,0.00020819464,0.0000021140227,0.0008348628],"genre_scores_gemma":[0.99935335,0.00021450485,0.00004427757,0.000049640337,0.000017924935,0.000008016756,0.000080180136,0.000001943959,0.0002301481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941075,0.00022045392,0.0000747834,0.00010665234,0.00013419443,0.00005320002],"domain_scores_gemma":[0.99855334,0.000503755,0.0006892724,0.000054576736,0.000079058824,0.00012001622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012266114,0.00014981197,0.0003144059,0.0005203022,0.00017689267,0.00034124168,0.00012209202,0.00020969305,0.0032772755],"category_scores_gemma":[0.0025954416,0.00012755298,0.00034118863,0.0003157483,0.00019817513,0.00023587905,0.00023892638,0.00022859036,0.00027632172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005042344,0.00014032943,0.9686506,0.000086412256,0.0003216636,0.00033419026,0.0007232257,0.000042270614,0.0025626814,0.00010897011,0.00027864226,0.02170874],"study_design_scores_gemma":[0.00004777412,0.00038345944,0.9985311,0.000009972741,0.00004480432,0.0003990592,0.00016679258,0.00003362419,0.000102636484,0.00004205662,0.00023446363,0.0000042109095],"about_ca_topic_score_codex":0.00043601816,"about_ca_topic_score_gemma":0.00074057095,"teacher_disagreement_score":0.0032772755,"about_ca_system_score_codex":0.00012792717,"about_ca_system_score_gemma":0.00012975004,"threshold_uncertainty_score":0.010963559},"labels":[],"label_agreement":null},{"id":"W4396766573","doi":"10.1007/s40263-024-01090-3","title":"FcRn Inhibitor Therapies in Neurologic Diseases","year":2024,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Immunology; Neonatal Fc receptor; Adverse effect; Myelin oligodendrocyte glycoprotein; Intravenous Immunoglobulin Therapy; Antibody; Myasthenia gravis; Clinical trial; Multiple sclerosis; Neuromyelitis optica; Immunoglobulin G; Pharmacology; Internal medicine; Experimental autoimmune encephalomyelitis","score_opus":0.019468459335931974,"score_gpt":0.3168302589198834,"score_spread":0.2973617995839514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396766573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026546689,0.94293565,0.0009554586,0.0043058298,0.0009536357,0.000032192955,0.000128371,0.000054912885,0.024087343],"genre_scores_gemma":[0.1750663,0.8012708,0.002822064,0.0032801018,0.0016589988,0.00009128423,0.00029066147,0.000013948491,0.015505862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989986,0.000023026878,0.000012016493,0.000010518221,0.00002756632,0.0000269797],"domain_scores_gemma":[0.9998472,0.000053890293,0.000037743597,0.000005419837,0.000033902586,0.000021850112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004877311,0.00042081022,0.000518624,0.00072204636,0.00028252738,0.00053491717,0.00033735042,0.0006129535,0.0041282084],"category_scores_gemma":[0.00037062413,0.000067673514,0.00030585882,0.00041621964,0.000285574,0.00038304614,0.00024164944,0.0008381084,0.00070465944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014984648,0.00045323485,0.0012293991,0.0018320107,0.00017718675,0.0009006884,0.0000479615,0.00065942004,0.012687046,0.007503271,0.024167184,0.9488441],"study_design_scores_gemma":[0.001675811,0.006699173,0.021870432,0.004877616,0.001085339,0.009172438,0.000212,0.001803518,0.0285077,0.012338386,0.91169995,0.000057546484],"about_ca_topic_score_codex":0.0020704996,"about_ca_topic_score_gemma":0.0065820566,"teacher_disagreement_score":0.0041282084,"about_ca_system_score_codex":0.0009055462,"about_ca_system_score_gemma":0.00090842956,"threshold_uncertainty_score":0.013810277},"labels":[],"label_agreement":null},{"id":"W4400179162","doi":"10.1007/s40263-024-01098-9","title":"The State of Synthetic Cannabinoid Medications for the Treatment of Pain","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; St. Michael's Hospital; Sinai Health System; McGill University; Arthritis Research Centre of Canada; Women's College Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psychopharmacology; Medicine; Cannabinoid; Synthetic cannabinoids; Neurology; Psychiatry; Neuroscience; Psychology; Internal medicine","score_opus":0.03449198301650314,"score_gpt":0.37169122874033544,"score_spread":0.3371992457238323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400179162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000634151,0.99907744,0.000049699047,0.00011664322,0.00009072884,0.000002737431,0.000014258977,0.000002685278,0.0005823205],"genre_scores_gemma":[0.00041209304,0.9989912,0.00010817946,0.00011752045,0.000106493455,0.0000031063635,0.000014242294,5.676948e-7,0.00024652062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997613,0.00004159746,0.000038488903,0.000043713375,0.000093175535,0.000021747786],"domain_scores_gemma":[0.9993579,0.0003914997,0.000090839945,0.000016294489,0.00010496396,0.000038471393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007508422,0.0007851985,0.001595546,0.0026604142,0.0003113909,0.0012904659,0.00092169485,0.0011442634,0.0058942693],"category_scores_gemma":[0.0011377687,0.00028297622,0.0006498103,0.0028698675,0.00059219834,0.0013867154,0.0006972612,0.0020011247,0.0016554989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016162505,0.00007838248,0.00011061474,0.028520811,0.000121796606,0.00013952762,0.00004794424,0.00027336163,0.0017443117,0.0034727675,0.014594813,0.95073396],"study_design_scores_gemma":[0.000058063153,0.00017021612,0.0008669626,0.007979452,0.00035299145,0.00090337376,0.00006954753,0.00014231805,0.0005319249,0.002478283,0.9864226,0.00002423539],"about_ca_topic_score_codex":0.0018520417,"about_ca_topic_score_gemma":0.004658887,"teacher_disagreement_score":0.0058942693,"about_ca_system_score_codex":0.0006539047,"about_ca_system_score_gemma":0.0014239711,"threshold_uncertainty_score":0.01971829},"labels":[],"label_agreement":null},{"id":"W4401654837","doi":"10.1007/s40263-024-01114-y","title":"Glutamatergic Modulators for Major Depression from Theory to Clinical Use","year":2024,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Treatment of Major Depression","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Glutamatergic; Psychopharmacology; Depression (economics); Neuroscience; Medicine; Psychology; Psychiatry; Glutamate receptor; Receptor; Internal medicine","score_opus":0.10415533249601573,"score_gpt":0.4413690056931374,"score_spread":0.3372136731971217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401654837","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018619957,0.9735477,0.0016034988,0.01075101,0.0021378212,0.00007422091,0.00020844434,0.00014993694,0.009665312],"genre_scores_gemma":[0.013795448,0.9654074,0.0024517113,0.009242684,0.0016736104,0.000100576006,0.00026069427,0.000024793517,0.007043059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974805,0.000066371336,0.00003949619,0.000037053767,0.00008240345,0.000026722955],"domain_scores_gemma":[0.99971575,0.00007315065,0.00004616472,0.000016446054,0.000107913635,0.000040561583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078354706,0.00058256567,0.00081484247,0.0008000314,0.00030714308,0.0012259259,0.0007189963,0.001144668,0.008731246],"category_scores_gemma":[0.0010775175,0.00021549693,0.0006486879,0.00048093108,0.0004184573,0.0010233017,0.0008109728,0.0025931587,0.0037671118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005127659,0.00020159117,0.0004057399,0.008993594,0.0001858892,0.00041916297,0.00015931396,0.00027126697,0.009630374,0.015205514,0.10278682,0.8612281],"study_design_scores_gemma":[0.00025737836,0.0008092927,0.0008548365,0.0037886484,0.00017869934,0.00089043606,0.000065846165,0.00016921462,0.0018416985,0.0065812897,0.98453563,0.000026972282],"about_ca_topic_score_codex":0.0005644953,"about_ca_topic_score_gemma":0.002150055,"teacher_disagreement_score":0.008731246,"about_ca_system_score_codex":0.0005562564,"about_ca_system_score_gemma":0.0007577326,"threshold_uncertainty_score":0.029208899},"labels":[],"label_agreement":null},{"id":"W4406514589","doi":"10.1007/s40263-024-01139-3","title":"Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries","keywords":"Chorea; Huntington's disease; Dose; Medicine; Disease; Psychopharmacology; Pediatrics; Neurology; Psychiatry; Internal medicine; Psychology","score_opus":0.017318823487690458,"score_gpt":0.285920947540357,"score_spread":0.26860212405266654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406514589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979413,0.0008707983,0.00011572489,0.000035415676,0.000018807208,0.00017953743,0.00036547336,0.000012124493,0.0004606958],"genre_scores_gemma":[0.9983034,0.00029328026,0.00028047225,0.000079828234,0.00002923661,0.00016797124,0.0004981297,0.0000050790013,0.00034266003],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984086,0.0008777096,0.0001463321,0.00029211555,0.00017382835,0.00010144212],"domain_scores_gemma":[0.99804425,0.0005711138,0.00060570904,0.00025231173,0.000197756,0.00032885093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00387013,0.00049804215,0.0012170562,0.00027299323,0.00028161518,0.0006215,0.00037583878,0.0006451642,0.001644628],"category_scores_gemma":[0.00263321,0.0002812819,0.0013649501,0.00028240835,0.0004186444,0.0005564807,0.00033493157,0.0011479334,0.0002281353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90295976,0.007948865,0.04755616,0.0003791265,0.0033679553,0.00008809631,0.0002500366,0.0004969201,0.008777504,0.00007086613,0.0005567327,0.027547894],"study_design_scores_gemma":[0.2280929,0.39771327,0.36049947,0.00008558606,0.0051838644,0.00028843622,0.00018615785,0.0017311664,0.0034098194,0.00019308209,0.002541543,0.00007466345],"about_ca_topic_score_codex":0.0007911085,"about_ca_topic_score_gemma":0.0023476153,"teacher_disagreement_score":0.00387013,"about_ca_system_score_codex":0.00035411396,"about_ca_system_score_gemma":0.0006606681,"threshold_uncertainty_score":0.02046746},"labels":[],"label_agreement":null},{"id":"W4407574412","doi":"10.1007/s40263-025-01164-w","title":"Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome; Université de Montréal; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; EMD Serono; Schweizerische Multiple Sklerose Gesellschaft; Università di Catania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Multiple Sclerosis Australia; Medical Research Council; Biogen; Celgene; Sanofi Genzyme; University of Melbourne; F. Hoffmann-La Roche; Monash University; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Bayer HealthCare; Sanofi; Atara Biotherapeutics; Universität Basel; Bristol-Myers Squibb; Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; National Science Foundation","keywords":"Relapsing remitting; Multiple sclerosis; Observational study; Medicine; Psychopharmacology; Neurology; Psychology; Internal medicine; Psychiatry","score_opus":0.23960495344703944,"score_gpt":0.3990076854640167,"score_spread":0.15940273201697727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407574412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899775,0.00039543086,0.00015313704,0.000038366972,0.0000057851375,0.00002733833,0.00028581623,0.0000019595661,0.00009435453],"genre_scores_gemma":[0.9989643,0.00016647457,0.00018375285,0.00006551129,0.00001129272,0.000038001614,0.000535935,0.0000015043969,0.000033173426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99358714,0.0034847995,0.00085445726,0.0011396518,0.0006390432,0.00029494002],"domain_scores_gemma":[0.9834857,0.0026241029,0.0107403835,0.001653813,0.0006765353,0.00081949704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005369295,0.00032512544,0.0007379327,0.0007279588,0.00059794285,0.0007252843,0.0008452986,0.00066658284,0.0007639341],"category_scores_gemma":[0.0110220555,0.000447029,0.001154512,0.0020880746,0.00042847468,0.00056877424,0.0007637438,0.0010708083,0.0001451746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006047384,0.0001116964,0.9975337,0.00003322428,0.00050026685,0.000053224165,0.00008272462,0.00005537716,0.000083657214,0.000025121039,0.00013109566,0.00078521634],"study_design_scores_gemma":[0.00021620968,0.00057675136,0.9971589,0.00003727965,0.00037372884,0.00038712707,0.0002441736,0.0005608127,0.000058999463,0.000048407983,0.0003271544,0.000010494471],"about_ca_topic_score_codex":0.0040873475,"about_ca_topic_score_gemma":0.003825599,"teacher_disagreement_score":0.005369295,"about_ca_system_score_codex":0.0006616675,"about_ca_system_score_gemma":0.0009601022,"threshold_uncertainty_score":0.028395891},"labels":[],"label_agreement":null},{"id":"W4408224561","doi":"10.1007/s40263-025-01171-x","title":"The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Huntington's disease; Psychopharmacology; Agonist; Pharmacology; Medicine; Neurology; Sigma-1 receptor; Disease; Sigma receptor; Psychiatry; Receptor; Internal medicine","score_opus":0.010175184945426548,"score_gpt":0.2802867210696093,"score_spread":0.2701115361241827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408224561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9375374,0.05456835,0.0039329436,0.00021922436,0.000060246184,0.00048622396,0.0014791839,0.000050290353,0.001666209],"genre_scores_gemma":[0.992816,0.0045170966,0.0014545622,0.00014225852,0.00007385379,0.000083324325,0.00067413226,0.0000077814375,0.0002310251],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971328,0.0014119957,0.00037169532,0.00032061062,0.00069811585,0.0000647704],"domain_scores_gemma":[0.9922874,0.0027494656,0.003200826,0.00042626265,0.0011285582,0.00020752996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007216754,0.00036929044,0.0011476148,0.0006962184,0.00020695772,0.00079768064,0.00037496004,0.0005645219,0.0011856502],"category_scores_gemma":[0.0055936375,0.00016971795,0.0016829162,0.0005284197,0.00034824404,0.00042092236,0.00028441162,0.00062194595,0.00017493154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13809331,0.00242962,0.19745302,0.012952478,0.042124975,0.0008448035,0.0007440761,0.0064786193,0.19014005,0.00043102444,0.0014739749,0.406834],"study_design_scores_gemma":[0.012186927,0.28164726,0.5590373,0.0010198471,0.04258823,0.0054402356,0.00039403856,0.006741389,0.07391715,0.00071807136,0.016132364,0.0001771595],"about_ca_topic_score_codex":0.0002229852,"about_ca_topic_score_gemma":0.00057130534,"teacher_disagreement_score":0.007216754,"about_ca_system_score_codex":0.0003497217,"about_ca_system_score_gemma":0.00049820857,"threshold_uncertainty_score":0.038166285},"labels":[],"label_agreement":null},{"id":"W4409119267","doi":"10.1007/s40263-025-01172-w","title":"Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail","year":2025,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Neuropeptides and Animal Physiology","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Université de Caen Normandie","keywords":"Holy Grail; Medicine; Opioid; Addiction; Chronic pain; Analgesic; Intensive care medicine; Methadone; Heroin; Buprenorphine; Morphine; Pharmacology; Neuropathic pain; Anesthesia; Drug; Psychiatry; Receptor; Internal medicine","score_opus":0.049801843465127726,"score_gpt":0.32548156395580086,"score_spread":0.27567972049067313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409119267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088008535,0.9976538,0.00015699158,0.0007840491,0.00043758473,0.0000017942305,0.000014743513,0.000006529043,0.0008566259],"genre_scores_gemma":[0.00073091174,0.99715245,0.00020394508,0.00066746195,0.00048358348,0.0000047689255,0.000019024777,0.0000019819865,0.0007358288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982494,0.000034221535,0.00001932361,0.000033534805,0.00006412171,0.000023911156],"domain_scores_gemma":[0.9995969,0.00021146795,0.00003829725,0.000013171059,0.00009532326,0.000044940385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008115484,0.0007472311,0.0011925759,0.0011484978,0.00030422234,0.0016739427,0.0010167805,0.0015148117,0.0039299135],"category_scores_gemma":[0.00085637096,0.00024340616,0.00032483696,0.0013572514,0.0012303324,0.0027694097,0.0008442686,0.003129006,0.001944542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018527832,0.00007063539,0.00017150599,0.00847379,0.000059470414,0.00023176937,0.00008911728,0.00041409308,0.002773128,0.028134279,0.052852686,0.9065442],"study_design_scores_gemma":[0.000017429047,0.00008272057,0.0003917531,0.0015823365,0.0000319786,0.0005423301,0.000078620964,0.000118527016,0.00026449637,0.007897093,0.98897517,0.000017444296],"about_ca_topic_score_codex":0.00077515683,"about_ca_topic_score_gemma":0.0023226873,"teacher_disagreement_score":0.0039299135,"about_ca_system_score_codex":0.00078637863,"about_ca_system_score_gemma":0.0012233836,"threshold_uncertainty_score":0.013146877},"labels":[],"label_agreement":null},{"id":"W4410719351","doi":"10.1007/s40263-025-01193-5","title":"Motor and Non-motor Complications Following Different Early Therapies in Parkinson’s Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"Ministère des Solidarités et de la Santé; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Parkinson's disease; Medicine; Neurology; Disease; Psychopharmacology; Cohort; Longitudinal study; Physical medicine and rehabilitation; Cohort study; Pediatrics; Psychiatry; Internal medicine; Pathology","score_opus":0.04695297528197971,"score_gpt":0.3447406105113509,"score_spread":0.2977876352293712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410719351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478406,0.0016802588,0.00014079579,0.000113537804,0.000014997434,0.000008108352,0.0029656417,0.0000072793787,0.00028542257],"genre_scores_gemma":[0.9962291,0.00029332726,0.0000913473,0.000033811135,0.00001158554,0.000011016396,0.003131796,0.000004552687,0.00019329372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984515,0.0004337244,0.00016440185,0.00047493327,0.00016285822,0.00031270398],"domain_scores_gemma":[0.99596053,0.0006995581,0.0018306961,0.0005591767,0.00055153924,0.0003985865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029036147,0.0005428112,0.0007864112,0.0014501647,0.00063971983,0.00124247,0.0006801196,0.00109211,0.001197664],"category_scores_gemma":[0.005231047,0.00035502782,0.001973161,0.0016903542,0.00042012404,0.0010166256,0.0009768974,0.0009523873,0.00017236978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006648116,0.000040842595,0.99628603,0.000016153612,0.00070740323,0.00007451099,0.00009950438,0.00017779644,0.00007776675,0.000048303795,0.00023946105,0.0015674195],"study_design_scores_gemma":[0.00001169948,0.00008489895,0.99904054,0.000011331471,0.0001363898,0.000110031404,0.0001308814,0.00018557788,0.000019513705,0.0000311288,0.00022802841,0.000009977468],"about_ca_topic_score_codex":0.0632152,"about_ca_topic_score_gemma":0.057536043,"teacher_disagreement_score":0.0632152,"about_ca_system_score_codex":0.0015136956,"about_ca_system_score_gemma":0.0009866956,"threshold_uncertainty_score":0.12569451},"labels":[],"label_agreement":null},{"id":"W4412492484","doi":"10.1007/s40263-025-01205-4","title":"Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy","year":2025,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tobacco Research Unit","funders":"","keywords":"Ethnic group; Medicine; Multiple sclerosis; Psychological intervention; Gerontology; Disease; Affect (linguistics); Health equity; Clinical trial; Race (biology); Public health; Psychology; Psychiatry; Gender studies; Pathology","score_opus":0.15206892879635742,"score_gpt":0.4136482932983195,"score_spread":0.26157936450196206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000811327,0.9997545,0.000010551601,0.000040586638,0.000023958979,0.0000031715483,0.000018848836,8.245468e-7,0.00006649766],"genre_scores_gemma":[0.00063450844,0.9991726,0.00005209831,0.000059966842,0.000029461466,0.0000046125847,0.000016413906,2.3548253e-7,0.000030012987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994605,0.00014472126,0.00015781692,0.00007448567,0.00013231595,0.00002999319],"domain_scores_gemma":[0.9984097,0.0010752038,0.0003212763,0.000019314963,0.00014112859,0.000033472075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012521842,0.00088395586,0.00378437,0.0033050366,0.00022322389,0.0010241035,0.00086037914,0.0008790767,0.0029376908],"category_scores_gemma":[0.0027482924,0.000310758,0.0018384999,0.0044878903,0.0003503661,0.00076817255,0.00061364006,0.0009871634,0.000307308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033162252,0.00008037835,0.0010054872,0.22806501,0.0027918895,0.00012601721,0.00011569725,0.00016702467,0.00044844075,0.00063259614,0.008680507,0.75755525],"study_design_scores_gemma":[0.0006836431,0.000753451,0.028479332,0.37866458,0.03383736,0.0031246555,0.0006856371,0.00024919634,0.00056571217,0.001946998,0.55086064,0.00014881889],"about_ca_topic_score_codex":0.0047004595,"about_ca_topic_score_gemma":0.013325631,"teacher_disagreement_score":0.0047004595,"about_ca_system_score_codex":0.00072010746,"about_ca_system_score_gemma":0.0015146451,"threshold_uncertainty_score":0.009827614},"labels":[],"label_agreement":null},{"id":"W4413867879","doi":"10.1007/s40263-025-01215-2","title":"International Trends in Opioid Prescribing by Age and Sex from 2001 to 2019: An Observational Study Using Population-Based Databases from 18 Countries and One Special Administrative Region","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute on Drug Abuse; Health and Medical Research Fund; LEO Pharma; National Science and Technology Council; DAK-Gesundheit; Servier; Astellas Pharma; National Health Research Institutes; Innovation and Technology Commission; University of New South Wales; Novo Nordisk; National Institute for Health and Care Research; Teva Pharmaceutical Industries; World Health Organization; Sanofi; European Commission; Pfizer; Amgen","keywords":"Observational study; Medicine; Psychopharmacology; Population; Opioid; Database; Family medicine; Psychiatry; Demography; Internal medicine; Environmental health; Computer science","score_opus":0.14927235239509537,"score_gpt":0.38727656495572643,"score_spread":0.23800421256063106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413867879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639974,0.005309558,0.0007998333,0.00019037025,0.00003184223,0.00015723419,0.02885691,0.00002315973,0.0006336118],"genre_scores_gemma":[0.9827557,0.0017300169,0.0010190968,0.00022110564,0.00002890922,0.0003351065,0.013756404,0.000008173536,0.00014539457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963452,0.0009289796,0.001065479,0.00083517993,0.0005817502,0.00024333717],"domain_scores_gemma":[0.99182314,0.00093169993,0.005378863,0.00061688875,0.00090570044,0.0003437972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026078855,0.0004750709,0.0010042427,0.0023312,0.0005377641,0.0008869704,0.00080160605,0.0006162828,0.0009578437],"category_scores_gemma":[0.0064728265,0.0007385172,0.002523496,0.006427119,0.00034340116,0.0009665664,0.0011206992,0.00080722355,0.00025916268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001929989,0.000033167653,0.9959132,0.00036953672,0.0014821162,0.00004995235,0.00009989731,0.00007518937,0.00006168633,0.000020633484,0.0004788769,0.0012227069],"study_design_scores_gemma":[0.000060207425,0.00010257962,0.99695337,0.00018048428,0.0010156133,0.00024582993,0.00027604494,0.00026439753,0.00008381963,0.000021962356,0.0007800278,0.000015733014],"about_ca_topic_score_codex":0.025090972,"about_ca_topic_score_gemma":0.035290834,"teacher_disagreement_score":0.025090972,"about_ca_system_score_codex":0.0010426437,"about_ca_system_score_gemma":0.0014239392,"threshold_uncertainty_score":0.049889863},"labels":[],"label_agreement":null},{"id":"W4416168683","doi":"10.1007/s40263-025-01247-8","title":"The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bipolar disorder; PsycINFO; Methadone; Psychopharmacology; (+)-Naloxone; Randomized controlled trial; Mood stabilizer; Treatment-resistant depression; Narrative review; Depression (economics)","score_opus":0.016627223066847947,"score_gpt":0.3125415261979551,"score_spread":0.29591430313110717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416168683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20505558,0.63674515,0.0020312292,0.03884683,0.0013226457,0.0001779568,0.0005892297,0.00009516979,0.11513622],"genre_scores_gemma":[0.75118256,0.22597411,0.0038120823,0.009543098,0.0018706089,0.00013210722,0.00026777835,0.000021677919,0.0071959896],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9995771,0.0002409156,0.000047429505,0.000032429172,0.00006849463,0.000033558255],"domain_scores_gemma":[0.99868625,0.00061270647,0.00031931567,0.000042878295,0.00015617153,0.00018268893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010084064,0.00028402006,0.0005916567,0.00042976977,0.00044472597,0.0009441943,0.00037848487,0.0010466016,0.0070724725],"category_scores_gemma":[0.002273691,0.00013907306,0.0004172758,0.00044172935,0.00045721434,0.000586029,0.00038555992,0.0010794413,0.00076114555],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007293132,0.0013765336,0.026905349,0.0035951226,0.00026751406,0.003027297,0.000364395,0.00043083105,0.03042987,0.009868417,0.014846571,0.9015949],"study_design_scores_gemma":[0.0065318956,0.03334724,0.307261,0.009423698,0.001623638,0.030514838,0.0026752395,0.003980697,0.0147536155,0.022578683,0.5671288,0.0001807314],"about_ca_topic_score_codex":0.0011116915,"about_ca_topic_score_gemma":0.007852519,"teacher_disagreement_score":0.0070724725,"about_ca_system_score_codex":0.0006200348,"about_ca_system_score_gemma":0.00087503315,"threshold_uncertainty_score":0.023659825},"labels":[],"label_agreement":null},{"id":"W4416841651","doi":"10.1007/s40263-025-01251-y","title":"Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Atrophy; Surrogate endpoint; Magnetic resonance imaging; Observational study; Cognitive decline; Neurology; Neurodegeneration; Clinical trial; Dementia","score_opus":0.14805935427086206,"score_gpt":0.42566074582562824,"score_spread":0.27760139155476615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416841651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026015071,0.9714182,0.00093853415,0.00041610494,0.00021809724,0.00026280966,0.00033643693,0.000013284453,0.00038152252],"genre_scores_gemma":[0.54381806,0.44821212,0.0036726852,0.0011830826,0.0011858214,0.00070451316,0.0010351891,0.000028076498,0.00016042416],"study_design_codex":"meta_analysis","study_design_gemma":"systematic_review","domain_scores_codex":[0.9587537,0.023678454,0.01004504,0.0030492654,0.0041521434,0.00032138318],"domain_scores_gemma":[0.7787113,0.1720238,0.035331994,0.0059559676,0.007104555,0.0008723502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058025427,0.0015991468,0.009192057,0.0029636517,0.00032283238,0.0033418823,0.0017566059,0.0018475192,0.0013034547],"category_scores_gemma":[0.1086111,0.00084399636,0.008165523,0.0041773478,0.0020418288,0.002300397,0.0012360505,0.0018013169,0.00020732568],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054054704,0.00047916657,0.12733808,0.2557147,0.33597732,0.0001611742,0.0006053404,0.0023585912,0.0013830529,0.0014064403,0.0017387851,0.21878263],"study_design_scores_gemma":[0.01750377,0.01354841,0.30538204,0.080747426,0.55132115,0.0005992123,0.00081718835,0.004850233,0.0017536451,0.005468958,0.017622987,0.0003849917],"about_ca_topic_score_codex":0.0015587348,"about_ca_topic_score_gemma":0.002495601,"teacher_disagreement_score":0.058025427,"about_ca_system_score_codex":0.0014339915,"about_ca_system_score_gemma":0.0017543506,"threshold_uncertainty_score":0.30687147},"labels":[],"label_agreement":null},{"id":"W4417331117","doi":"10.1007/s40263-025-01252-x","title":"Assessing Cognitive Function over Time in Patients with Refractory Chronic Migraine Who Received Ketamine Infusions: A Prospective, Observational Study","year":2025,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Johns Hopkins University","keywords":"Ketamine; Observational study; Cognition; Chronic Migraine; Refractory (planetary science); Migraine; Neurology; Neuropsychology","score_opus":0.025562890167183706,"score_gpt":0.3166538224132983,"score_spread":0.2910909322461146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417331117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930716,0.00020817178,0.00003857252,0.000019877789,0.000004833187,0.0000273872,0.00024046679,0.0000014655417,0.0001519773],"genre_scores_gemma":[0.99890244,0.00020997768,0.000112374735,0.000076126526,0.000023399818,0.00004356338,0.0005647203,0.000001514134,0.000065900735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999138,0.00020938323,0.00014273943,0.00020982198,0.00016799019,0.00013211265],"domain_scores_gemma":[0.9979984,0.0002719793,0.0010406811,0.00013767897,0.00018595392,0.0003653082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010959217,0.00048173187,0.0010355351,0.0008421672,0.00094091165,0.00096760574,0.00050574116,0.00094461505,0.00081301166],"category_scores_gemma":[0.0025954489,0.00058194826,0.0010919034,0.0015866893,0.00037719123,0.00090414344,0.00052160345,0.0010758343,0.00026256405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003311529,0.00017767935,0.9985397,0.000017742004,0.00012169661,0.00008899601,0.00008258446,0.00001584089,0.00011271316,0.0000051199213,0.00005296784,0.00045377467],"study_design_scores_gemma":[0.00006412138,0.00069035863,0.998343,0.000009333713,0.00009533379,0.0002992617,0.00020054057,0.00013792301,0.000022321015,0.00000875891,0.00012210284,0.0000070448914],"about_ca_topic_score_codex":0.008260915,"about_ca_topic_score_gemma":0.010128925,"teacher_disagreement_score":0.008260915,"about_ca_system_score_codex":0.0005290978,"about_ca_system_score_gemma":0.00058757793,"threshold_uncertainty_score":0.01642567},"labels":[],"label_agreement":null},{"id":"W52030589","doi":"10.2165/00023210-200620010-00005","title":"Prescription Privileges for Psychologists","year":2006,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Healthcare Decision-Making and Restraints","field":"Psychology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medical prescription; Mental health; Context (archaeology); Psychology; Health care; Scope (computer science); Public relations; Medicine; Psychiatry; Political science; Law; Nursing","score_opus":0.1496865604322397,"score_gpt":0.4961522133049184,"score_spread":0.34646565287267866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52030589","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002942819,0.99533373,0.000085289306,0.0013947723,0.00026133322,0.000007873372,0.000017832315,0.0000054759685,0.0025994992],"genre_scores_gemma":[0.0033401297,0.9938193,0.00018346368,0.0012162685,0.00030498081,0.000014712753,0.000023016406,0.0000013753236,0.00109673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99927074,0.00027345686,0.000096436845,0.00006706616,0.0002258862,0.00006635104],"domain_scores_gemma":[0.9980484,0.0011185529,0.00046754946,0.000055441673,0.0001581483,0.0001518884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001370456,0.000510024,0.0013807281,0.0019576596,0.0007005926,0.0012576459,0.0007887216,0.0013623344,0.006685963],"category_scores_gemma":[0.004617335,0.0003183681,0.0007033428,0.0024855435,0.0011157693,0.0010422182,0.0013007809,0.0022239813,0.0008854644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001275802,0.00012571983,0.00066505274,0.016044976,0.00017787461,0.00019653598,0.00012550804,0.00016153911,0.00021473029,0.0042748004,0.060286403,0.91759926],"study_design_scores_gemma":[0.00017767171,0.00011073915,0.0061531463,0.021908514,0.0004769495,0.0017346115,0.00020051465,0.00009464996,0.00021363981,0.003335314,0.96556926,0.000024954248],"about_ca_topic_score_codex":0.0043621273,"about_ca_topic_score_gemma":0.018353244,"teacher_disagreement_score":0.006685963,"about_ca_system_score_codex":0.0015224229,"about_ca_system_score_gemma":0.0050666183,"threshold_uncertainty_score":0.022366822},"labels":[],"label_agreement":null},{"id":"W52111744","doi":"10.2165/00023210-200317140-00004","title":"The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia","year":2003,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Dementia; Willingness to pay; Adverse effect; Population; Medicine; Health economics; Economic evaluation; Psychology; Gerontology; Disease; Public health; Environmental health; Internal medicine; Economics; Nursing","score_opus":0.21388832466335742,"score_gpt":0.39824230767505586,"score_spread":0.18435398301169845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52111744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81958985,0.12649703,0.0059420955,0.028929673,0.0007577717,0.00025866297,0.003248982,0.00007085906,0.0147050535],"genre_scores_gemma":[0.99098724,0.0074059977,0.00047503252,0.0003761483,0.000108964094,0.00002757115,0.00024599314,0.0000021847118,0.00037097695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969502,0.0023678837,0.00018111407,0.000066673085,0.00024337838,0.00019080465],"domain_scores_gemma":[0.9932272,0.005570954,0.0005359097,0.000093129376,0.00023846714,0.00033442845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036228867,0.00048828725,0.0011319693,0.0013374412,0.00025133102,0.0012363383,0.00042695145,0.0016708061,0.0018155038],"category_scores_gemma":[0.022860035,0.00030232678,0.0013359663,0.0012104823,0.00071891886,0.0010233617,0.0005884399,0.0013004947,0.00008027763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08576853,0.0018216239,0.16151889,0.0073979287,0.011220372,0.0025442836,0.00033130226,0.23634979,0.0020810673,0.04184692,0.017256381,0.431863],"study_design_scores_gemma":[0.018364888,0.01704343,0.44887748,0.0047366796,0.028171642,0.007281005,0.0022402888,0.31574416,0.0035033852,0.12505183,0.028459044,0.0005261923],"about_ca_topic_score_codex":0.0119878845,"about_ca_topic_score_gemma":0.0095863445,"teacher_disagreement_score":0.0119878845,"about_ca_system_score_codex":0.003124507,"about_ca_system_score_gemma":0.0019465153,"threshold_uncertainty_score":0.023836255},"labels":[],"label_agreement":null},{"id":"W74776018","doi":"10.2165/11538990-000000000-00000","title":"Sleep Problems in the Child with Attention-Deficit Hyperactivity Disorder","year":2010,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"Purdue University; Eli Lilly and Company","keywords":"Irritability; Attention deficit hyperactivity disorder; Restless legs syndrome; Psychiatry; Sleep (system call); Insomnia; Bedtime; Sleep disorder; Psychology; Psychopharmacology; Neurology; Medicine; Cognition","score_opus":0.03032443102086022,"score_gpt":0.31768415016061613,"score_spread":0.2873597191397559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W74776018","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013419932,0.99929357,0.00003127307,0.000101277794,0.00008498591,0.0000020974342,0.000015010636,0.0000028557192,0.00033469053],"genre_scores_gemma":[0.0007444319,0.99870944,0.00009064675,0.00009874731,0.00011522622,0.0000026105254,0.000022761928,7.8621974e-7,0.00021535429],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998323,0.000025601104,0.000038099726,0.000030552943,0.00005903765,0.000014392769],"domain_scores_gemma":[0.99949265,0.00025748048,0.00012221701,0.000007358793,0.000077655626,0.00004253741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036078776,0.0009380374,0.0019706695,0.0027367037,0.0002244243,0.00065905973,0.00086570345,0.00086731755,0.0020925116],"category_scores_gemma":[0.0007109722,0.00031292415,0.0005733111,0.0024690093,0.0004233963,0.00082776207,0.0005715491,0.0013212621,0.000704259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010565362,0.00009214218,0.001071066,0.026243234,0.00022159396,0.0007468818,0.00005087803,0.00023698139,0.0006684166,0.0004959365,0.025799,0.94426835],"study_design_scores_gemma":[0.00014484744,0.00029239064,0.017220695,0.02563935,0.0014571025,0.017658234,0.0003779811,0.00041341735,0.000698106,0.0011083983,0.9349032,0.00008615096],"about_ca_topic_score_codex":0.006112648,"about_ca_topic_score_gemma":0.017334979,"teacher_disagreement_score":0.006112648,"about_ca_system_score_codex":0.00065538706,"about_ca_system_score_gemma":0.0009928278,"threshold_uncertainty_score":0.012154102},"labels":[],"label_agreement":null},{"id":"W90711603","doi":"10.2165/00023210-200013010-00005","title":"Pharmacoeconomics of Clozapine, Risperidone and Olanzapine","year":2000,"lang":"en","type":"article","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Riverview Hospital; University of British Columbia","funders":"","keywords":"Pharmacoeconomics; Olanzapine; Risperidone; Clozapine; Medicine; Psychiatry; Schizophrenia (object-oriented programming); Intensive care medicine; Ziprasidone; Health care; Quality of life (healthcare); Cost effectiveness; Nursing; Political science","score_opus":0.012169393553419741,"score_gpt":0.3037392562900297,"score_spread":0.29156986273660995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W90711603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482272,0.038191054,0.00028762146,0.0048843813,0.00012598535,0.00014211352,0.002140094,0.000020140458,0.0059813145],"genre_scores_gemma":[0.9927205,0.0050183646,0.00021872082,0.0008223766,0.0001608539,0.000049614835,0.0005160972,0.0000048065353,0.00048879575],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855727,0.00088012795,0.00014884672,0.00004020397,0.0002964428,0.00007717075],"domain_scores_gemma":[0.99686474,0.0020012585,0.0006513343,0.00005597452,0.00020750106,0.00021913469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001249623,0.00024195468,0.0007788638,0.00053226633,0.00022526809,0.0007223808,0.00023291988,0.00063678296,0.0017968742],"category_scores_gemma":[0.0076755947,0.00015702727,0.00095856475,0.0007953297,0.00021598567,0.00031809355,0.000203852,0.0007836266,0.00009180451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37914723,0.0017316905,0.25760198,0.0024171437,0.010396047,0.0026411726,0.00030297355,0.008088145,0.005853749,0.002927384,0.0072303973,0.3216621],"study_design_scores_gemma":[0.010052516,0.009346156,0.9429302,0.0003401126,0.010852541,0.0023435499,0.00050943793,0.007646862,0.0023150241,0.0019780803,0.011603217,0.00008231122],"about_ca_topic_score_codex":0.010913851,"about_ca_topic_score_gemma":0.03200668,"teacher_disagreement_score":0.010913851,"about_ca_system_score_codex":0.00258381,"about_ca_system_score_gemma":0.0019414482,"threshold_uncertainty_score":0.02170062},"labels":[],"label_agreement":null},{"id":"W91356277","doi":"10.2165/00023210-200115090-00001","title":"Choosing the Right Dose of Antipsychotics in Schizophrenia","year":2001,"lang":"en","type":"review","venue":"CNS Drugs","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"","keywords":"Medicine; Adverse effect; Antipsychotic; Schizophrenia (object-oriented programming); Positron emission tomography; Haloperidol; Population; Pharmacology; Neuroimaging; Psychosis; Psychiatry; Internal medicine; Dopamine; Nuclear medicine","score_opus":0.04690341841344119,"score_gpt":0.3661368305843829,"score_spread":0.3192334121709417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W91356277","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006367009,0.9992317,0.00006831787,0.00022046236,0.000111909154,0.0000039209267,0.000008372073,0.0000035008168,0.00028814023],"genre_scores_gemma":[0.00052504824,0.99864596,0.00026137373,0.00026141433,0.000098055534,0.000003573758,0.000010996469,9.4283706e-7,0.0001925939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949276,0.00014754098,0.000120868724,0.00006233008,0.00015463016,0.000021913409],"domain_scores_gemma":[0.9991047,0.000511759,0.00019130435,0.00002005014,0.00013671386,0.000035467383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014652796,0.0012337643,0.0030526419,0.0021826667,0.0002939101,0.001007023,0.0013295239,0.0016052679,0.0025154206],"category_scores_gemma":[0.0022760753,0.00048301273,0.00073271635,0.0030846947,0.0005937441,0.0014401816,0.00051036855,0.0020233681,0.00093152456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025439705,0.00006140776,0.00012887518,0.027064335,0.0001641759,0.0001883543,0.000033321612,0.00045003742,0.00063888193,0.0012974032,0.018346354,0.9513725],"study_design_scores_gemma":[0.00037911884,0.00036448776,0.0018594487,0.023030141,0.0012677286,0.0021697578,0.00014113418,0.00035071053,0.0007894868,0.004498723,0.965084,0.00006516758],"about_ca_topic_score_codex":0.0038966285,"about_ca_topic_score_gemma":0.0114764115,"teacher_disagreement_score":0.0038966285,"about_ca_system_score_codex":0.0010473955,"about_ca_system_score_gemma":0.0015710875,"threshold_uncertainty_score":0.008414984},"labels":[],"label_agreement":null}]}